|
|
·|û¡Ghung120110149413 µoªí®É¶¡:2020/6/24 ¤U¤È 02:11:23
|
¥«³õº¨£·sÃÄ(¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸) Àø®Ä¤ÀªR p=0.009 6634 ªYÄ£ ªÑ¥»: 3.832»õ ¥Dn·~°È: ¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo ¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤) ¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤) Ä~Äò©¹¤U¬Ý...! ============================================================================= ²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ) ¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢ ²£«~Àu¶Õ: 1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ« 2.¥«³õº¨£·sÃÄ(First-in-class) 3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x 4.µL¦w¥þ©Ê°ÝÃD ¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C Ävª§¤O: 1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢ 2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯× 3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x ¬ãµo¶¥¬q: 1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á 2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ Àø®Ä¤ÀªR¡G 1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n 2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009) ============================================================================= ²£«~02¡GSNP-630 ¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢ ²£«~Àu¶Õ: 1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE) 2.¥«³õº¨£·sÃÄ(First-in-class) 3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x 4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~ ¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C Ävª§¤O: 1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢ 2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯× 3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡ 4.µL¦w¥þ©Ê°ÝÃD ¬ãµo¶¥¬q: 1.Á{§É«e 2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C 3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C Àø®Ä¤ÀªR¡G 1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05 ============================================================================= ²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯) ¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯) ²£«~Àu¶Õ: 1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê 2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs) 3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q ¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ Ävª§¤O: 1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ« 2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^ 3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O ¬ãµo¶¥¬q: 1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç 2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D 3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç ============================================================================= ²£«~04¡GSNP-830/ SNP-840 ¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh) ²£«~Àu¶Õ: 1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è 2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q ¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ Ävª§¤O: 1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è 2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä 3.¦³¨Ï¥Î±M§Q¡A¥iקï©Î§R°£FDA¨x¬rĵ»y 4.¥i¼W¥[¤AñQÓi×ô¾¯¶q ¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î 5.¤GªÌ¾Ü¤@±ÂÅv 6.¥i¼W¥[¥«¦û²v ¬ãµo¶¥¬q: 1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ ============================================================================= ***************************************************************************** SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G 1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005 1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005 ============================================================================= ***************************************************************************** ¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G 1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv 2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv 3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv ============================================================================= ***************************************************************************** ¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º §Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó ¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄÆªÑ ----------------------------------------------------------------------------- ¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×) |
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/20 ¤U¤È 01:29:12²Ä 2331 ½g¦^À³
|
F2~F3Á{§É:clinicaltrials.gov/ct2/show/NCT02970942 Drug: Semaglutide Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg) Drug: Placebo Once daily administration subcutaneously ( s.c., under the skin) ---------------------------------------------------------- F4Á{§É: Drug: Semaglutide Drug: [Placebo (semaglutide)] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/20 ¤U¤È 12:02:19²Ä 2330 ½g¦^À³
|
1.¥¢±Ñªº71¤HÁ{§É(F4¹ï·Ó²Õ(¦w¼¢¾¯)Àu©ó¥ÎÃIJÕ???) clinicaltrials.gov/ct2/show/NCT03987451?term=NCT03987451&draw=2&rank=1 Drug: Semaglutide Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks Drug: Placebo (semaglutide) Semaglutide placebo s.c. given once-weekly for 48 weeks 2.¦N§Q¼w»P¿Õ©M¿Õ¼w(Semaglutide)¦³¦X§@¤@Ó¤G´ÁÁ{§É440¤HªºF4¶i¦æ¤¤ clinicaltrials.gov/ct2/show/NCT04971785 --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 12:27:15²Ä 2205 ½g¦^À³ NASH«Í¾î¹M³¥¡C ¦³¬ð¯}©ÊÀøªkªº¿Õ©M¿Õ¼wsemaglutide¦bF4¸T°Ï±¾¤F!!! 2022.7.1 www.healio.com/news/gastroenterology/20220630/ozempic-boosts-cardiometabolic-markers-falls-short-for-fibrosis-in-nashrelated-cirrhosis |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/8/20 ¤W¤È 09:55:53²Ä 2329 ½g¦^À³
|
Novo Nordisk (¿Õ©M¿Õ¼w)ªº semaglutide ¦b NASH F2/F3 stage ªí²{«G²´¡A¦ý F4 Á{§É¤G´Á¨S¦³¹F¼Ð¡C In the study of 71 NASH patients with compensated cirrhosis (the F4 stage of the disease), only 10.6% of those who received a weekly 2.4 mg dose of semaglutide saw an improvement in liver fibrosis coinciding with no worsening of NASH. The figure for those on placebo was 29.2%. As a secondary endpoint, 34% of patients on semaglutide saw a resolution of NASH¡Xwhich means improvement in liver inflammation and liver cell ballooning¡Xversus 20.8% on placebo. ¥þ¤å¥X³B¡G www.fiercepharma.com/pharma/after-phase-2-flop-novo-nordisk-next-list-fail-nash |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/19 ¤U¤È 07:30:38²Ä 2328 ½g¦^À³
|
¤ñ°_2¦~«e¾D©Úªº¼Æ¾Ú¡AIntercept¬°¤F®øÀ±FDA¹ï©óªø´Á¨Ï¥Îªº¦w¥þ©ÊÅU¼{¡A³o¦¸¥Ó½Ð¬O¦³¦¬¶°¼Æ¾Ú¡C ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-positive-data-fibrosis-due-nash-new-analysis ...Safety was evaluated in 2,477 subjects who took at least one dose of study drug (placebo, OCA 10 mg, or OCA 25 mg). Compared to the original analysis, the safety population in this new interim analysis had significantly longer exposure to study drug (median 42 months vs. 15 months), yielding more than 8,000 total patient-years and 3.4 times more exposure. Nearly 1,000 subjects had been on study drug for four years. |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/8/19 ¤U¤È 03:07:48²Ä 2327 ½g¦^À³
|
www.genetinfo.com/international-news/item/61022.html ¥H¤Wz³ø¾É¨Ó¬Ý Intercept ´£¥Xªº·s¤ÀªR¼Æ¾Ú¡A¦ü¥G¨S¦³¤°»ò«G²´ªº¦a¤è¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/19 ¤W¤È 04:59:40²Ä 2326 ½g¦^À³
|
Intercept¤µ¤Ñ¦¬19.7¡A´N®t0.8¤¸¯}52¶g°ª¡A¦ü¥G¦³À¸¥i¥H¬Ý? ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 04:48:53²Ä 2164 ½g¦^À³ Ocaliva[²×§½¤§¾Ô]´N¦b7¤ë! ²Ä1¤äNASHÃĪ«? ... ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/18 ¤W¤È 07:49:34²Ä 1600 ½g¦^À³ ·Q[½ä]¤@©]P´I?³o®aIntercept pharmaceuticalsªº[²×§½¤§¾Ô]¦³¼Éº¦10~20¿ªº¹ê¤O»P¾÷·|?! ì¦]: 1.ªÑ»ù¾ú¥v°ª 2014.1.6 $497¡A¾ú¥v§C:2021.8.16 $11.6 2.¬Q¤é¦¬½Lº¦7.96% ¦¬$17.76----¬ü°ê§ë¸êªÌ¶}©l©ãª`Ocalivaªº[²×§½¤§¾Ô] 2022.1.7---2022 ¦~¤£¥i¿ù¹Lªº 3¶µ....¹ï©ó³o¨Ç»sÃÄ°Ó¨Ó»¡¡A³o¥i¯à¬O«D±`¿E°Ê¤H¤ßªº¤@¦~¡C 3.¤@¾Ô¨M¥Í¦º®É¶¡:2022¦~¤W¥b¦~ 2021.12.20 Intercept ¥i¯à·|¦b 2022 ¦~¤W¥b¦~»P FDA «·s´£¥æ·|ij¡C 4.Ó¤H¤£·|©ãª`³o³õ½ä§½¡A°lÂÜFDA§å㪺²Ä1¤äNASHÃĪ«¥Î¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/19 ¤W¤È 04:29:28²Ä 2325 ½g¦^À³
|
VERU¤µ¤Ñ¦hªÅ¥æ¾Ô¿E¯P±Y21.47%(¸³¨ÆMario Eisenberge¶g¤@½æªÑ¡A¿ðº¢¤µ¤Ñ¤ÏÀ³?)¡AªÅÀY³o»ò¸vµL§Ò¼ª? ¹ï¤ñ½÷·ç»PÀq§J»´¯gÃĪ«¡AFDA¹ï«¯gÃĪ«EUA§å±o¦ü¥G¦³ÂIºC? ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/16 ¤W¤È 09:18:42²Ä 2316 ½g¦^À³ Veruªºeua±q6/7´£¥æ¤w¹L2Ó¤ë¡A FDA¬°¦óÁÙ¤£§å? ¦s¦³20%¤£¹LÃöªº²z¥Ñ: 1.5/10 :Veru»PFDA¶}pre-eua meeting 6/7:Veru¤½§i°e¥Xeua¥Ó½Ð¡C EUAÄÝ©óºu°Ê¦¡¥Ó½Ð¡A¶}pre-eua meeting®É¡A7/8ªÅ¤è©Ò½èºÃªº¼Æ¾Ú¬O¦³¥i¯àÁÙ¨S¦¬»ô´£¥æFDA¡C 2.[Sabizabulin ªvÀø²Õªº±wªÌ¼Æ¶q¬O¦w¼¢¾¯ªº1¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84]»P[¦w¼¢¾¯²Õ¤¤¦³11.5%ªº±wªÌ¬OWHO 6 ±wªÌ¡A¦ÓSabizabulin²Õ¥u¦³ 5.1%]¡X¬Ý°_¨Ó¤£¹³¬OÀH¾÷??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/18 ¤U¤È 12:44:04²Ä 2324 ½g¦^À³
|
¥k¤âÂå«O°ê½Íªk®×¤j¤M¬åÃÄ»ù¡A¥ª¤â¤Sµ¹¤F¥v¤W³Ì©ù¶QªºÃĪ«»ù280¸U¬ü¤¸! 2022.8.18 ¥v¤W³Ì©ù¶QªºÃĪ«©w»ù°ª¹F280¸U¬ü¤¸ ¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)¶g¤T(17¤é)³q¹L¤Fbluebird bioªº°ò¦]ÀøªkÃĪ«¡A¥iªvÀø¨u¨£¯e¯f±wªÌ¡C·sÃÄ©w»ù°ª¹F280¸U¬ü¤¸¡A¬°¥v¤W³Ì©ù¶QªºÃĪ«¡C MoneyDJ XQ¥þ²yĹ®a¨t²Î³ø»ùÅã¥Ü¡A17¤ébluebird bio´¤É3.04%¡B¦¬6.78¬ü¤¸¡AIJ¤Î240¤é½u¡C ¸ô³zªÀ¡B µØº¸µó¤é³ø³ø¾É¡A·sÃĦW¬°¡uZynteglo¡v¡A¥Î¨ÓªvÀø»Ý©w´Á¿é¦åªº¤A«¬¦a¤¤®ü³h¦å(beta-thalassemia)±wªÌ¡CFDAªí¥Ü¡AZynteglo¬°º´Ú¤A«¬¦a¤¤®ü³h¦åªº°ò¦]Àøªk¡C ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/8 ¤W¤È 08:53:22²Ä 2306 ½g¦^À³ ®Á¤F¬ü°êÂå«O°ê½Íªk®×¤@°O´e´Ò¡A[ÃĤý¶Ç©_]¦¹«áÃø¦³?! 2022.8.5 ¬üª©¡§医«O国谈¡¨ªk®×¤L¥GªO¤W钉钉¡A业¬É¤@¤ù哗µM www.phirda.com/artilce_28513.html?cId=1 ... |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/8/17 ¤U¤È 01:52:20²Ä 2323 ½g¦^À³
|
ÄY«¨xÅÖºû¤Æ±yÃö¥Í©R¦s¤`¡A¥²µM»ùȶW°ª¡Fµ¥¦P¬O¯«ÃįżƤ~¯à¦³¦p¦¹Àø®Ä¡F³o³¡¤À°Ó¾÷¤ñ²vÁö¤£ºâ¤Ó°ª¡A¦ýÁn¶Õ·|Ån¬A¨xÃĬɡA¥un¨S¤°°Æ§@¥Î¡A¥DnÀø®Ä³¡¤À»â¥ý«e±´XÁûÃÄ¡A¥¼¨Ó¼ÖÆ[¡C²Ä¤@Ó¦X§@ÃļtÀt¤F¥b¤ÑÁÙ¤£±ÂÅv¡A¥L©ú©ú¨S¦³¤£±ÂÅv±ø¥ó¡mY¤£±ÂÅv¡A¦Ñ¹«¦Y´¶®³¯k¦º¥ú¹êÅç¬ã¨s¦ÛµM·|¤£¤p¤ßÃn¥ú¡Aº¡Áy¨§ªá¡n·l¥¢ºG«¡CµL¬r¤îµh¾¯±ÂÅv®ø®§¦~©³«e¥i¯à·|¦³®ø®§¡C |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/8/17 ¤U¤È 12:40:04²Ä 2322 ½g¦^À³
|
Roger¤j¡A¥«³õ¤j¡Aµ¥±ÂÅv¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/17 ¤W¤È 10:22:46²Ä 2321 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/17 ¤W¤È 07:42:01²Ä 2319 ½g¦^À³ Peter Lin¤j,±z·|³ßÅw°¨û¤µ¤Ñªº³o¥y¡G[³oÓ««×¯×ªÕ¨x¦pªG¦¨¥\ªº¸Ü¡A©Ò¦³«e±ªº¥[°_¨Óªº»ùȳ£¤£¤Î³oÓ¡I²{¦bÁÙ¦¡I] ----------------------------------------------------------------------------------------------------- ªYÄ£¤pªÑ¥»¨»´¦p¿P¡A¤@¤é¯×ªÕ¨xª¢NASHÃĪ«¦¨¥\¡A³o¥y¡§¤jÄP¤@¤é¦P·°_,§ß·nª½¤W¤E¸U¨½¡C¡¨±N«Ü¶K¤Á¡C §ë¸ê¤@©w¦³·ÀI¡A§OÀ£¨®a(ÁÙ¤£¨ì®ÉÔ)! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/17 ¤W¤È 08:55:50²Ä 2320 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤W¤È 11:10:40²Ä 2291 ½g¦^À³ ´¼Àº¤p²ÓMªÍÀù¸Ñª¼©|¤£¯à¤U©w½×¡AmOS»PORR»PmPFS§¹¾ã¼Æ¾ÚÁÙ¨S¤½¥¬¡C ¤G½uÃĪ«´N2¤ä:Topotecan»PLurbinectedin ¡AÂå±w¥i¿ï¾ÜÃĪ«¤Ó¤Ö! ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/18 ¤U¤È 12:34:36²Ä 2243 ½g¦^À³ «¥¦³¤@ÓPÈ0.06·L¤j©ó0.05¡AFDAµoµ¹ÃÄÃÒ¦a®×¨Ò¦p¤U 1. 2020.12.12 www.fiercepharma.com/marketing/where-do-you-stand-fda-reviewers-argue-for- novartis-entresto-committee-meeting-file FDA staffers highlighted that the result¡¦s p-value, at 0.06, is ¡§only slightly above the 0.05 target¡¨ to achieve statistical significance, hinting that they¡¦re willing to give that miss a pass. --------------------------------------------------------------------------------------------------- ¥D¼ÐpÈ0.06¡AFDAµ¹ÃÄÃÒ! °²Y´¼Àº¤½¥¬mOS p¦b0.06~0.08¡A¦Ó¦¸¼ÐORR¬O2¿©óTopotecan-->ORR»¡¥Õ¸Ü:¥Î´¼ÀºÃĪ«ªvÀø¨Ï¸~½FÁY¤pªº±wªÌ¤H¼Æ¬OTopotecanªº2¿¡AFDA·|¤£·|µoµ¹Ãįg??? µ²½×:±z¥i¥H¬ÝªÅ¡A¦ý¤£n°µªÅ! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/17 ¤W¤È 07:42:01²Ä 2319 ½g¦^À³
|
Peter Lin¤j,±z·|³ßÅw°¨û¤µ¤Ñªº³o¥y¡G[³oÓ««×¯×ªÕ¨x¦pªG¦¨¥\ªº¸Ü¡A©Ò¦³«e±ªº¥[°_¨Óªº»ùȳ£¤£¤Î³oÓ¡I²{¦bÁÙ¦¡I] www.genetinfo.com/investment/featured/item/58585.html?start=2 ...¤é«e¤w¦³¬ã¨s«ü¥XADI-PEG20¦b««×¯×ªÕ¨x»P«D°sºë©Ê¨xª¢ªºªvÀø®ÄªG¨Î¡AY¥¼¨Ó¦³¾÷·|¥ç¥i´Â«DÀù¯g»â°ìÂX¤j¬ãµo.... --------------------------------------------------------------------------------------------------- ·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/6 ¤U¤È 01:51:41²Ä 2194 ½g¦^À³ ROGER¥S °¤â©ö¥Í.....¬O¬Ý¬Ý´N¦n¡A°£«D¤Q¤j°ê»ÚÃļt½Í±ÂÅvªº®ø®§¥X¨Ó¡A»ùȦô¤£¥X¨Ó¡A§Ú¤£¸Iªº¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/16 ¤U¤È 04:27:24²Ä 2318 ½g¦^À³
|
§Ú·|¬°¡§¦n¬Ý¡¨¶R³æ´îªÎ! ¡§ÃCȸgÀÙ¡¨: ³o¬O¤@Ó¬ÝÁyªº®É¥N¡A©ÎªÌ»¡¬ÝÃCȪº®É¥N¡C m.21jingji.com/article/20210530/herald/fd370e54f45dfecbff7049c4877f2ec7_zaker.html |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/8/16 ¤U¤È 01:47:04²Ä 2317 ½g¦^À³
|
´î«Ãijq±`¤j¥b®³¤£¨ì«OÀIµ¹¥I¡A¨S·Q¨ì³ºµM¯à½æ³o»ò¦n¡A»á¤H¥O¤H·N¥~¡C ¬d¤F¤@¤U¡Aì¨Ó¥xÆW¤w¸g¦³«Ü¦hÂå¥ÍÀ°·Q´îªÎªº¤H¨Ï¥Î¸zªc¯ÀÃĪ«(off lable use)¡A¥L̳qºÙ½G½G°w¡A¤@¦~ªºÃĪ«¶O¥Î 8~10 ¸U¡C Ò\«e¸pªø´¿°Ý¹LJ±Ð±Â¡ASNP-610/630 ¯à¤£¯à·í´îªÎÃĨϥΡAJ¯ºµÛ¦^»¡¤£¦æ¡C±µµÛ¤S»¡ªA¥Î SNP-610/630 ´Nºâ¦³¯×ªÕ¨x¤]¤£¦AÅܦ¨¯×ªÕ¨xª¢¡A¤£¥²´îªÎ¡C ¸zªc¯ÀÃĪ«¬O±q°§C¹¼¤¤Î©µ¿ð±ÆªÅG³¡ªº®ÄªG¨Ó¹F¦¨´îªÎªº®ÄªG¡A¦Ó SNP-610/630 ¬O´î¤Ö¯×ªÕ§Î¦¨¤ÎÂà´«¨x¯×ªÕªº¯S©ÊÅܦ¨¤£¶Ë¨x¡A¤£¬O±q¼ö¶qÄá¨ú·½ÀYµÛ¤â¡A§Ú²q®ÄªG¥i¯à¨S¦³¸zªc¯ÀÃĪ«¨ÓªºÅãµÛ´î¤ÖÅé«¡A¦ýªÖ©w¬O¦³¨ó¦Pªº®ÄªG¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/16 ¤W¤È 09:18:42²Ä 2316 ½g¦^À³
|
Veruªºeua±q6/7´£¥æ¤w¹L2Ó¤ë¡A FDA¬°¦óÁÙ¤£§å? ¦s¦³20%¤£¹LÃöªº²z¥Ñ: 1.5/10 :Veru»PFDA¶}pre-eua meeting 6/7:Veru¤½§i°e¥Xeua¥Ó½Ð¡C EUAÄÝ©óºu°Ê¦¡¥Ó½Ð¡A¶}pre-eua meeting®É¡A7/8ªÅ¤è©Ò½èºÃªº¼Æ¾Ú¬O¦³¥i¯àÁÙ¨S¦¬»ô´£¥æFDA¡C 2.[Sabizabulin ªvÀø²Õªº±wªÌ¼Æ¶q¬O¦w¼¢¾¯ªº1¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84]»P[¦w¼¢¾¯²Õ¤¤¦³11.5%ªº±wªÌ¬OWHO 6 ±wªÌ¡A¦ÓSabizabulin²Õ¥u¦³ 5.1%]¡X¬Ý°_¨Ó¤£¹³¬OÀH¾÷??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/15 ¤U¤È 12:11:31²Ä 2315 ½g¦^À³
|
NovoªÑ»ù«l´50%¡A¥»¯q¤ñ¸û¦P·~°ª¥X70%¡C§¨ÓªÑ»ù¬ù¬°300¬ü¤¸¡A¥»¯q¤ñ¬O¦P·~ªº¨â¿¡C 2022.8.12 www.barrons.com/articles/buy-eli-lilly-novo-nordisk-stock-price-picks-weight-loss-drugs-51660319418?tesla=y §¨Óªº¸zªc¯ÀÃĪ«¦W¬°tirzepatide¡C¾¨ºÞtirzepatide©|¥¼®Öã¥Î©ó´îªÎ¡A³o´Ú·sÃĤwÅý§¨ÓÅD©~µØº¸µóªº³Ì·R¤§¤@¡C¥Ø«e§¨ÓªÑ»ù¬ù¬°300¬ü¤¸¡A¬O¥¼¨Ó12Ó¤ë¬Õ¾l¹w´Áªº34¿¡A¥»¯q¤ñ¬O¦P·~ªº¨â¿¡C ---------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:11:51²Ä 2295 ½g¦^À³ §O§â´îªÎ¥«³õ¬Ý¤p¤F! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/15 ¤W¤È 08:33:31²Ä 2314 ½g¦^À³
|
2022.8.15 ·s´î«ÃĮĪG¨Î ®Æ¦¨¥v¤W³ÌºZ¾PÃÄ Â§¨ÓªÑ»ù«N(§¨ÓºÙ·sÃÄ¥i¥Ï1/5Åé« ®ÄªG¦p¤â³N) ªÎD¬O¥þ²y¤j°ÝÃD¡A«Â¯Ù¨ì5»õ¤Hªº©Ê©R¡A¦p¤µ¥X²{¦w¥þ¦³®Äªº·sÃÄ¡A¯àÅý¤H´î±¼20%Åé«¡A¥i±æ¦¨¬°¥v¤W³ÌºZ¾PÃĪ«¡C¬ãµoÃļtNovo Nordisk©M§¨Ó(Eli Lilly)±N¬O¶W¯ÅĹ®a¡C Barron`s³ø¾É¡A¸zªc¯À(incretin)ªº´î«®ÄªG«e©Ò¥¼¨£¡A¬ã¨sÅã¥Ü¡A¦¹ºØ·sÃįàÅý¥Á²³¦w¥þ¥Ï±¼1/5Åé«¡A¦³±æÅD©~¥þ²yªº³Ì¼ö¾PÃÄ«~¡C¥~¬É¦ôp¡A2030¦~°_¸zªc¯Àªº¦~«×¾P°â±N¬ð¯}500»õ¡B¬Æ¦Ü600»õ¬ü¤¸¡A¦¹¤@¥«³õ±N¥ÑNovo©M§¨Ó´x±±¡C ..... -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤W¤È 08:50:42²Ä 2302 ½g¦^À³ DGAT1§í¨î[´î¤Ö¯×ºw§Î¦¨] + Cyp2e1§í¨î[¯à¶q®ø¯Ó¼W¥[] ¤£±´¨sªÎDªvÀø(1+1>2¨ó¦P®ÄÀ³) ? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/13 ¤U¤È 05:35:14²Ä 2313 ½g¦^À³
|
²¦³ºVeruªº¼Æ¾Ú¯u¹ê©Ê¥ÑCRO¡BIDMC¡BFDAµû¼f¹L¡A«¥ªº«O¦u¥u¬O~100%´î¬°8¦¨·|¹L¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/13 ¤U¤È 05:09:16²Ä 2312 ½g¦^À³
|
Veru stock³o2¤éÃzº¦¡A¦³½g¸ê®Æ¥i¬Ý¤@¤U! 2022.7.18 Veru ªºP3¸ÕÅç¥X²{·sªº¦MÀI«H¸¹¡Aªí©ú FDA ¥i¯à·|©Úµ´ whitediamondresearch.com/research/new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/ ¦w¼¢¾¯²Õªº§C¦å®ñ¹¡©M«× ±q¤w¤½§Gªº¦w¼¢¾¯²Õ°ò½u¦å®ñ¹¡©M«×(OS)½d³ò¨Ó¬Ý¡A§Ú̪¾¹D52¦W¦w¼¢¾¯±wªÌ¤¤³Ì§CªºOS¬OVeru¦P¦æµû¼f½×¤å¤¤ªº48¡C³oÅãµM¬O¤@Ó¯f±o«Ü«ªº¯f¤H¡A¤£ºÞªvÀø¦p¦ó¡A¥Lªº©R¹B´X¥G³£¬O²³©Ò©Pª¾ªº¡C [Sabizabulin ªvÀø²Õ¾¨ºÞ±wªÌ¼Æ¶q¼W¥[¤F¤@¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84¡C] [Sabizabulin ªvÀø²Õ¾¨ºÞ±wªÌ¼Æ¶q¼W¥[¤F¤@¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84¡C] ... ¦w¼¢¾¯²Õ¤¤¦³ 11.5% ªº±wªÌ¬O WHO 6 ±wªÌ¡A¦Ó Sabizabulin ²Õ¥u¦³ 5.1%¡C³o¬O Veru «ù¤[¹B®ðªº¤@Ó¨Ò¤l¡A [³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C][³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C][³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C] µ²½×:¤£ª¾¹D¸ê®Æ¯u°°©Ê¡A«¥Âର«O¦u¬Ý«ÝEUA! ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 08:56:23²Ä 2262 ½g¦^À³ ¶¢²áVERU ªñ´ÁªÑ»ùªí²{¤£¨Î¥i¯àì¦]? 2022.7.8: ½æªÅ¶°¹ÎCulper Researchµoªí¤F¤@¶µ·s¤ÀªR¡A¹ï¨ä³¡¤ÀÁ{§É¸ÕÅç¼Æ¾Ú´£¥X½èºÃ¡C www.fool.com/investing/2022/07/08/why-veru-stock-got-dented-today/ -------------------------------------------------------------------------------------------------- µ²½×:1.Àò±oDSMBªº«Øij´£¦µ²§ôÁ{§É¸ÕÅç¡A¶i¦æ¸Ñª¼¡C 2.5¤ë10¤éÁ|¦æFDAªº±¹ï±°Q½×·|ij¡AFDA¨S¦³n¨D´£¨ÑÃB¥~¼Æ¾Ú¥B·í¤Ñ´N«ØijVERU»¼¥æEUA¥Ó½Ð¡C 3.6¤ë7¤éVERU«Å¥¬°e¥XEUA¥Ó½Ð «¥»{¬°¹LÃö¾÷²v~100%¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/11 ¤U¤È 07:43:09²Ä 2311 ½g¦^À³
|
¥Ó½ÐPRE-EUA meeting»PEUAnªá«Ü¦h¿ú¶Ü? (FDA:§K¶O §K¶O §K¶O) ¸ê®Æ¶}ªù¨£¤s¼gµÛ:FDA offers formal advice at no cost to developers of medicines regulated by both CDER and CBER, with the aim of supporting medicinal product development from Phase 1 through to marketing. FDA§K¶O¬°¨üCDER©MCBERºÊºÞªºÃÄ«~¶}µo°Ó´£¨Ñ¥¿¦¡«Øij¡A¥Øªº¬O¤ä«ùÂåÃIJ£«~±q²Ä¤@¶¥¬q¨ì¤W¥«ªº¶}µo.... ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³ ¡§³Õ¾Ç¤§¡A¼f°Ý¤§¡A·V«ä¤§¡A©ú¿ë¤§¡A¿w¦æ¤§¡¨ ..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦bÓ¤H): www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/11 ¤W¤È 10:03:19²Ä 2310 ½g¦^À³
|
2022.8.10(¤j³°) º´Ú国产·s«a药ª«©wɲ¤£¨ì300¤¸¡A¥H¶q换ɲ¡Hwww.drugtimes.cn/2022/08/10/shoukuanguochanxinguanyaowudingjiabudao300yuanyilianghuanjia/ ... 从ɲ®æ¤è±来¬Ý¡Aº个国产§Ü·s«a¤fªA药ªº©wɲ仅为进¤f§Ü·s«a¤fªA药(辉·çPaxlovid)ªº约1/10¡C®ÚÕu¨C²~¤£¨ì300¤¸ªºÉ²®æ计ºâ ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/2 ¤W¤È 10:17:29²Ä 2286 ½g¦^À³ ..¤»ºØª¢¯g«ü¼Ð¤¤ªº¤ºØ¤¤¡A¤½¥q¨S¥æ¥N²M·¡5ºØp < 0.05¬O¨º´XºØ?(¤å·NÀ³¸Ó¤£¬O5ºØ) ¥t¥~¡A»´¯gÃĪ«ªº»ù®æ«ÜÃöÁä¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/8/10 ¤U¤È 03:42:31²Ä 2309 ½g¦^À³
|
·sÃĤñ¥É®i§C¡A§Ú¤£ªA!!!! §Ö¯}¦Ê§r |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/9 ¤U¤È 05:22:55²Ä 2308 ½g¦^À³
|
50¥H¤U¦³º¡¤Àªº[¼É§Q¬ü¾Ç]! 2Ãä¶]¦³ÂI²Ö. --------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤W¤È 10:38:08²Ä 1600 ½g¦^À³ ·s«a¥¢ª¼¶^¶Õ¦³ÂI·N¥~ªº²`¡A¤½¥q®Ö¤ß»ùȦb2¤äBTDÃĪ«¡A50¥H¤U¥ýÅu¤@¨Ç¡C¾¬±æ¤ß®®¦¨¥\Åý«¥¸É¦^¨Ó¤@¨ÇÃĵتº¿ò¾Ñ¡C ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/3 ¤W¤È 11:15:22²Ä 1593 ½g¦^À³ À£·s«aªº¶}µPÂ÷³õ¡A§ÚÀ£2¤äBTD³o¶g¤J³õ¡AÅ¥µP¸Õ¤â®ð! |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/8/9 ¤W¤È 10:58:56²Ä 2307 ½g¦^À³
|
Roger¤j, ¤ß®®§A¶iÔ·¨S¡H¤î¶^½L¤F¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/8 ¤W¤È 08:53:22²Ä 2306 ½g¦^À³
|
®Á¤F¬ü°êÂå«O°ê½Íªk®×¤@°O´e´Ò¡A[ÃĤý¶Ç©_]¦¹«áÃø¦³?! 2022.8.5 ¬üª©¡§医«O国谈¡¨ªk®×¤L¥GªO¤W钉钉¡A业¬É¤@¤ù哗µM www.phirda.com/artilce_28513.html?cId=1 ... ªk®×ªº实¬I·N¨ýþÓ¹³Humira这ý©¦b¬ü国¥«场经¤[¤£°Iªº传©_¦¹¦Z³£难¦³¤F¡C ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 07:24:51²Ä 2305 ½g¦^À³ 2021¦~¿Õ©M¿Õ¼wGLP-1ÃþÃĪ«ºâ¤W´îªÎ»â°ì¦Xp°^ÄmÀ禬¹F95»õ¬ü¤¸! Y¦bNASH¤]®³¨ìÃÄÃÒ¡A¿Õ©M³o¤äGLP-1ÃÄ(¿}§¿¯f+´îªÎ+NASH)°ª®pÀ禬µ´¹ï¯}200»õ¬ü¤¸¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 07:24:51²Ä 2305 ½g¦^À³
|
2021¦~¿Õ©M¿Õ¼wGLP-1ÃþÃĪ«ºâ¤W´îªÎ»â°ì¦Xp°^ÄmÀ禬¹F95»õ¬ü¤¸! Y¦bNASH¤]®³¨ìÃÄÃÒ¡A¿Õ©M³o¤äGLP-1ÃÄ(¿}§¿¯f+´îªÎ+NASH)°ª®pÀ禬µ´¹ï¯}200»õ¬ü¤¸¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 06:53:40²Ä 2304 ½g¦^À³
|
«¥ªº20»õ±o©¹¤W+17=37»õ¬ü¤¸¤F! 2022.3.8§â¿}§¿¯f药卖¦¨ú£ªÎ药¡I诺©M诺¼w2025¦~¡§发»}¡¨n卖¨ì37亿¬ü¤¸ www.sohu.com/a/527948439_359980 ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:54:17²Ä 2297 ½g¦^À³ ´N¾Ì[¿Õ©M¿Õ¼w»¼¥æ¤F¤@±iÀu¥ý¼f¬d¾ÌÃÒ¡]PRV ,»ùÈ>1»õ¬ü¤¸¡^¨Ó¥[³t´îªÎÃÄNDA¼f¬d(FDA§Ö³t¦b4Ӥ뤺§åã¤W¥«] ³æ¬Ý´îªÎ¥ÎÃÄ¡A¥q¬ü®æ鲁肽ª`®g²GÃĮĴ20%+Åé«(µ¥¦P´îªÎ¤â³N®ÄªG)¡A¥þ²y½æÓ20»õ¬ü¤¸¨S¤°°ÝÃD¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 06:46:31²Ä 2303 ½g¦^À³
|
¿Õ©M¿Õ¼w¥Ö¤Uª`®gªº°¿}药ª«¦bªÀ¥æ¥¥x¤W摇¨¤@变¦¨¤F¡§ú£ªÎ¯«¾¹¡¨ 2022.7.17 ¡§¤@针½G4¤ç¡Aªá费¤£¨ì3000¡¨ m.cyol.com/gb/articles/2022-07/17/content_O5W2YfWya.html ¥q¬ü¦b³¡¤À¦a区¥X现断货¡Cªñ¤é¡A¤¤·s经纬¥H®ø费ªÌ¨¥÷«t询¤@¦ì药¥N¡A对¤è称¡G¡§经济条¥ó¤¹许ªº¦}¥B¨Ï¥Î过¥q¬üªº¡A¤@©wn§y药¡I现¦b¥«场«Ü¤£稳©w¡A说¤£©wþ¤Ñ断货¡A断¦h¤[¤]说¤£©w.... ...¨ä风Ãûì¦]¡A¤@¤è±¡A¦b¤_¨äú£ªÎ®ÄªG¡C¤Wz药¥Nªí¥Ü¡A®ÄªG¦]¤H¦ÓÉÝ¡A对¤_¤j°ò数ú£ªÎ§ó¦³®Ä¡A¨Ï¥Î©P´Á3-6个¤ë¡A¤§¦Z¤£会¤Ï弹¡A«e´Á½Gªº¬O¥Ö¤U¯×ªÕ¡A¦Z´Á¬O内脏¯×ªÕ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤W¤È 08:50:42²Ä 2302 ½g¦^À³
|
DGAT1§í¨î[´î¤Ö¯×ºw§Î¦¨] + Cyp2e1§í¨î[¯à¶q®ø¯Ó¼W¥[] ¤£±´¨sªÎDªvÀø(1+1>2¨ó¦P®ÄÀ³) ? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤W¤È 08:38:30²Ä 2301 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/24 ¤U¤È 02:27:37²Ä 1062 ½g¦^À³ 2020.05.13 »®»®¦³¦Wªº¬ü¤k¬ì¾Ç®a(¬ü°êÃÀ³N»P¬ì¾Ç°|¥~Äy°|¤h)¡AÃC¹ç½ÒÃD²Õ1Ó¤ë®É¶¡¤º4½g³»¥Z¡C ´¦¥Ü¯×ªÕ¦X¦¨ÃöÁä酶DGAT1µ²ºc¤Î¶Ê¤Æ¾÷¨î --------------------------------------------------------------------------------------------------- Nature¡G«½S¡I¬ì¾Ç®aº¦¸´¦¥Ü¤HÃþ¾÷Åé»s³y¥Ìªo¤T઺¤À¤l¾÷²z¡I ... ¬ã¨sªÌµo²{¡ADGAT1¯à¦b½¤¤¤§Î¦¨¤@ºØ¤jªº¡§·t¼Ñ¡¨¡A³oÅý¬ã¨s¤Hû«D±`¤£¥i«äij¡A³oºØ¡§¤ÏÀ³¼Ñ¡¨¯à¦b½¤¤º¤ÀÂ÷¥X¤@ӪŶ¡¡A±q¦ÓÀ°§U¶i¦æ¥Ìªo¤T઺酶Ãþ¦X¦¨¡C¤ÏÀ³ª«·|¦b¡§¤ÏÀ³¼Ñ¡¨¤¤¬Û¹J±q¦Óµo¥Í¤ÏÀ³¡AÀH«á¥Ìªo¤Tà´N·|±q¯×ºwªº½¤¤¤²£¥Í¡A¦Ó¯×ºw¯à±N¥Ìªo¤Tà±a¨ì²ÓM»Ýn¥¦Ìªº¦a¤è¡C¦¹«e¬ã¨s¤Hû¨Ã¥¼¸Ô²Ó´¦¥Ü¹LDGAT1ªº3-Dµ²ºc¤Î¨ä§@¥Î¾÷¨î¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤W¤È 08:28:27²Ä 2300 ½g¦^À³
|
DGAT1³Q认为¬O«nªºªv疗[ªÎD]¤Î¿}§¿¯fªº药ª«¹v点¡C CYP2E1-PPAR £\¶b©w¸q¬°[ªÎD]ªvÀøªº·sªvÀø¹vÂI¡C µ²½×:SNP·sÃĬODGAT1+CYP2E1§í¨î¡A¤£±´¨sªÎDªvÀø(1+1>2¨ó¦P®ÄÀ³) ? ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/24 ¤U¤È 02:27:37²Ä 1062 ½g¦^À³ 2020.05.13 »®»®¦³¦Wªº¬ü¤k¬ì¾Ç®a(¬ü°êÃÀ³N»P¬ì¾Ç°|¥~Äy°|¤h)¡AÃC¹ç½ÒÃD²Õ1Ó¤ë®É¶¡¤º4½g³»¥Z¡C picture.iczhiku.com/weixin/message1592580325817.html ´¦¥Ü¯×ªÕ¦X¦¨ÃöÁä酶DGAT1µ²ºc¤Î¶Ê¤Æ¾÷¨î ... DGAT1¦X¦¨¤T酰°ò¥Ìªoà¡A¬O¤HÃþ¶¼¹¯×ªÕ§l¦¬©M¯×ªÕ¦sÀx©Ò¥²»Ýªº¡C DGAT1Äݩ󽤵²¦XªºO-酰°òÂಾ酶¡]MBOAT¡^¶W®a±Ú¡A¨ä¦¨û¦s¦b©ó©Ò¦³¥Í©R¤ý°ê¤¤¡A¨Ã°Ñ»P¯×½è©M³J¥Õ½èªº酰¤Æ§@¥Î¡C©|¤£²M·¡¤HÃþDGAT1©MMBOAT®a±Úªº¨ä¥L¦¨û¦p¦óÃѧO¨ä©³ª«¨Ã¶Ê¤Æ¨ä¤ÏÀ³¡C¯Ê¥F¤Tºûµ²ºc¤]§«Ãª¤F¥X©óªvÀø¥Øªº¦X²z¹v¦VDGAT1¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 09:08:16²Ä 2299 ½g¦^À³
|
SNPÃĪ«ªº·s¾AÀ³¯gªÎDªvÀø? ³o¨Ç½×¤åµoªí³£¬Oªñ¦~ªº¿N¿S¿S~ ----------------------------------------------------------------------------------- 2021.8.1 Áú°ê¤jªô¤j¾Çªº¬ã¨s ²ÓM¦â¯À P450 2E1 (CYP2E1) ¥¿¦V½Õ¸`¯×½è¤À¸Ñ¥NÁ¨û¤¾É 3T3-L1 ¥Õ¦â¯×ªÕ²ÓM½ÅÅÜ www.sciencedirect.com/science/article/abs/pii/S0024320521006342 ....§Ú̪º¼Æ¾Ú´¦¥Ü¤F CYP2E1 ¦b 3T3-L1 ¥Õ¦â¯×ªÕ²ÓM¤¤½Õ¸`½ÅÅܪº¤@ºØ¥ý«e¥¼ª¾ªº¾÷¨î¡Aªí©ú CYP2E1 ¬OªvÀøªÎD¤Î¨ä¬ÛÃö¯e¯fªº¦³§Æ±æªº¤À¤l¹v¼Ð¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 08:55:44²Ä 2298 ½g¦^À³
|
SNPÃĪ«ªº·s¾AÀ³¯gªÎDªvÀø? -------------------------------------------------------------------------------------------- 发¥¬时间¡G2022-07-08 ¤ý©ý课题组¦bBiochem Pharmacol发ªí¬ã¨s论¤å¡G细M¦â¯ÀP450 2E1°ò¦]ºV°£©Î§í¨î³q过调节¯à¶q®ø¯Ó预¨¾°ª¯×饮¹诱导ªºªÎD 为¤°¤\¦³ªº¤H¤@¯ë饮¹´N®e©ö发D¡A¦Ó¦³ªº¤H«ç¤\¦Y³£¤£D¡H这¥i¯à©MÊ^内CYP2E1¥N谢酶¬Û关¡CCYP2E1¬O¨x脏细M¦â¯ÀP450¥N谢酶®a±Úªº«n¦¨员¡A调节药ª«ªº处¸m©M内·½©Êª«质ªº¥Íª«转¤Æ¡C虽µM¤§«eªº¬ã¨s发现CYP2E1ÉO¯à¶q¥N谢¦³关¡A¦ýCYP2E1¦b维«ù¯à¶q稳态¤¤ªº§@¥Î¤´¤£²M·¡¡C¥»¬ã¨sªí©ú¡A¤j¹«Cyp2e1°ò¦]¯Ê¥¢¥i¥H预¨¾°ª¯×饮¹诱导ªºªÎD¡B¯×ªÕ¨x©M¯Ø岛¯À©è§Ü¡CÉó¨î¬ã¨sªí©ú¡ACyp2e1¯Ê¥F¤£仅¼W¥[´Ä¦â¯×ªÕ组织¡]BAT¡^©M¥Ö¤U¯×ªÕ组织¡]SAT¡^¤¤产热°ò¦]ªºªí达¡A¦Ó¥B«P进¨x脏©MBAT¤¤ªº¯×ªÕ»Ä¥N谢¡C¯S别¬O¡ACyp2e1¯Ê¥F³q过¼W¥[¨x脏¥Í¦¨ªº酰°ò¦×þé¦Ó¼W¥[¯à¶q®ø¯Ó¡A酰°ò¦×þé¥i¥H«P进´Ä¦â¯×ªÕ产热¦}¼W¥[£]-®ñ¤Æ¡C¦³½ìªº¬OCYP2E1§í¨î剂¡A¨Ò¦p双²¸仑¡A¥i¥H¥Î来预¨¾¤j¹«°ª¯×饮¹诱导ªºªÎD¡C总ªº来说¡A¥»¬ã¨s¸Ñ释¤FCYP2E1ÉO¯à¶q¥N谢ªº关¨t¡A为ªÎDªº预¨¾©Mªv疗´£¨Ñ¤F·sªº视¨¤¡C -------------------------------------------------------------------------------------------- |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:54:17²Ä 2297 ½g¦^À³
|
´N¾Ì[¿Õ©M¿Õ¼w»¼¥æ¤F¤@±iÀu¥ý¼f¬d¾ÌÃÒ¡]PRV ,»ùÈ>1»õ¬ü¤¸¡^¨Ó¥[³t´îªÎÃÄNDA¼f¬d(FDA§Ö³t¦b4Ӥ뤺§åã¤W¥«] ³æ¬Ý´îªÎ¥ÎÃÄ¡A¥q¬ü®æ鲁肽ª`®g²GÃĮĴ20%+Åé«(µ¥¦P´îªÎ¤â³N®ÄªG)¡A¥þ²y½æÓ20»õ¬ü¤¸¨S¤°°ÝÃD¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:44:28²Ä 2296 ½g¦^À³
|
SNPÃĪ«ªº·s¾AÀ³¯gªÎDªvÀø? 杨¨q伟团队ªº½×¤å´N¬O2022.5¤ë³o½gwww.sciencedirect.com/science/article/pii/S2211383522000545 µ²½×:¦b¥»¬ã¨s¤¤....³o¨Çµo²{±N CYP2E1-PPAR £\¶b©w¸q¬°ªÎDªvÀøªº·sªvÀø¹vÂI¡C --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/27 ¤U¤È 12:18:28²Ä 2025 ½g¦^À³ µ²½× ¦b¥»¬ã¨s¤¤....³o¨Çµo²{±N CYP2E1-PPAR £\¶b©w¸q¬°ªÎDªvÀøªº·sªvÀø¹vÂI¡C ------------------------------------------------------------------------------------ SNP-610¬O CYP2E1§í¨î¡A¤£±´¨sªÎDªvÀø¤Ó¥i±¤¤F!!! ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤W¤È 12:23:43²Ä 2029 ½g¦^À³ 2003.12.30 ¤@½g¾Ç³N¬ã¨s¥ÎÁ{§É¸ÕÅç (16¦WªÎD¨ü¸ÕªÌ¶}G´î«¤â³N VS 16¦WÅé«¥¿±`ªº¹ï·Ó²Õ) ±w¦³«D°sºë©Ê¯×ªÕ¨xªº¯fºAªÎDªÌ¦b´îªÎ«e«áªºCYP2E1¬¡©Ê aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1053/jhep.2003.50342 ...Á`¤§¡A¦b¯fºAªÎD¨ü¸ÕªÌ¤¤¡A¨xŦ CYP2E1 ¬¡©Ê¤W½Õ¡C³N«e¯×ªÕÅܩʵ{«×»PCYP2E1¬¡©Ê¤§¶¡¥H¤Î³N«áªÎDµ{«×»PCYP2E1¬¡©Ê¤§¶¡¦s¦b¥¿¬ÛÃö¡A³oªí©úCYP2E1ªº»¤¾É»P¯fºAªÎD¾ÉPªº¨xż¯fÅܦ³Ãö©Î¥Ñ¨ä¤Þ°_¡C ----------------------------------------------------------------------------------------------- ³oÓ¤HÅé¸ÕÅçµ²ªG¡Aµ¹ªYÄ£ªºNASH (CYP2E1§í¨î)Á{§É¸ÕÅç¤j¥[¤À¡C «Øij§âªÎD¥[¤JªvÀø¾AÀ³¯g! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:11:51²Ä 2295 ½g¦^À³
|
§O§â´îªÎ¥«³õ¬Ý¤p¤F! 1.2022.7.27 k.sina.com.cn/article_2051747990_7a4b309600101gc0y.html?from=health [转]·s«¬¡uú£ªÎ药¡v卖断货¡H¦h®a药¥ø¥[³t¥¬§½ ¦b诺©M诺¼w©xÊI¤W¡A¥Ø«e¥q¬ü®æ鲁肽ª`®g²G³¡¤À剂¶q¤w经显¥Ü货¶qµu¯Ê¡C诺©M诺¼w¦b声©ú¤¤写¹D¡G¡§¥q¬ü®æ鲁肽ªº»Ý¨D¤w经¶W过¤F¤§«e预¦ôªº¥«场»Ý¨D¡A¦P时¡A¦b±À¥X该产«~¦Z¤£¤[¡A诺©M诺¼w¦X§@ªºCMO¥X现问题¡A这¨Ç问题³£导P¤F¨Ñ应µu¯Ê¡C¡¨ ¦ýÕu业内¤H¤h¤ÀªR¡A¤j·§²vÉO¨ä³Q认¥iªº¡§ú£ªÎ¥\®Ä¡¨¦³关¡C 2. 2022.8.4 诺©M诺¼w2022H1¡G营¦¬113.8亿¬ü¤¸¡Aú£ªÎ药¤j卖¡Iwww.drugtimes.cn/2022/08/04/nuohenuode2022h1yingshou1138yimeiyuanjianfeiyaodamaikoufusim/ ---------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/27 ¤U¤È 09:34:47²Ä 2028 ½g¦^À³ ªYÄ£ SNP-610»PSNP-820À³¸Ó±´¨sªvÀøªÎD¯g! ¿Õ©M¿Õ¼w»¼¥æ¤F¤@±iÀu¥ý¼f¬d¾ÌÃÒ¡]PRV ,»ùÈ>1»õ¬ü¤¸¡^¨Ó¥[³t´îªÎÃÄNDA¼f¬d(FDA§Ö³t¦b4Ӥ뤺§åã¤W¥«) Àu¥ý¼f¬d¾ÌÃÒ¨S¦³¯d«ÝNASH NDA¼f¬d®É¦A¨Ï¥Î¡Aªí¥Ü´îªÎÃÄ°Ó¾÷¤]«Ü¤j¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤W¤È 07:53:19²Ä 2294 ½g¦^À³
|
·Pı¨ºùةǩǦa! ¤@¬d¯u¬Ogeneonlineªº¤å¦r±Ôz¤£ºë½T:FDA«ü¥X¡A¸ÓÃĪ«ªº¤¤¦ì¼ÆµL¯e¯f¦s¬¡²v¡]DFS¡^[¥¼¹F¼Ð·Ç]-->À³¸Ó§ï¦¨¤¤¦ìÀH³XªºDFS[©|¥¼]¹F¨ì¼Ð·Ç¡C ©³¤U¬O¸ÕÅç³Ì²×¼Æ¾Ú¤ÀªR: www.onclive.com/view/adjuvant-atezolizumab-shows-improvement-in-dfs-time-to-relapse-in-pd-l1-stage-ii-iiia-nsclc-subgroups ... DFS ¬° 42.3 Ó¤ëP=.02¡C µ²½×:ÀH³X(¸ÕÅç)µ²§ô«áªºDFS¬O¦³¹F¨ì¼Ð·Ç¡C -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤U¤È 12:26:30²Ä 2293 ½g¦^À³ ¥Dn«ü¼Ð¥¼¹F¼Ð·Ç!FDAÁÙ¬O®ÖµoTecentriq«D¤p²ÓM»²§UÀøªkÃÄÃÒ! 2021.10.18 geneonline.news/tecentriq-fda-nsclc/ FDA «ü¥X¡A¸ÓÃĪ«ªº¤¤¦ì¼ÆµL¯e¯f¦s¬¡²v¡]DFS¡^¥¼¹F¼Ð·Ç(¥Dn«ü¼Ð³á!)¡A¦]¬°¬Û¤ñ¹ï·Ó²Õ¡ATecentriq ¯à°§CII-IIIA ´Á¨ü¸ÕªÌ34% ªºÀù¯g´_µo»P¦º¤`·ÀI! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤U¤È 12:26:30²Ä 2293 ½g¦^À³
|
¥Dn«ü¼Ð¥¼¹F¼Ð·Ç!FDAÁÙ¬O®ÖµoTecentriq«D¤p²ÓM»²§UÀøªkÃÄÃÒ! 2021.10.18 geneonline.news/tecentriq-fda-nsclc/ FDA «ü¥X¡A¸ÓÃĪ«ªº¤¤¦ì¼ÆµL¯e¯f¦s¬¡²v¡]DFS¡^¥¼¹F¼Ð·Ç(¥Dn«ü¼Ð³á!)¡A¦]¬°¬Û¤ñ¹ï·Ó²Õ¡ATecentriq ¯à°§CII-IIIA ´Á¨ü¸ÕªÌ34% ªºÀù¯g´_µo»P¦º¤`·ÀI! clinicaltrials.gov/ct2/show/NCT02486718?term=impower010&draw=2&rank=1 ---------------------------------------------------------------------------------------- ©Ò¥H´¼Àº©|¤£¯à¤U©w½×! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤W¤È 11:20:06²Ä 2292 ½g¦^À³
|
2018¦~12¤ëFDAµoªí¡u¥Î©ó®Öã§ÜÀùÃÄ«~¤Î¥Íª«»s¾¯ªºÁ{§É¸ÕÅçÀø®Ä«ü¼Ð¡v«ü¤Þ «ÈÆ[¤ÏÀ³²v(Objective response rate¡AORR)¡G©w¸q¬°¸~½FÁY¤p¹F¥ý«e©w¸q¶q¨Ãºû«ù¤@¬q®É¶¡¤§[¯f¤H¤ñ¨Ò]¡A¬°§¹¥þ½w¸Ñ (CR)©M³¡¤À½w¸Ñ(PR)¤§Á`©M¡C ´¼Àº¦b³oÓ«ü¼Ð¬O2¿©óTopotecan! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤W¤È 11:10:40²Ä 2291 ½g¦^À³
|
´¼Àº¤p²ÓMªÍÀù¸Ñª¼©|¤£¯à¤U©w½×¡AmOS»PORR»PmPFS§¹¾ã¼Æ¾ÚÁÙ¨S¤½¥¬¡C ¤G½uÃĪ«´N2¤ä:Topotecan»PLurbinectedin ¡AÂå±w¥i¿ï¾ÜÃĪ«¤Ó¤Ö! Wµ¥20¦~¡A¤p细MªÍÀù终¤_¬ß来·s¤Æ疗药Lurbinectedin zhuanlan.zhihu.com/p/107950829 |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/8/4 ¤W¤È 09:42:12²Ä 2290 ½g¦^À³
|
©ö¤â°¥Í³o¤UªÝ¤ñQ¤F¡C .... .... Q:´¼Àº¤p²ÓMªÍÀù¸Ñª¼¯à¥H¥¢±Ñ½×? A:³o¬O¸ò¤W¥«¤ÆÀøÃÄTopotecan§@[ÀY¹ïÀY]¸ÕÅç¡A¥Dn»P¦¸n³£¹F¼Ð®É¡A¥s§@§¹³ÓÁÓÀ£(Àu®Ä©Ê)¡C ±q [´¼Àº±j½Õ¡A¡u¦w¯à±o¡v¤p²ÓMªÍÀùªºÁ{§É¸ÕÅçµ²ªG¡A¤´±N¥H¦¸n«ü¼Ð¤Î²Ä¤T«ü¼Ðª§¨ú¥Ó½ÐÃÄÃÒ] «¥»{¬°¬O¥D¼ÐmOS(¼Æ¾Ú¨S¤½¥¬)¤ñTopotecan·L¦n¦ý¤£ÅãµÛ(³o¥s¥¤À¬î¦â)¡A¦Ó¦¸¼Ð«ÈÆ[½w¸Ñ²v(ORR)¬OTopotecanªº2¿(³o¥s¥e¤W·)¡C µ²½×:¤£±Æ°£®³¨ì¤p²ÓMªÍÀùÃįg!(Åý±wªÌ»PÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃĪ«) -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 06:22:25²Ä 2260 ½g¦^À³ Àu®Ä©Ê¡]superiority¡^¸ÕÅç:¦b©óÃÒ¹ê·sÃĤñÂÂÃÄ¡]©Î¦w¼¢¾¯¡^¦³®Ä¡A¥H«K©ó¥H·sÃĥΨӨú¥NÂÂÃÄ¡C µ¥®Ä©Ê¡]equivalence¡^¸ÕÅç:·s¡BÂÂÃĮĬ۷í¡A¦¹ºØ¬ã¨s³]p±`³Q®³¨Ó»P¡u«D¦H©Ê¸ÕÅç¡v¤@°_°Q½×¡C «D¦H®Ä©Ê¡]non-inferiority¡^¸ÕÅç: ¥Øªº¦b©óÀË©w·sÃÄÀø®Ä¦Ü¤Ö¤£¿éÂÂÃÄ¡AÅýÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃÄ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤W¤È 06:22:03²Ä 2289 ½g¦^À³
|
Q:´¼Àº¤p²ÓMªÍÀù¸Ñª¼¯à¥H¥¢±Ñ½×? A:³o¬O¸ò¤W¥«¤ÆÀøÃÄTopotecan§@[ÀY¹ïÀY]¸ÕÅç¡A¥Dn»P¦¸n³£¹F¼Ð®É¡A¥s§@§¹³ÓÁÓÀ£(Àu®Ä©Ê)¡C ±q [´¼Àº±j½Õ¡A¡u¦w¯à±o¡v¤p²ÓMªÍÀùªºÁ{§É¸ÕÅçµ²ªG¡A¤´±N¥H¦¸n«ü¼Ð¤Î²Ä¤T«ü¼Ðª§¨ú¥Ó½ÐÃÄÃÒ] «¥»{¬°¬O¥D¼ÐmOS(¼Æ¾Ú¨S¤½¥¬)¤ñTopotecan·L¦n¦ý¤£ÅãµÛ(³o¥s¥¤À¬î¦â)¡A¦Ó¦¸¼Ð«ÈÆ[½w¸Ñ²v(ORR)¬OTopotecanªº2¿(³o¥s¥e¤W·)¡C µ²½×:¤£±Æ°£®³¨ì¤p²ÓMªÍÀùÃįg!(Åý±wªÌ»PÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃĪ«) -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 06:22:25²Ä 2260 ½g¦^À³ Àu®Ä©Ê¡]superiority¡^¸ÕÅç:¦b©óÃÒ¹ê·sÃĤñÂÂÃÄ¡]©Î¦w¼¢¾¯¡^¦³®Ä¡A¥H«K©ó¥H·sÃĥΨӨú¥NÂÂÃÄ¡C µ¥®Ä©Ê¡]equivalence¡^¸ÕÅç:·s¡BÂÂÃĮĬ۷í¡A¦¹ºØ¬ã¨s³]p±`³Q®³¨Ó»P¡u«D¦H©Ê¸ÕÅç¡v¤@°_°Q½×¡C «D¦H®Ä©Ê¡]non-inferiority¡^¸ÕÅç: ¥Øªº¦b©óÀË©w·sÃÄÀø®Ä¦Ü¤Ö¤£¿éÂÂÃÄ¡AÅýÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃÄ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/3 ¤W¤È 09:42:57²Ä 2288 ½g¦^À³
|
·s«a3®a¸Ñª¼ª¬ªp: 1.°ê¹©1/5¸Ñª¼:ªø´ÁÄY««K¯µ6Ó¤ë¤SºÆ¨¥ºÆ»y(¯f¯g¤£©ú) 2.¤ß®®8/1¸Ñª¼:¥Dn/¦¸n/pÈ©Ô3¤é¤~°®²b(»´·L¸¡Âm©|¥i) 3.¶h¹F8/3¸Ñª¼:¥Dn/¦¸n/pȤ@¤Ñ´N°®°®²b²b(°·±d³Ì¨Î) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/3 ¤W¤È 08:49:50²Ä 2287 ½g¦^À³
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/7/31 ¤W¤È 10:55:14²Ä 2271 ½g¦^À³ ¦b¤U¤~²¨¾Ç²L¡A¤£¸Ñ¦p¦¹ªºÁ{§É¼Æ¾Ú¡A¤½¥q¦ó¨Ó«i®ð°e¥ó¥Ó½Ð EUA ¡H ------------------------------------------------------------------------------------------------ Àu®ÄÂùª¼¸ÕÅ窺¸Ñª¼¯àê¦i©Ò«ä»¡¥X:p¹º®Ñªº¶±¨ÃµL´£¤Î¥Dn«ü¼Ðn¸ò¦w¼¢¾¯¤ñ¸û¡C ·Q·íµMº¸¬Op¹º®Ñªº¶±¨ÃµL´£¤Î»Ý¦³²Îp¾Ç¤Wªº·N¸q¤~¯à´£¥X¥Ó½Ð¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/2 ¤W¤È 10:17:29²Ä 2286 ½g¦^À³
|
S¤jªº¸ÑªR¨¬¨o¡A«¥´N¬Ý¨º2ÓBTDÃĪ«¡C ¤»ºØª¢¯g«ü¼Ð¤¤ªº¤ºØ¤¤¡A¤½¥q¨S¥æ¥N²M·¡5ºØp < 0.05¬O¨º´XºØ?(¤å·NÀ³¸Ó¤£¬O5ºØ) ¥t¥~¡A»´¯gÃĪ«ªº»ù®æ«ÜÃöÁä¡C |
|
|
·|û¡G¦N¦Ì¦Ï10000583 µoªí®É¶¡:2022/8/2 ¤W¤È 09:53:32²Ä 2285 ½g¦^À³
|
¤£ª¾R¤j¹ï©ó¤ß®®·s«a¤G´Á¸Ñª¼¡A¥Dn«ü¼Ð¯f¬r¶q¥¼¦³ÅãµÛ®t²§¡A¦ýª¢¯g§ïµ½«o¦³¦h¶µ¹F¼Ð¦³¦ó¨£¸Ñ¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/2 ¤W¤È 09:53:29²Ä 2284 ½g¦^À³
|
[©Ò¦³¾Ö¦³2өΧó¦hBTDªº¤½¥q³£³Q¤j»sÃĤ½¥q§]¨Ö¤F]-³oÓ¤~¬O«¥§ë¸ê¤ß®®ì¦]¡A¦Ó¤£¬O·s«aÃĪ«¡A¬Q¤é½¶Â«á¤w¶R¤J¤p³¡¦ì¡Aµø9¤ëªìªºÁ{§É¤ÀªRµ²ªG¦A°Ê§@¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/2 ¤W¤È 09:37:12²Ä 2283 ½g¦^À³
|
ÅS¥XÀ£½c3¦~ªºBTD»ùÈÂÃÄ_¹Ï¬O¹w®I¥ñµ§¡A¥´ºâ¤é«á³o®a¤½¥q[¯u]³Q¨ÖÁʮɮ³¨ÓÄmÄ_»¡¼L¡A¨S·Q¨ì¤@²{¥@¡AÃѳfªÌ°®©[¤j®¿²¾XX·|¡A¬JµM¦p¦¹«¥¤]´N¶¶¤ô±À¦à¡A©Ò¿×2ÓBTDªº¤½¥q¬O«ü¤ß®®¡C -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 10:22:06²Ä 2281 ½g¦^À³ ©Ò¦³¾Ö¦³2өΧó¦hBTDªº¤½¥q³£³Q¤j»sÃĤ½¥q§]¨Ö¤F...¥ô¦ó¾Ö¦³2өΧó¦hBTDªº¤½¥q³£±N³B©ó³Q¦¬Áʪº¼öªù°Ï°ì¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/8/1 ¤W¤È 10:30:38²Ä 2282 ½g¦^À³
|
°ê³»ªº¥Dn¥Ø¼Ð¥¼¹LªùÂe ªÑ»ù¥¼½ö¥¡A³ºµM¦p¦¹¤§±j¡C ·sÃÄ¡A°ò¥»±¸ò¨ä¬Û¤ñ¤j³Ó¡C ªÑ»ù¤§®z¡A¤]µLªk¬Û¤ñ¡C ©Î³\¬O¡F®É¶¡¥¼¨ì¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 10:22:06²Ä 2281 ½g¦^À³
|
©Ò¦³¾Ö¦³2өΧó¦hBTDªº¤½¥q³£³Q¤j»sÃĤ½¥q§]¨Ö¤F...¥ô¦ó¾Ö¦³2өΧó¦hBTDªº¤½¥q³£±N³B©ó³Q¦¬Áʪº¼öªù°Ï°ì¡C All the companies with 2 or more BTDs were gobbled up by big pharma. This list essentially represents low hanging fruit for a Big Pharma acquisition. Any company with 2 or more BTDs would be in the hot zone for acquisition. ------------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 09:36:25²Ä 2279 ½g¦^À³ µ²½×:¥i¯d·N¦³2ÓBTDªº¤½¥q! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/8/1 ¤W¤È 10:03:03²Ä 2280 ½g¦^À³
|
¬Ý¬Ý³o°ê¤§¤j¹© Ã꺯}¦Ê²Ä¥S!!!¤Ó±j¤F ¦A¬Ý¬Ý·sÄ£ ¯uªºµLªk¤F¸Ñ ¤Õ©ú¥S¤]«Ü·|ª£ ¾Ç¤@¤UÆp¥Û ============================================ ³o¦³¨S¦³§®ªÑ°ÝÃD??¦pªG©ú©úª¾¹D°T®§½T¤£¤½¥¬ §ó¥¿: 1. 2022.1.5¸Ñª¼:¥Dnµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ97.9%(¹ï·Ó²Õ¨S»¡)¡C 2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨çn¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0% 2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100% 2. ¥Dnµû¦ô«ü¼Ð¨S¦³²ÎpÅãµÛ·N¸q¡]P=0.5304¡^ -------------------------------------------------------------------------------------------------- ¼Æ¾Ú¤@ÅܦAÅÜ¡A¤½¥q«HÅA±½¦a! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 09:36:25²Ä 2279 ½g¦^À³
|
¬ð¯}©ÊÀøªk»{©wªº¯u¥¿»ùÈ seekingalpha.com/article/4314267-real-value-of-breakthrough-therapy-designation ... Takeover offers typically increase with breakthrough therapy designations. Takeover offers for a company with 2 breakthrough therapy designations increase significantly and quickly. ------------------------------------------------------------------------------------------------ µ²½×:¥i¯d·N¦³2ÓBTDªº¤½¥q! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 07:17:07²Ä 2278 ½g¦^À³
|
¡uª¾¤vª¾©¼¡A¦Ê¾Ô¤£¬p¡v §¨ÓBebtelovima ¹ïOmicron¦³Àø®Ä¡A©Ò¥H®³¨ìEUA¡C Adagio ADG20Àø®Ä¦³²Îp¾Ç·N¸q¡A¦ý¹ïOmicronÀø®Ä¼Æ¾Ú©Ê¤£¨¬¡A¼È°±´£¥æ EUA ½Ð¨D¡C ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 11:06:36²Ä 2276 ½g¦^À³ ®³Â§¨ÓªºBebtelovima EUA°µ¹ï·Ó¡A¥u¯à»¡¤½¥q¨S¥Í§Þ¤H¤~¤F. --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 07:04:07²Ä 2277 ½g¦^À³ ®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 07:04:07²Ä 2277 ½g¦^À³
|
°ê¹©¤G´ÁÁ{§É¼Æ¾Ú¤£¨ã¦³²Îp¾Ç·N¸q¡AOmicron¯f¨Ò¤H¼Æ¦³¦h¤Ö? BA.2ÅÜÅé¬O«üOmicron. 2022.4.14 Adagio ¼È°±EUA½Ð¨D(AdintrevimabÀø®Ä¬O¨ã¦³²Îp¾Ç·N¸q¦a!) ì¦]:®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C ®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C ®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C markets.businessinsider.com/news/stocks/adagio-pauses-fda-emergency-use-request-for-its-covid-19-therapy-1031357425 --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/3 ¤U¤È 01:50:12²Ä 1859 ½g¦^À³ ...2022.3.30 Adagio «Å§G ADG20¡]adintrevimab )Àø®Ä¹F¼Ð¡A²Ä2©u¦VFDA´£¥æEUA¥Ó请! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 11:06:36²Ä 2276 ½g¦^À³
|
®³Â§¨ÓªºBebtelovima EUA°µ¹ï·Ó¡A¥u¯à»¡¤½¥q¨S¥Í§Þ¤H¤~¤F. °ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æ? --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/3 ¤U¤È 01:50:12²Ä 1859 ½g¦^À³ ..®t²§¦h¤j¦Û¤v¥h¬Ý¬ü°êÃļt¬O¦p¦ó¤½¥¬¼Æ¾Ú¹F¼Ð¡AÁÙ¦³¬°¤°»ò²{¦b¥Ó½ÐEUA¼Æ¾Ú¤À¦¨Omicron[«e]»P[«á]¥Î·N???(³o´N¬O§Ú¦b1/22´£°Ý°ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æªºì·N) 2022.3.30 Adagio «Å§G ADG20¡]adintrevimab )Àø®Ä¹F¼Ð¡A²Ä2©u¦VFDA´£¥æEUA¥Ó请! www.thepharmaletter.com/article/strong-showing-for-adagio-s-adg20-in-pre-and-post-exposure-settings-for-covid-19 ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/22 ¤U¤È 02:22:40²Ä 1614 ½g¦^À³ ¶K´X«h°T®§¡A§ë¸ê¤H[¿W¥ß«ä¦Ò]²´¤UFDA±ÂÅvEUA¦a±ø¥ó??? 1.°ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æ? 2. ¬ü°ê¦b2021.11.27«eOmicron¯f¨Ò 0¡A ¬ü°êÁp¨¹¯e¯f¨¾ªv¤¤¤ß(CDC)ºI¦Ü2022.1.1¤é°ê¤º95.4%ªº·s¯f¨Ò¡ADeltaÅܺدf¬r«h³QÀ£ÁY³Ñ¤U4.6% |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 11:01:32²Ä 2275 ½g¦^À³
|
§¨ÓªºBebtelovimaÁ{§É(©Û¦¬1755¦W) FDA EUA :www.fda.gov/media/156151/download Á{§É: clinicaltrials.gov/ct2/show/NCT04634409?term=blaze+4&draw=2&rank=1 ------------------------------------------------------------------------------------------------ ®ÉªÅI´º: 2021.11¤ë©³Omicron³vº¥¨ú¥NDletaÅܦ¨¬ü°ê¥Dn¬y¦æ¯f¬r®è¡A¦Ó¨ä¥L®aªº³æ§Ü¹ïOmicron¥¢®Ä¡A©Ò¥HBebtelovima®³¨ìEUA. ±q®É¶¡¤W±ÀÂ_°ê¹©¦¬ªvªº124¦W±wªÌÀ³¸Ó¬O·¥¤Ö¬Æ¦Ü¨S¦³Omicron±wªÌ? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 09:51:11²Ä 2274 ½g¦^À³
|
¸Ñª¼®É©~»¡»¡¥~¦æ¸Ü:¥Dn«ü¼Ð¤W¡u¨S¦³¼g»¡n¸ò¦w¼¢¾¯¤ñ¸û¡C¡v 2022.7.31¸É¥R¤½§i:¦Óp¹º®Ñ¦b¥Dn«ü¼Ðªº¶±¨ÃµL´£¤În»P¹ï·Ó²Õ¬Û¤ñ¡A¦]¦¹·í®É»{¬°¤£»Ýn»P¹ï·Ó²Õ¬Û¤ñ¡C [¤§«á»PCRO¤½¥q¶}·|°Q½×±oª¾¥»¸ÕÅç¥Dn«ü¼Ð»Ý»P¹ï·Ó²Õ¬Û¤ñ¸û¡C] [¤§«á»PCRO¤½¥q¶}·|°Q½×±oª¾¥»¸ÕÅç¥Dn«ü¼Ð»Ý»P¹ï·Ó²Õ¬Û¤ñ¸û¡C] ¤t´¶·|ðݦºXXXX!---XXXX¸Ñ½X---¤t´¶·|ðݦº°ê¹©¯SÅv(¤£¥În¸ò¦w¼¢¾¯¤ñ¸û)¡C --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/29 ¤W¤È 08:00:29²Ä 2266 ½g¦^À³ ¤t´¶¤O±Àªº¡u¯«ÃÄ¡v¡A¥@½Ã¥s°±ªº¡u¬rÃÄ¡vßm´â喹¡A¦b¥Dn«ü¼Ð¤W¡u¨S¦³¼g»¡n¸ò¦w¼¢¾¯¤ñ¸û¡C¡v ¦]¬°²Îp¤ÀªR¨S¹F¼Ð¥¢±Ñ¡A¤t´¶·|ðݦºXXXX! ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/5 ¤W¤È 10:46:00²Ä 1864 ½g¦^À³ °ê¹©¥i¥H®³¥XFDA¯Sã¼Æ¾Ú¤£¥Î»P¦w¼¢¾¯PK¤å¥ó¶Ü?(¬JµM§¹¥þ²Å¦X¬ü°êFDA µo¥¬©ó2020¦~5¤ëªº·s«aªÍª¢Á{§É«ü¾É³W©w) ...°ê¹©¥Í§ÞÁ{§ÉÂå¾Ç³¡³¯¨Ø©gÂå®v«ü¥X...§¹¥þ²Å¦X¬ü°êFDA µo¥¬©ó2020¦~5¤ëªº·s«aªÍª¢Á{§É«ü¾É³W©w¡A°w¹ïÃļt¶}µo·s«aªÍª¢ªºªvÀø©M¹w¨¾ÃĪ«¤Î¥Íª«»s¾¯ªº«ü¾É¡A³W©w¶·±Ä¥Î³Ì°ª¯Åªº³]p¡A¤]´N¬OÁ{§É¸ÕÅ窺³]p¥²¶·¬°ÀH¾÷¡BÂùª¼¡B¦Ó¥B¦³¦w¼¢¾¯¹ï·Ó(randomized, placebo-controlled, double-blind clinical trials)ªº¸ÕÅç¡A¤~¬O¥\®Ä©ÊÅçÃҳ̥i«HªºÃÒ¾Ú |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 07:48:31²Ä 2273 ½g¦^À³
|
7/30«e³£¬O¥ÎÃIJÕ(97.9%©Î100%)·L¦n©ó¹ï·Ó²Õ¡A½Ö®Æ¨ì³Ì²×¼Æ¾Ú¬O¹ï·Ó²Õ100%[°fÂà]Àu©ó¥ÎÃIJÕ97.9%¡Aªí©ú¤½¥q¤§«e©ÜÅS¤£¹ê¼Æ¾Ú¡A³o¬O[«D±`] [«D±`] [«D±`] ÄY«ªº¸Û«H°ÝÃD! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/31 ¤U¤È 06:21:17²Ä 2272 ½g¦^À³
|
³o¦³¨S¦³§®ªÑ°ÝÃD??¦pªG©ú©úª¾¹D°T®§½T¤£¤½¥¬ §ó¥¿: 1. 2022.1.5¸Ñª¼:¥Dnµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ97.9%(¹ï·Ó²Õ¨S»¡)¡C 2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨çn¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0% 2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100% 2. ¥Dnµû¦ô«ü¼Ð¨S¦³²ÎpÅãµÛ·N¸q¡]P=0.5304¡^ -------------------------------------------------------------------------------------------------- ¼Æ¾Ú¤@ÅܦAÅÜ¡A¤½¥q«HÅA±½¦a! |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/7/31 ¤W¤È 10:55:14²Ä 2271 ½g¦^À³
|
¦b¤U¤~²¨¾Ç²L¡A¤£¸Ñ¦p¦¹ªºÁ{§É¼Æ¾Ú¡A¤½¥q¦ó¨Ó«i®ð°e¥ó¥Ó½Ð EUA ¡H Æp¥Û¥Í§Þ¿³Âdªk»¡·|¡AÆp¥Û¥Í§Þ©xºô¦³¼v¹³ÀÉ¡A¥i¥H¥hťť¥L̬O«ç»òµû»ù¤@¶¡¤½¥q¯à¤£¯à§ëªº¡AÓ¤Hı±o³o¬O«Ü¦nªº¾Ç²ß¨å½d¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤W¤È 07:05:18²Ä 2270 ½g¦^À³
|
¦]¬°¿ï¾Üªº¨Æ«á¤ÀªR¡A¥i¯à·|¨ü¨ì¡u·Q¦¨¥\¡vªº¼¤±æ©ÒÁÍ¡A¨äµ²ªG¥i¯à·|¦³©Ò°¾®t¡C ------------------------------------------------------------------------------- ¦b¥DnÀø®Ä¤ÀªRµ²ªGµ²½×¬°¡u¥¢±Ñ¡v®É¡AFDA±µ¨ü¨Æ«á¤ÀªR¯S©wªºµû¦ô«ü¼Ð¡A¨º¯E¹©OBI-822ªº¸Ñª¼´N¬Oªk³W¤W¦¨¥\¥B¬ì¾Ç¤W¦¨¥\! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/30 ¤U¤È 09:27:38²Ä 2269 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/28 ¤W¤È 09:12:02²Ä 2264 ½g¦^À³ FDAÁ{§ÉªvÀø²×ÂI«ü¾Éì«h: ..¦¸n«ü¼Ðªº¥¿¦Vµ²ªG¡A¶È¦³¦b¥Dn«ü¼Ð®a±ÚªºÀø®Ä¤w¸gÀò±oÃÒ©ú®É¤~¥i¸ÑŪ -------------------------------------------------------------------------------------------- ¦b¬ü°êFDA¤§¦h«µû¦ô«ü¼Ð«ü¤Þ¯ó®×¤¤©ú½T³¯z¡A³æ¾Ì¨Æ«á¤ÀªR(post-hocanalyses)µ²ªG¡A¬OµLªkÃÒ©úÃÄ«~ªºÀø®Ä¡C¥ç§Y¡A·í¸ÕÅç¥DnÀø®Ä¤ÀªRµ²ªGµ²½×¬°¡u¥¢±Ñ¡v®É¡A¨Æ«á¤ÀªR¯S©wªºµû¦ô«ü¼Ð¡A¤]³\¦³§U©ó±N¨Ó¥i¯à¶i¦æªº°²»¡ÀË©w¡A±©µLªk»{©w¬°¸ÕÅ礧½T»{©Êªºµ²ªG¡F¦]¬°¿ï¾Üªº¨Æ«á¤ÀªR¡A¥i¯à·|¨ü¨ì¡u·Q¦¨¥\¡vªº¼¤±æ©ÒÁÍ¡A¨äµ²ªG¥i¯à·|¦³©Ò°¾®t¡C ©Ò¥H¦p°ª¦åÀ£ (Antroquinonol 38.7% vs. ¹ï·Ó²Õ22.6%) ©M¿}§¿¯f(Antroquinonol 24.2% vs.¹ï·Ó²Õ14.5%)¥H¤Î¨k©Ê±wªÌªº¤ñ¨Ò§ó°ª---Y³o¨Ç«ü¼Ð¬O¨Æ«á¤ÀªR¦aµ²ªG¡AFDA«ç»ò¬Ý? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/30 ¤U¤È 08:19:46²Ä 2268 ½g¦^À³
|
§ó¥¿: 1. 2022.1.5¸Ñª¼:¥Dnµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ97.9%(¹ï·Ó²Õ¨S»¡)¡C 2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨çn¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0% 2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100% 2. ¥Dnµû¦ô«ü¼Ð¨S¦³²ÎpÅãµÛ·N¸q¡]P=0.5304¡^ -------------------------------------------------------------------------------------------------- ¼Æ¾Ú¤@ÅܦAÅÜ¡A¤½¥q«HÅA±½¦a! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/30 ¤U¤È 08:06:06²Ä 2267 ½g¦^À³
|
¨âÓ«GÂI: 1. 2022.1.5¸Ñª¼:¥Dnµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ100%(¹ï·Ó²Õ¨S»¡)¡C 2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨çn¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0% 2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100% 2. ¥Dnµû¦ô«ü¼Ð¨S¦³²ÎpÅãµÛ·N¸q¡]P=0.5304¡^ ------------------------------------------------------------------------------------------- 1.¨Æ¹êµo¥Í¤é:111/07/30 2.¤½¥q¦WºÙ:°ê¹©¥Íª«¬ì§ÞªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: °ê¹©¥Í§Þ©ó111¦~07¤ë30¤é¦¬¨ì©Ò©e°U¤§CRO¤½¥q¤§³Ì²×CSR(clinical study report)¡A ¨Ì¾Ú¸ÓCSR«ÂI¤º®e¤Î¾ãÅéµ²½×»¡©ú¦p¤U: (1)¸ÕÅçÃĪ«¦WºÙ: Antroquinonol (Hocena) (2)¸ÕÅçpµe¥N¸¹: GHCovid-2-001 °ê¹©¥Í§Þ·s«aªÍª¢(COVID-19)¬ãµo¤¤·sÃÄAntroquinonol©ó¬ü°ê¡B¯µ¾|¤Îªü®Ú§Ê©Ò ¶i¦æªº¤HÅé¤G´ÁÁ{§É¸ÕÅç¡AÁ`¦@¦¬ªv124¦ì¯f±w¡C¸Ó¸ÕÅç¬O±ÄÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯ ¹ï·Ó¬ã¨s¡A¥Î©ó¦]·s«aªÍª¢¦Ó¦í°|ªº»´«×¦Ü¤¤«×±wªÌ¤§¦w¥þ©Ê©M¦³®Ä©ÊªºÅçÃÒ¬ã¨s¡A ±wªÌ¨Ã±N±µ¨ü¤@¤Ñ¨â¦¸¤fªA100mg Antroquinonol©Î¦w¼¢¾¯¡AÁp¦X¼Ð·ÇªvÀø(SoC) Á`¦@14¤Ñ¡C (3)¥»¸ÕÅç¼Æ¾ÚÅã¥Ü: ¥Dnµû¦ô«ü¼Ð¡G±d´_²v(recovery ratio)¡A¦b²Ä14¤Ñ¦s¬¡¥BµL©I§l°IºÜªº±wªÌ¤ñ¨Ò¡C ¸ÕÅçµ²ªGÅã¥Ü¡A¦bAntroquinonolªvÀø«áªº²Ä 14 ¤Ñ¦] COVID-19¾ÉPªÍª¢¦í°|±wªÌ ¦s¬¡¥BµL©I§l°IºÜªº¤ñ¨Ò¬°97.9%¡A¦Ó¦b¹ï·Ó²Õªº¤ñ¨Ò¬°100%¡A³oºØ¤ñ¸û¨S¦³²Îp ÅãµÛ·N¸q¡]P=0.5304¡^¡CµM¦Ó¡A»P¹ï·Ó²Õ¬Û¤ñ¡AAntroquinonol²Õªºcomorbidities ¦X¨Ö¯g¡A¦p°ª¦åÀ£ (Antroquinonol 38.7% vs. ¹ï·Ó²Õ22.6%) ©M¿}§¿¯f (Antroquinonol 24.2% vs.¹ï·Ó²Õ14.5%)¥H¤Î¨k©Ê±wªÌªº¤ñ¨Ò§ó°ª¡A³o¨âÓ¦]¯À³£ ·|ÅãµÛ¼W¥[·s«aªÍª¢´c¤Æ¬°«¯g(©I§l°IºÜ)©Î¦º¤`ªº¤ñ¨Ò¡F¦AªÌ¡A¸ÕÅ窺²Ä¤@¤Ñ¦b Antroquinonol²Õ´N¦³6Ó¨ü¸ÕªÌ´c¤Æ¬°©I§l°IºÜ¡A¦Ó¹ï·Ó²Õ¬Û¹ï¸û¤Ö¥u¦³1Ó©I§l °IºÜ¡C ¦¹¥~¡A¹ï·Ó²Õ±µ¨ü¥Ö½èÃþ©T¾J©M·ç¼w¦è³§@¬°¼Ð·ÇªvÀø( SoC )ªvÀøªº±wªÌ¦Ê¤À¤ñ °ª©óAntroquinonol²Õ¡C¥H¤W¦]¯À¥i¯à¬O¾ÉP¥Dn²×ÂI¦³®Ä©Ê¤£©ú½Tªºì¦]¡A§Y«K ¦p¦¹¡A¦b¥»¸ÕÅç´Á¶¡¥HDelta¬°¥Dn·s«aÅܲ§¯f¬rªº±¡ªp¤U¡AAntroquinonol²Õ¦b ²Ä14¤Ñ¥H«á¡A§Y¥¼¥X²{©I§l°IºÜ¡A¤]¨S¦³¥X²{¦º¤`¡A¨ä±d´_²v¬°¦Ê¤À¤§¦Ê¡C (4)¦¸nµû¦ô«ü¼Ð¡G ¥»¬ã¨sÁö¥¼Åã¥ÜAntroquinonol²Õ¬Û¹ï©ó¹ï·Ó²Õªº«¤jÀu¶Õ( superiority )¡A ³o¥i¯à¬O¥Ñ©ó¬ã¨s¤H¸s¦b¸ÕÅç¨â²Õ¤¤³£±µ¨ü¤F¼Ð·ÇÀøªk( SoC )ªºªvÀø¡A¥B¹ï·Ó²Õ ¦³¸û§Cªº·ÀI¦]¤l¡C§Y¨Ï¦p¦¹¡A¥»¸ÕÅ礴µM¦b·s«aªÍª¢( COVID-19 )¦í°|±wªÌªº ¤@¨Ç¯gª¬¤W¡AÆ[¹î¨ì§Q©óAntroquinonol ªº§ïµ½ÁͶաA¥]¬A¤¤¦ì¼Æ¦í°|®É¶¡´î¤Ö¤F 1 ¤Ñ¡A¥@¬É½Ã¥Í²Õ´¤§Á{§ÉÅܤƵû¤À§ïµ½¨ì¹sªº¤¤¦ì¼Æ®É¶¡¤]´î¤Ö¤F 2 ¤Ñ¡A¦Ó«¯g ¥[Å@¯f©Ðªº¦í°|®É¶¡§ó¬O´î¤Ö¤F 9.5¤Ñ¡C³Ìªñ¡A¦b COVID 19 ·P¬VªÌ¤¤³ø§i¤F COVID 19 ªø´Á¼vÅT(Long COVIDªø´Á·s«a¯gª¬) ªº¥Dn¯gª¬¡A¥]¬A©I§l§xÃø¡B¦Ù¦× µmµh©M¨ýı©Î¶åı³à¥¢¡C¯÷¤À§O»¡©ú¦p¤U: ©I§l§xÃø: ¸ÕÅçµ²ªG²Ä28¤Ñ¤´¦³¦¹¯gª¬ªº¯f¤H¤À§O¬OAntroquinonol²Õ¦³6.1%¡A ¹ï·Ó²Õ«h¦³17.8%ªº¯f¤H(P=0.0327)¡C ¦Ù¦×µmµh: ¸ÕÅçµ²ªG²Ä7¤Ñ¤´¦³¦¹¯gª¬ªº¯f¤H¤À§O¬OAntroquinonol²Õ¦³3.6%¡A ¹ï·Ó²Õ«h¦³11.8% (P-value=0.0525)¡C ¶åı©Î¨ýı³à¥¢: ¸ÕÅçµ²ªG²Ä28¤Ñ¤´¦³¦¹¯gª¬ªº¯f¤H¤À§O¬O: ¥ÎÃIJզ³0%¡A¹ï·Ó²Õ «h¦³6.7%ªº¯f¤H(P-value=0.1059)¡AAntroquinonol²Õªº¨ü¸ÕªÌ³£ ¨S¦³¨ýı©Î¶åıªº³à¥¢¤F¡C ¥H¤WÁö¥¼¦³²ÎpÅãµÛ·N¸q¡A²Ä28¤Ñªº©I§l§xÃø(P=0.0327)©M²Ä7¤Ñªº¦Ù¦×»Äµh (P=0.0525)³£Åã¥ÜAntroquinonol¦³§Q©ó¿n·¥´î¤Ö¯gª¬ªºÁͶաC «¯g¥[Å@¯f©Ð(ICU)ªºªvÀø®É¶¡: ¸ÕÅçµ²ªGAntroquinonol²Õªº¯f¤H¤¤¦ì¼ÆªvÀø¤Ñ¼Æ ¬°13.5¤Ñ¡A¹ï·Ó²Õ¬°23¤Ñ(P-value=0.5404)¡C ¦í°|®É¶¡: ¸ÕÅçµ²ªGAntroquinonol²Õªº¯f¤H¤¤¦ì¼Æ¦í°|®É¶¡¬°4¤Ñ¡A¹ï·Ó²Õ¬°5¤Ñ ( P-value=0.9951 )¡C WHO§Ç¼Æ¶qªí´ú¶qªºÁ{§ÉÅܤƵû¤À§ïµ½®É¶¡:¸ÕÅçµ²ªGAntroquinonol²Õªº¯f¤H§ïµ½¨ì scale¬°0ªº¤¤¦ì¼Æ¤Ñ¼Æ¬°29¤Ñ¡A¹ï·Ó²Õ ¬O31¤Ñ(P-value=0.7034)¡C ²M°£¯f¬rªº®É¶¡: ¸ÕÅçµ²ªGAntroquinonol²Õªº¤¤¦ì¼Æ¤Ñ¼Æ¬°14¤Ñ¡A¹ï·Ó²Õ¬O15¤Ñ (P- value= 0.5422)¡C ¥H¤WÁö¥¼¦³²ÎpÅãµÛ·N¸q¡A¦b¦³«ez¨â²Õ¶¡ªº¤£¹ïµ¥·ÀI¦]¤l¤§¤U¡A©M¹ï·Ó²Õ¬Û¤ñ¡A Antroquinonol²Õªº¤¤¦ì¼Æ¦í°|®É¶¡¤´µM´î¤Ö¤F 1 ¤Ñ¡AWHOÁ{§ÉÅܤƵû¤À§ïµ½¨ì¹sªº ¤¤¦ì¼Æ®É¶¡¤]´î¤Ö¤F 2 ¤Ñ¡A¦Ó«¯g¥[Å@¯f©Ðªº¦í°|®É¶¡§ó¬O´î¤Ö¤F 9.5 ¤Ñ¡C (5)¦w¥þ©Ê¤è±: ¯f¤H@¨ü©Ê¨}¦n¡AµL»Ýn¶i¤@¨B±´°Qªº¦w¥þ©ÊijÃD¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/29 ¤W¤È 08:00:29²Ä 2266 ½g¦^À³
|
¤t´¶¤O±Àªº¡u¯«ÃÄ¡v¡A¥@½Ã¥s°±ªº¡u¬rÃÄ¡vßm´â喹¡A¦b¥Dn«ü¼Ð¤W¡u¨S¦³¼g»¡n¸ò¦w¼¢¾¯¤ñ¸û¡C¡v ¦]¬°²Îp¤ÀªR¨S¹F¼Ð¥¢±Ñ¡A¤t´¶·|ðݦºXXXX! -------------------------------------------------------------------------------------------------- www.sciencedirect.com/science/article/pii/S2589537021000535 ...For all analyses, two-sided p-values<0.05 were considered significant. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/28 ¤U¤È 04:21:51²Ä 2265 ½g¦^À³
|
Á{§É¸ÕÅ礧µû¦ô«ü¼Ð¡Aªk³Wn¨Dªº½d³ò(Âù§ÀpÈ<0.05) ------------------------------------------------------------------------------------------------- Á{§É¸ÕÅ礧µû¦ô«ü¼Ð¡A±N®Ú¾Ú«ü¤Þªº©w¸q¤À§O¦CÄݤTÓµû¦ô«ü¼Ð®a±Ú(¥Dnµû¦ô«ü¼Ð®a±Ú¡B¦¸nµû¦ô«ü¼Ð®a±Ú¡B±´¯Á©Êµû¦ô«ü¼Ð®a±Ú)¡A¨Ã¨Ì´`«ü¤Þ©Ò«Øij¤§²ÎpÀË©wµ¦²¤¡A±±¨î¾ãÅéType I Error©óªk³Wn¨Dªº½d³ò¤º(Âù§ÀpÈ<0.05) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/28 ¤W¤È 09:12:02²Ä 2264 ½g¦^À³
|
FDAÁ{§ÉªvÀø²×ÂI«ü¾Éì«h: 2017¦~FDA¨î©wMultiple Endpoints in Clinical Trials Guidance for Industry¡A «ÂI¦b±±¨îÁ{§É¸ÕÅ窺¥Dn«ü¼Ð©M¦¸n«ü¼ÐªºType I Error, Type II Error, and p-value ! «ÂI¦b±±¨îÁ{§É¸ÕÅ窺¥Dn«ü¼Ð©M¦¸n«ü¼ÐªºType I Error, Type II Error, and p-value ! 1.FDA Multiple Endpoints in Clinical Trials Guidance for Industry www.fda.gov/files/drugs/published/Multiple-Endpoints-in-Clinical-Trials-Guidance-for- Industry.pdf 2.°]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ß¦ÒFDA¨î©w¤§ Draft Guidance for Industry: Multiple Endpoints in Clinical Trials (2017)¨î©w¡uÁ{§É¸ÕÅç¦h«ÀË©w¦Ò¶q¡v«ü¾Éì«h¡A§@¬°Á{§É¸ÕÅç³]p»P³W¹ºªº«n°Ñ¦Ò¨Ì¾Ú¡C www.cde.org.tw/Content/Files/Knowledge/%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E5%A4%9A%E9%87%8D%E6%8C%87%E6%A8%99%E4%B9%8B%E7%B5%B1%E8%A8%88%E6%8C%87%E5%B0%8E%E5%8E%9F%E5%89%87_%E7%AC%AC%E4%B8%80%E7%89%88.pdf ¦¸n«ü¼Ðªº¥¿¦Vµ²ªG¡A¶È¦³¦b¥Dn«ü¼Ð®a±ÚªºÀø®Ä¤w¸gÀò±oÃÒ©ú®É¤~¥i¸ÑŪ 3.¬ü°êFDA¡uÁ{§É¸ÕÅç¦h«µû¦ô«ü¼Ð«ü¤Þ¯ó®×¡v¤¤¤åª© www3.cde.org.tw/Content/Files/Knowledge/068bfcb1-e8d9-4b17-857e-13c08a3159a8.pdf |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/27 ¤U¤È 12:53:45²Ä 2263 ½g¦^À³
|
ªñ´Á°ê¤H¦ÛÄ@ÀË´ú¯×ªÕ¨xª¢¡A¿©±w²v³º°ª¹Fªñ7¦¨¡AÂå¥Í¹w´ú¨x¯×ª¢±N¬O°ê¯f¡CÁö¤£¯àµø¬°±`ºA¦ý¤@©w·|¶WÅD¦¶¸³¹w¦ôªº2¦¨5¡F¦Ó2¦¨5¦ô¥@¬É¿©±w²v¼ç¦b°Ó¾÷¹F7¤d7¦Ê»õ¬ü¤¸¡A¦]¦¹¨x¯×ª¢¥ÎÃÄ¥«³õ«D±`¤j¡F§Æ±æ¦n¥Î§Ö³tÀË´ú¤èªk¥[³t6¨t¬ãµo¡AÅýÀuµ¥¥Í¶W³t¡I¥[ªo¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 08:56:23²Ä 2262 ½g¦^À³
|
¶¢²áVERU ªñ´ÁªÑ»ùªí²{¤£¨Î¥i¯àì¦]? 2022.7.8: ½æªÅ¶°¹ÎCulper Researchµoªí¤F¤@¶µ·s¤ÀªR¡A¹ï¨ä³¡¤ÀÁ{§É¸ÕÅç¼Æ¾Ú´£¥X½èºÃ¡C www.fool.com/investing/2022/07/08/why-veru-stock-got-dented-today/ -------------------------------------------------------------------------------------------------- µ²½×:1.Àò±oDSMBªº«Øij´£¦µ²§ôÁ{§É¸ÕÅç¡A¶i¦æ¸Ñª¼¡C 2.5¤ë10¤éÁ|¦æFDAªº±¹ï±°Q½×·|ij¡AFDA¨S¦³n¨D´£¨ÑÃB¥~¼Æ¾Ú¥B·í¤Ñ´N«ØijVERU»¼¥æEUA¥Ó½Ð¡C 3.6¤ë7¤éVERU«Å¥¬°e¥XEUA¥Ó½Ð «¥»{¬°¹LÃö¾÷²v~100%¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 06:30:15²Ä 2261 ½g¦^À³
|
·í»¡´N»¡¤£¥Î¿ß°_¨Ó! ¤§«e»EµJ¦b°ê¹©¥Ó½ÐPRE-EUA meeting¦A¤T©µ¿ðªº®É¶¡©Ê¡AµÛ¹ê¨S¯d·N¨ìFDA©xºô¦³¬q[Requests for Type B and Type B (EOP) meetings will be honored except in unusual circumstances.Generally ]¡A·N§YFDA³q±`¤£·|©Úµ´Type B»PType B (EOP)ªº·|ij¥Ó½Ð¡C ---------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³ ..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦bÓ¤H): www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 06:22:25²Ä 2260 ½g¦^À³
|
FDA¤£·|¦Û¥´¼L¤Ú¡A¹O¶V¦ÛqªºÁ{§É«ü¾É³W©w: ªvÀøCOVID-19ªºÃĪ«À³±Ä¥Î[Àu®Ä©Ê³]p]ªº [ÀH¾÷]¡B[¦w¼¢¾¯¹ï·Ó]¡B[Âùª¼]Á{§É¸ÕÅç¶i¦æµû¦ô¡C ºK¦Û°ê¹©¦Û®aªº¦õÃÒ¸ê®Æ: °ê¹©¥Í§ÞÁ{§ÉÂå¾Ç³¡³¯¨Ø©gÂå®v(¼B¸³¤k¨à?)«ü¥X¡A°ê¹©ªº·s«aªÍª¢´ÁÁ{§É¬O¥¿¦¡ªº¤G´ÁÁ{§É¡A§¹¥þ²Å¦X¬ü°êFDA µo¥¬©ó2020¦~5¤ëªº·s«aªÍª¢Á{§É«ü¾É³W©w¡A°w¹ïÃļt¶}µo·s«aªÍª¢ªºªvÀø©M¹w¨¾ÃĪ«¤Î¥Íª«»s¾¯ªº«ü¾É¡A³W©w¶·±Ä¥Î[³Ì°ª¯Å]???ªº³]p¡A¤]´N¬OÁ{§É¸ÕÅ窺³]p¥²¶·¬°[ÀH¾÷]¡B[Âùª¼]¡B¦Ó¥B[¦³¦w¼¢¾¯¹ï·Ó]ªº¸ÕÅç¡A¤~¬O¥\®Ä©ÊÅçÃҳ̥i«HªºÃÒ¾Ú¡A«áÄò¤~¥i½×¤Î¥Ó½Ð¬ü°êºò«æ¨Ï¥Î±ÂÅv(EUA) ----------------------------------------------------------------------------------------- FDA·s«aªÍª¢Á{§É«ü¾É³W©wì¤å: FDA strongly recommends that drugs to treat COVID-19 be evaluated in randomized, placebo-controlled, double-blind clinical trials using a [superiority design]. ¦Ó [superiority design]¬O³Ì°ª¯ÅÁÙ¬OÀu®Ä©Ê? 3ºØÁ{§É¸ÕÅç³]p: Àu®Ä©Ê¡]superiority¡^¸ÕÅç:¦b©óÃÒ¹ê·sÃĤñÂÂÃÄ¡]©Î¦w¼¢¾¯¡^¦³®Ä¡A¥H«K©ó¥H·sÃĥΨӨú¥NÂÂÃÄ¡C µ¥®Ä©Ê¡]equivalence¡^¸ÕÅç:·s¡BÂÂÃĮĬ۷í¡A¦¹ºØ¬ã¨s³]p±`³Q®³¨Ó»P¡u«D¦H©Ê¸ÕÅç¡v¤@°_°Q½×¡C «D¦H®Ä©Ê¡]non-inferiority¡^¸ÕÅç: ¥Øªº¦b©óÀË©w·sÃÄÀø®Ä¦Ü¤Ö¤£¿éÂÂÃÄ¡AÅýÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃĪ«¡Aµ¹¤©¬Û¦P¯e¯f¤§¤£¦P±wªÌ¡C µ²½×: ÃĪ«¸ÕÅçÀø®Ä«ÜÅãµÛ¡ADSMBªº«Øij¡A¸Ó¬OVERU»P¥_·¥¬Pªº´£¦µ²§ôÁ{§É¸ÕÅç¡A¶i¦æ¸Ñª¼¡C «¥¤p½¼¦ÌÁÙ·í¤£¤F§ßÀs¤ý¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/24 ¤W¤È 08:02:40²Ä 2259 ½g¦^À³
|
§ó¥¿:2006¦~µÜ´µ¤º½×¤å¬Oµo¦b³»¦y´Á¥Z¡mNature¦ÛµM¡n¤W¡A²{¦b¥t¤@³»¦y´Á¥Z¡mScience¬ì¾Ç¡n½ðÃz½×¤å¥i¯à³y°²¡C ³y°²³¡¤À¬O§âWestern blot½Æ»s¶K¤W¡A£]¾ý¯»¼Ë³J¥ÕÁÙ¬O¦³¨Ç¤H«½Æ°µ±o¥X¡C ¨Æ¥ó¸òÁú°ê¶À¬ê¿üªº½Æ»s·F²ÓM³y°²(§O¤H¨Sªk½Æ»s«²{µ²ªG)¦³©Ò¤£¦P¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/24 ¤W¤È 07:30:45²Ä 2258 ½g¦^À³
|
2022.7.22 ¬ì¾Ç¬ÉÅå¤ÑÁà»D¡I ªü¯÷®üÀq¯gÃöÁä½×¤åºÃ³y°² »~¾É¥~¬É16¦~ ...½ðÃzµÜ´µ¤º½×¤åªº¤j¶q¹Ï¤ù¥i¯à³y°²¡AY½T¹ê¦p¦¹¡A¨º»ò¾Ç¬É¹ï©óªü¯÷®üÀq¯gªº¬ã¨s¤è¦Vµ¥©ó¬O³Q»~¾É¤F16¦~¤§¤[¡C µ²½×:[·L]׹Ϫí«Ü¥¿±`°Ú¡C¦ýµo¦b³»¦y´Á¥Z¡m¬ì¾Ç¡nªº«¤j»P·N¸q¥i´N¤£¤@¼Ë! --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/23 ¤U¤È 10:56:57²Ä 2257 ½g¦^À³ ¥Ñª¢¯g¤¶导ªºCYP2E1ªº变¤Æ¦b[¨x]内ªº调±±Éó¨î¤w较为©úÚÌ¡A¦ý¬O对[¤¤枢内] CYP2E1ªº变¤Æ±¡úG¬ã¨s较¤Ö¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/23 ¤U¤È 10:56:57²Ä 2257 ½g¦^À³
|
¥Ñª¢¯g¤¶导ªºCYP2E1ªº变¤Æ¦b[¨x]内ªº调±±Éó¨î¤w较为©úÚÌ¡A¦ý¬O对[¤¤枢内] CYP2E1ªº变¤Æ±¡úG¬ã¨s较¤Ö¡C ------------------------------------------------------------------------------------------- 2016¦~ 脑CYP2E1参ÉO¯×¦h¿}诱导ªº¯«经¤¸损伤 html.rhhz.net/ZGYLXTB/html/201607010.htm ¬ã¨s´£¥Ü¡A©¬ª÷´Ë¯f¡Bªüûدý®üÀq¯f¡B¦h发©Êµw¤Æ¡B¦Ùµä缩侧¯Áµw¤Æ¯gµ¥¯«经°h¦æ©Ê¯e¯fªº¯f²z¥Í²z学§ï变ÉO«ù续ªºª¢¯g¤Ï应过µ{±K¤Á¬Û关[1-3]¡AµM¦Ó¨ä¯f²zÉó¨î©|»Ý²`¤J¬ã¨s¡C 细M¦â¯ÀP450¡]cytochrome P450¡ACYP¡^¶W®a±Ú酶¨t参ÉO内·½©Êª«质¡]¦p¯×ªÕ»Ä¡B维¥Í¯À¡B胆»Ä¡^©M¥~·½©Êª«质¡]¦p药ª«¡B¬rª«¡B«ePÀùª«¡^ªº¥N谢¥¢¬¡¤Î¬¡¤Æ¡CCYP¶W®a±Ú酶¨t虽¥Dnªí达¦b¨x脏¡A¦ý¤]ªí达¤_¨x¥~¾¹©x¡A¦p脑¡C¦bCYP亚«¬¤¤¡ACYP2E1³J¥ÕªÅ间结Ìۨ㦳¥i变©Ê¡A ...¦Ó°ªªí达CYP2E1¥i¥[«LPS©ÒP¯«经¤¸损伤¡C¥Ø«e¡A¥Ñª¢¯g¤¶导ªºCYP2E1ªº变¤Æ¦b¨x内ªº调±±Éó¨î¤w较为©úÚÌ¡A¦ý¬O对¤¤枢内CYP2E1ªº变¤Æ±¡úG¬ã¨s较¤Ö¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/23 ¤U¤È 10:48:06²Ä 2256 ½g¦^À³
|
ªñ¦~¨Ó¡A²ÓM¦â¯À P450 酶 (CYP) ªº«n©Ê¤w¶W¥X¨ä¦b¨xŦ¤¤ªº§@¥Î??? CYP2E1 ¬O¤@ºØ¤½»{ªº°Ñ»P¦UºØ¤º·½©Ê©M¥~·½©Êª«½è¥NÁªº³æ¥[®ñ酶¡A¦b¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö«nªº§@¥Î¡C CYP2E1ªº [¹Lªí¹F]¦ü¥G¹ï¦h¤ÚÓi¯à¯«¸g¤¸¦³®`¡C ---------------------------------------------------------------------------------- 2021.07.29 www.eurekaselect.com/article/116960 I´º¡Gªñ¦~¨Ó¡A²ÓM¦â¯À P450 酶 (CYP) ªº«n©Ê¤w¶W¥X¨ä¦b¨xŦ¤¤ªº§@¥Î¡C¿ò¶Ç¡BÀô¹Ò¬r¯À¡BÃĪ«¥Íª«Âà¤Æ©M¼ç¦b¯e¯fµ¥¦]¯À¤¶¾É¤F³o¨Ç酶ªºªí¹F¡C¦b CYP 酶¤¤¡ACYP2E1 ¬O¤@ºØ¤½»{ªº°Ñ»P¦UºØ¤º·½©Ê©M¥~·½©Êª«½è¥NÁªº³æ¥[®ñ酶¡A¦b¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö«nªº§@¥Î¡C CYP2E1 ªºªí¹F¦b¤£¦Pªº¤j¸£°Ï°ì¤¤¦³©Ò¤£¦P¡A¨Ï±o¬Y¨Ç°Ï°ì¤ñ¨ä¥L°Ï°ì§ó¯Ü®z¡C CYP2E1 ªí¹F¬O¥i»¤¾Éªº¡A¥¦²£¥Í¾ÉP®ñ¤ÆÀ³¿E¡B½u²ÉÅé¥\¯à»Ùê©M³Ì²×¯«¸gÅܩʪº²Õ´·l¶Ë¦Û¥Ñ°ò¡C ¥Øªº¡G¹ï CYP2E1 ¦b¤¤¼Ï¯«¸g¨t²Î¤¤ªº§@¥Î¤F¸Ñ¸û¤Ö¡A¦]¦¹¥»¬ã¨sªº¥Øªº¬O±´°Q»P©¬ª÷´Ë¯f¬ÛÃöªº CYP2E1 酶ªºªí¹F»P¬¡©Ê¤§¶¡ªºÃö«Y¡A¨Ã½T©w CYP2E1 ªºªí¹F¬O§_¼W¥[¡C»P¯«¸g°h¤Æ¦³Ãö¡C ¤èªk¡G¥»¬ã¨sªº¥Ø¼Ð¬O³q¹L±Ä¥Î¤@ºØ«D¨t²Îªººî¦X¤åÄmºîz¤èªk¨Ó¹ê²{ªº¡A¦b¸Ó¤èªk¤¤¡A¤åÄm³Q©w©Ê¤ÀªR¡B§å§P©Êµû»ù¡A¨Ã´£¥X¤F¤@ºØ¹ï¾÷¨î¦³¾ãÅé¬Ýªkªº·s²z½×¡C µ²ªG¡Gµo²{ CYP2E1 ¦b©¬ª÷´Ë¯fµo®i¤¤ªº°^Äm¬OÅãµÛªº¡A¦]¬° CYP2E1 ªºt±¼vÅT±»»\¤F¨ä«OÅ@©Ê¸Ñ¬r§@¥Î¡C µ²½×¡GCYP2E1ªº¹Lªí¹F¦ü¥G¹ï¦h¤ÚÓi¯à¯«¸g¤¸¦³®`¡A¦]¦¹¡A¬°¤F§JªA³o¤@ÂI¡A»Ýn¦X¦¨¥Í¤Æª«½è¡A³o¬°¶i¤@¨B¬ã¨s©M¶}µo¦³»ùȪº¥Íª«¤À¤lçE¥¤F¹D¸ô¡C |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/22 ¤W¤È 11:59:54²Ä 2255 ½g¦^À³
|
¨ºÓ¦a¤Ñ®õ§â·|²£¥ÍºÒ±Æªº¦³¾÷¼o±óª«§Ö³tµo»Ä(3¤p®É)¬°¦³¾÷ªÎ¡A¥i¥H©TºÒ¡A§â®ðºAºÒ©TºÒ¦^¤gÄ[¡A¤S¯à°ö¨|¦a¤O¡A«e´º¬Û·í¤£¿ù¡C µ¥·Å«Ç®ðÅé´î¶q¤ÎºÞ²zªk×¥¿¯ó®×¹L¤F¡A¦³ºÒÅv¥i¥H½æ¡A´N¦³»¤¦]¤j¦¨ªø¡C enews.epa.gov.tw/DisplayFile.aspx?FileID=26E59EF644F21D93 |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/22 ¤W¤È 11:53:30²Ä 2254 ½g¦^À³
|
roger¤j. ¥Ã¥Í²ÓM¤]¬O¤£¿ùªº¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/21 ¤U¤È 08:47:42²Ä 2253 ½g¦^À³
|
2022.7.21Æp¥Û¥Í§Þ7/25µn³°¿³Âd ¥Ø¼Ð°ö¨|¦h®a¥Í§Þ¿W¨¤Ã~ ...Æp¥Û¥Í§Þ¦@¦³ 10 ®aÂà§ë¸ê¤½¥q¡A°£¤F¦X¤@¡BÁÞ°ò¥~¡A¸ô¤Õ©ú¬Ý¦n¡A¤U¤@¶¥¬q¥HªYÄ£¥ÍÂå»P¥Ã¥Í²ÓMªº¦¨ªø©Ê³Ì¨ü´Á«Ý¡AªYÄ£¬°·sÃĶ}µo¤½¥q¡A§Y±N±q¿³ÂdÂà¤WÂd¡B¥Ã¥Í²ÓM»P¦a¤Ñ®õ¹A·~¥Í§Þ¤]¦³¾÷·|¦b©ú¡B«á¦~¶i¤J¸ê¥»¥«³õ¡C ------------------------------------------------------------------------------------------------- ¸ô¤Õ©ú¬Ý¦n¡A¤U¤@¶¥¬q¥HªYÄ£¥ÍÂå»P¥Ã¥Í²ÓMªº¦¨ªø©Ê³Ì¨ü´Á«Ý???? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/20 ¤U¤È 09:09:34²Ä 2252 ½g¦^À³
|
·Q¾x±oº¡«°·«BÁÙ¬O¥ÀR¸¨¹õ? ¼Æ¾Ú¥æªk°|¤½¶}»{ÃÒ? Âd¶R¤¤¤ßµL¥¢Â¾? |
|
|
·|û¡G±iÄ£¤¯10152866 µoªí®É¶¡:2022/7/20 ¤U¤È 07:38:56²Ä 2251 ½g¦^À³
|
§A²ö¦W¨ä§®¡A¦bªYÄ£³oÃä¡A³y°ê¹©ªºÁÁ¡I ¦s¤ß¤£¨}¡A¤p¤ß¦V°ê¹©ÀËÁ|§A¡I |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/7/19 ¤U¤È 03:05:02²Ä 2250 ½g¦^À³
|
¹ï©ó¥Í§Þ¤p¼t¨Ó»¡ ¦æ¾P¬O«Ü§xÃøªº ¤j¼t¦´N§G«Ø³q¸ô nµØÃĪº¦æ¾P¦ÒÅç¤~èn¶}©l ¥Ø«eªºÀ禬¬O¤£¬O¥ª¤â´«¥k¤â¡H ©|«Ý¥¼¨ÓªºÅçÃÒ¡I |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/19 ¤U¤È 02:05:31²Ä 2249 ½g¦^À³
|
¯à¼W¸êÂX¤j§Q¼í¬OÓ¤H«ä¦Ò¸ô½u¡A¦Ü©ó§xÃø«×¹ê¦b¤£²M·¡¤]¤£À´¡F¥»ª©¦Ü²{¦b³£¨S¦³¤H»¡ªYÄ£·|¬OªÑ¤ý¡A¤j®a³£¥H¥i¯à¬OªÑ¤ý¹w¦ô²q´ú¡C¨ä¹ê¥|ÁûÃĶW¹L10»õ¬ü¤¸¹w¦ô¬Û·í«O¦u¡A®M¤W°ê»ÚºâªkªÑ»ù´N¬O2000¤¸¡A¥ú¾a±ÂÅv´N¬OªÑ¤ý¡FY¥H¤À¼íª÷¦ôªÑ»ù§ó°ª¡CY¥H§ë¸ê¨¤«×¬Ý¡AÃĵØÃĬO«Ü¬Ý¦n¨S¿ù¡A¦ý§ë¸ê³ø¹S²vªYÄ£¥i¯à°ª«Ü¦h¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/19 ¤U¤È 12:13:25²Ä 2248 ½g¦^À³
|
ªYÄ£±N¨ÓY¯à¦A100¤¸¼W¸ê10»õ¤¸¦@Äw¸ê100»õ¤¸¡A¥H¥R¸Î¸êª÷¨«¦V¦Û¤v³c°â¤§¸ô¡A«K¯àÀ½¨§ó°ª§Q¼íÃļt¤§¦C¡A´Á«Ý¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/19 ¤W¤È 10:03:20²Ä 2247 ½g¦^À³
|
Æ[¹î¦¹ª©µo¨¥ªÌ¡A¤£¥~¥G2ºØ¥i¯à©Ê:¤@¦³ªYÄ£¡A¤G¦³°ê¹©¡C ¶À°êÛÃã¥ô¸³¨Æ¡AEUA¨Æ¥ó¦pªG¾ÉP¨p¶Ò¤£¦¨ ¡A°ê¹©¦ó¥h¦ó±q? ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/21 ¤W¤È 08:11:06²Ä 2130 ½g¦^À³ ¤é ´Á¡G2022¦~06¤ë20¤é ¤½¥q¦WºÙ¡G°ê¹© (4132) ¥D ¦®¡G°ê¹©¸³¨ÆÃã¥ôº[¸³¨ÆÅܰʹF¤G¤À¤§¤@ ------------------------------------------------------------------------------------ ¦M¨o!!! |
|
|
·|û¡G§d°ê¥°10151930 µoªí®É¶¡:2022/7/19 ¤W¤È 09:31:52²Ä 2246 ½g¦^À³
|
ªYÄ£½Íªº¬O±ÂÅvª÷ ¥ú¾Ì³o¤@ÂI´Nn·í¤WªÑ¤ý¨º¬O¤£¥i¯àªº¨Æ 6446¥L¬O¥þ²y¿W¤@µL¤Gªº¦åÀù¥ÎÃÄ ¦Û¤vª¾¹D¦Û¤v¾P°â ¥L·í¤WªÑ¤ý¤ñ¸û¦³¾÷·| |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/19 ¤W¤È 06:46:00²Ä 2245 ½g¦^À³
|
1.CYP®a±Úªº±ÂÅv®×¡A³æ³æñ¬ùª÷´N®³¤F2.9»õ¬ü¤¸(Á`¨½µ{ª÷¤£ª¾)¡A[¤Û·Q]SNP¨t¦CªºCYP2E1§í¨î¤]¯à¬Ý»ô! 2.«Dªü¤ù类镇µh·s药JMKX000623 ¦b¤j¤¤华区¥H¥~ªº开发¡B¥Í产¤Î°Ó业¤Æ权§Q¡A预¥I´Ú1500ÉE欧¤¸¡A总权¯qª÷数额¥i观 ------------------------------------------------------------------------------------------------ 2022.7.13--2.9亿¬ü¤¸预¥I´Ú¡IÀq§J©M Orion «Å¥¬´N ODM-208 (CYP11A1) ªº开发©M°Ó业¤Æ开®i¥þ²y¦X§@www.phirda.com/artilce_28325.html?cId=1 ...ªñ´Á¡AOrionÉO济¥Á¥i«HºX¤U¤l¤½¥q¤W®ü济·Ô达¦¨¤@项独®a¦X§@协议¡A获±o¤W®ü济·Ô¦Û¥D¬ã发ªº«Dªü¤ù类镇µh·s药JMKX000623 ¦b¤j¤¤华区¥H¥~ªº开发¡B¥Í产¤Î°Ó业¤Æ权§Q¡A预¥I´Ú1500ÉE欧¤¸¡A总权¯qª÷数额¥i观 ªñ´Á¡AOrionÉO济¥Á¥i«HºX¤U¤l¤½¥q¤W®ü济·Ô达¦¨¤@项独®a¦X§@协议¡A获±o¤W®ü济·Ô¦Û¥D¬ã发ªº«Dªü¤ù类镇µh·s药JMKX000623 ¦b¤j¤¤华区¥H¥~ªº开发¡B¥Í产¤Î°Ó业¤Æ权§Q¡A预¥I´Ú1500ÉE欧¤¸¡A总权¯qª÷数额¥i观 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/18 ¤U¤È 12:42:05²Ä 2244 ½g¦^À³
|
FDA COVID-19ÃĪ««ü«nwww.fda.gov/media/137926/download FDA ¡§±j¯P«Øij¨Ï¥Î [Àu®Ä©Ê] ³]pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B[Âùª¼] Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z ----------------------------------------------------------------------------------------- ·s«aÃĪ«Á{§É¸ÕÅç·ÓFDA«ü«n³]p:ÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡BÂùª¼»P¨Ï¥Î¼Ð·ÇÅ@²z¡A¨º»ò¼Æ¾Ú¹F¼Ðn¨D´N¬O[Àu®Ä©Ê]! ¤£À´[Àu®Ä©Ê]? ¸Û¤ß«Øij»·Â÷·sÃħë¸ê! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/18 ¤U¤È 12:34:36²Ä 2243 ½g¦^À³
|
¬Ý¨ì¤@Ó¤£¿ù¦a°ÝÃD¡A ¤âÄo¦^µª¤@¤U! ¦Ü©óµoÃÒ¸Ô²Ó²z¥Ñ¡A¦³¿³½ì¦Û¤v¬d¡A§K±o¨S§¹¨S¤F! --------------------------------------------------------------------------------------------- Q:¦P¾Ç·|¦³¤H°Ý¦³Á{§ÉpȤj©ó0.05~0.5¡A FDA¤´µMµ¹ÃÄÃÒ¡BEUAªº®×¨Ò¶Ü¡H A:«¥¦³¤@ÓPÈ0.06·L¤j©ó0.05¡AFDAµoµ¹ÃÄÃÒ¦a®×¨Ò¦p¤U¡A ¨S¬Ý¹LµoEUA¦a! 1. 2020.12.12 www.fiercepharma.com/marketing/where-do-you-stand-fda-reviewers-argue-for- novartis-entresto-committee-meeting-file FDA staffers highlighted that the result¡¦s p-value, at 0.06, is ¡§only slightly above the 0.05 target¡¨ to achieve statistical significance, hinting that they¡¦re willing to give that miss a pass. 2.2021.2.17 ¤ß°I«½S®ø®§¡I¬ü国FDA§åã诺华Entresto(诺ªY§´)¡Gªv疗®g¦å¤À数«O¯d¤ß¤O°IºÜ(HFpEF)ªº药ª«! news.bioon.com/article/6784283.html Entresto¬O²Ä¤@个¤]¬O°ß¤@¤@个³Q§åã¥Î¤_ªv疗«ü«n©wú媺¤ß¤O°IºÜ±wªÌªºªv疗¤èªk¡A¥]¬A®g¦å¤À数°§Cªº¤ß¤O°IºÜ±w ªÌ¡]HFrEF¡^©M®g¦å¤À数°§Cªº¤ß¤O°IºÜ±wªÌ¡]HFpEF¡^¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/15 ¤W¤È 07:54:51²Ä 2242 ½g¦^À³
|
¤£²Å¦XFDAªºCOVID-19ÃĪ««ü«nªº¸ÕÅçµ²ªG(¤£¨ãÀu®Ä©Ê»P«DÂùª¼)¡A¥Ó½ÐEUA´N¬O½t¤ì¨D³½! °ê¹©¥Í§ÞÁ`¸g²zĬ¸g¤ÑÂÔ·Vªí¥Ü¡A·|¥ý¦VFDA¥Ó½Ð¡uPre-EUA¡vªº·|ij¡C³oÓ³Qµø¬°¥Ó½ÐEUA«e [¿Ô¸ßªº¦æ°Ê].... [¿Ô¸ßªº¦æ°Ê][¿Ô¸ßªº¦æ°Ê][¿Ô¸ßªº¦æ°Ê] VS. ¦pªG¸Á»e¸ÕÅç°e¥X¤å¥ó¥Ó½ÐPRE-EUA meeting[¿Ô¸ßªº¦æ°Ê]¡A¨Ì©x¤è¤å¥ó¦¬µo³W©w¡A¤@¼ËµoӤ帹µ¹±z¡Aªí¥Ü¦³¦¬¤å¥ó¡C µM«áFDAªº¼f¾\¤H¥´¶}¸ê®Æ®Éªºµe±-->ÀY¤W¯Q¾~¸¹L¡A¸£¸ÌXXX¡C ÀH«áµo¥÷[COVID-19ÃĪ««ü«n]¥s±z¦n¦n¬ãŪ¡A§O½M·d! ------------------------------------------------------------------------------------------------ FDA COVID-19ÃĪ««ü«nwww.fda.gov/media/137926/download FDA ¡§±j¯P«Øij¨Ï¥Î [Àu®Ä©Ê] ³]pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B[Âùª¼] Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/14 ¤W¤È 10:25:18²Ä 2241 ½g¦^À³
|
«¥¦³¬ö¿ýªº! ¨ä¹êFDA¦³CTAP¡]«aª¬¯f¬rªvÀø¥[³tpµe¡^¡A¥[³t¼f¬d¦b24¤p®É¤º§Y¦^ÂÐ(±ÀÂ_Veru¬O¦b24¤p®É¤º±o¨ìFDA¦P·N¶}·|) ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 04:11:11²Ä 2212 ½g¦^À³ ¥u¦³¼Æ¾ÚÁà¤~·|ÂÃþÓ±³þÓ©È别¤Hª¾¹D!!! ¼B¸³¦b¸Ñª¼°OªÌ·|»¡n¥Ó½ÐEUA¡A¦A±À°U¤£°e¥ó¡A§ë¸ê¤H¤@©w·|´£§i! ±µ¤U¨ÓFDA¦b21¤Ñ¤º·|µ¹¥X¦P·N©Î¤£¦P·N¶}pre-EUA meeting¡A³o³õEUA¾x¼@¤]´N¸¨¹õ¤F¡C ¤§«á¨p¶Ò¸U¤@¨S¦¨¡A³o®a¤½¥q¤j·§´N¥h¤F¤F! ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³ ¡§³Õ¾Ç¤§¡A¼f°Ý¤§¡A·V«ä¤§¡A©ú¿ë¤§¡A¿w¦æ¤§¡¨ ..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦bÓ¤H): www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda |
|
|
·|û¡G¦N¦Ì¦Ï10000583 µoªí®É¶¡:2022/7/14 ¤W¤È 10:19:05²Ä 2240 ½g¦^À³
|
R¤j¡A§Aªº®É¶¡ÂI¦ü¥G¤ñ¸û¼e¤j³á¡Aªþ¤WS¤j¤À¨Éªº¸ê°T Suggested dates and times (e.g., morning or afternoon) for the meeting ( «Øij·|ijªº¤é´Á©M®É¶¡¡]¨Ò¦p¡A¤W¤È©Î¤U¤È¡^) TYPE B Meeting ªº³W©w Confirmation of scheduling : 21 days ( ½T»{®É¶¡ªí : 21 ¤Ñ ) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/14 ¤W¤È 10:17:18²Ä 2239 ½g¦^À³
|
¸Á»e¸ÕÅç¼Æ¾ÚÅã¥ÜÀu®Ä©Ê¹F¼Ð¡A«¥¬°¦ó»¡¸Á»eÁ{§É¥Ó½Ð¤£¤FEUA ¡C ÃöÁä´N¦b¸Á»eÁ{§É¤£¬OÂùª¼(¸Á»e¤ôªº¨ý¹D¤ÓÃø±»¹¢¤F)¡AOpen-label¤£²Å¦XFDAªºCOVID-19ÃĪ««ü«n¡C ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/22 ¤W¤È 09:09:37²Ä 1809 ½g¦^À³ ...2020.5.11 FDA COVID-19ÃĪ««ü«nwww.fda.gov/media/137926/download ...FDA ¡§±j¯P«Øij¨Ï¥Î [Àu®Ä©Ê] ³]pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B[Âùª¼] Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z¡C ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/16 ¤U¤È 08:08:06²Ä 1599 ½g¦^À³ °ê¹©¼B³Ó«i:¦ý¬O¤W¬ü°ê°ê®a½Ã¥Í¬ã¨s°|NIHºô¯¸¥h¬d¡A°ê¹©³Q®Öã¶i¦æªº·sÃÄAntroquinonol¤G´Á¸ÕÅç´N¦b¤W±¡C¡v ±¹ï¥~¬Éªº¤@¨Ç§åµû¡A¼B³Ó«iªí¥Ü¡A¥L»Ýn¹ï¥~»¡©ú¡A¸ÕÅç¤H¼Æ¯à¤£¯à¦³¥Nªí©Ê¡A´N¬ÝFDA¬O§_³q¹L®ÖãÅý°ê¹©¶i¦æ¤G´Á¸ÕÅç¡AÃĪ«¦³¨S¦³®Ä¡A´N¬ÝFDA¬O§_¦P·NÅý°ê¹©¨ú±oEUA¡C ---------------------------------------------------------------------------------------------------- ¯º¸Ü! ¦bÄY«¯f¨Ò¤¤,¸Á»e¥ÎÃIJկf¨Ò¦b²Ä10¤Ñ¥X°| PK °ê¹©¥ÎÃIJժºªvÀø®É¶¡ÁYµu¤F9.5¤Ñ¡C §Ú¤]¥i¥H»¡¸Á»eÀø®Ä¹F¼Ð¡A°ê¹©¨S¦³¤½¥¬§¹¾ã¼Æ¾Ú¡A´N¬O¤½»¡¤½¦³²z¡A±C»¡±C¦³²zªºª§°õ¤£¤U¡C (¸Á»eÁ{§É¥Ó½Ð¤£¤FEUA) ¸Á»e³Q®Öã¶i¦æªvÀø·s«aªÍª¢Á{§É¤]¦bNIHºô¯¸¡A¤£¶È¬O¤T´Á¡A¹ï·Ó²Õ¼Æ¾Ú³£¦³! ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/5 ¤U¤È 04:14:55²Ä 1548 ½g¦^À³ °ê¹©«ç¤£´£¨Ñ¹ï·Ó²Õ¼Æ¾Ú? ©³¤U¸Á»e©M¶ÂºØ¯ó¡]¤]ºÙ¬°¶Â§¶µM¡^3´ÁÁ{§É¸ê®Æ(µLªk½Æ»s¶K¤W«¥¤j·§¼g¤@¤U): »P¹ï·Ó²Õªº7¤Ñ»P13¤Ñ¬Û¤ñ,µo²{¥ÎÃIJզb¤¤¦Ü«¯g¯f¨Ò¤¤¤À§O¦b4¤Ñ»P6¤Ñ¤º½w¸Ñ·s«a¯gª¬(P<0.0001)¡C »P¹ï·Ó²Õ¬Û¤ñ,¥ÎÃIJզb¤¤¦Ü«¯g¯f¨Ò¤¤ªº¯f¬r²M°£¤]´£¦4¤Ñ¡C ¥ÎÃIJÕÁÙ°§C¤F«¯g¯f¨Òªº¦º¤`²v(P=0.029) ¦b¤¤«×¯f¨Ò¤¤,96.26%ªº¤¤«×¯f¨Ò±wªÌ¦b²Ä10¤é«ì´_¤é±`¬¡°Ê,¦Ó¹ï·Ó²Õ¬°68.93%¡C ¦bÄY«¯f¨Ò¤¤,¥ÎÃIJկf¨Ò¦b²Ä10¤Ñ¥X°|,¦ÓÆ[¹î¨ì¹ï·Ó²Õ¤´»Ý¦í°|ªvÀø»P»Ýn®ñ®ð¡C ¹ï·Ó²Õªº30¤Ñ¦º¤`²v¬°18.87%, ¦Ó¥ÎÃIJլ°4%¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/14 ¤W¤È 08:57:06²Ä 2238 ½g¦^À³
|
1¶g¤F¡A¾÷²v³Ñ94%¡C ¥Ó½ÐPRE-EUA¯Âºé¬OÀ³¥I1/5¸Ñª¼¦¨¥\»P6¤ëªÑªF·|ªºµªÂСA¦ý¼B¸³¦b1¤ë5¤é»¡ªº[¸Ñª¼¦¨¥\]±N¥Ó½ÐEUA·|¦p¦P²î¹L¤ôµL²ª??? PÈÂÃþÓ±³þÓ¬OnÃhL10Ó¤ë¤~¥Í±o¥X¨Ó??? --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤W¤È 09:36:36²Ä 2204 ½g¦^À³ ...¤£¤NÃø¼B¸³¡A¯à»PFDA¶}pre-EUA meeting¾÷²v¡A©ú¤é°_ºâ1¤Ñ´î1%¡Aº¡¦Ê¤é«h¾÷²v¬°0¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 10:35:36²Ä 2237 ½g¦^À³
|
2022.7.12 «ôµn¬F©²±N©µªø COVID ¬ðµo¤½¦@½Ã¥Í¨Æ¥ó 7/15 PHE¨ì´Á100%®i©µ¡A¿ïÁ|«á¤~µ²§ôPHE¡C ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/25 ¤W¤È 08:48:35²Ä 2140 ½g¦^À³ ¿ï²¼¦Ü¤W!!! 2022.6.23 «ôµnªº¤ä«ù²v³sÄò²Ä¥|©P¤U°¡A³Ð¤U¾ú¥v·s§C ³o¬O¤@Óĵ§i«H¸¹¡Aªí©ú¥L©ÒÄݪº¥Á¥DÄÒ¥i¯à¦b 11 ¤ë 8 ¤éªº¤¤´Á¿ïÁ|¤¤¥¢¥h¹ï¬ü°ê°ê·|ªº±±¨î¡C 7/15 PHE¨ì´Á~100%¦A®i©µ¡A¿ïÁ|«á¤~µ²§ôPHE¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 09:52:26²Ä 2236 ½g¦^À³
|
¦³¤Ö¼Æ¤p¤À¤lÃĦX¦¨¨BÆJ¦h¥B²£²v·¥§C¡A¦¨¥»°ª©ó¤j¤À¤lÃÄ!(SNP-630«ÜÃø¦X¦¨!!!) ¨Ò¦p: µµ§ü¾Jì®Æ»ù®æ±qè¶}©lªº¨C¤½§J¤K¦Ê¬ü¤¸¡A·Æ¸¨¨ì¥Ø«eªº¤T¦Ê¬ü¤¸...¡C 2021.8.4àF´£·ÒªvÀùª«½è¡uµµ§ü¾J¡v§lª÷¤W»õ¤¸¡@¤ÑÀº¥Í§Þt³d¤H§P¦D©wù©www.ettoday.net/news/20210804/2047435.htm ¶}µo¤¤°ê®aªº§åµo¦¨¥»¨C100²@§J¬ù¬°7.06¦Ü13.48¬ü¤¸(*10¿=70.06~130.48/§J)¡A¦Ó¦b^°ê«h¬ù¬°66.85^Âé¡]¬ù88¬ü¤¸*10¿=880¬ü¤¸/§J¡^¡C VS. ¤j³W¼Ò¥Í²£®É¡A³æ®è§ÜÅ骺¥Í²£¦¨¥»³q±`§C©ó¨C§J100¬ü¤¸ VS. ®Ö»Ä¾AÅé¥i¥H©T¬Û¦X¦¨§Þ³N¥Í²£¡A¥Í²£®É¶¡¬ù¼Æ¤p®É¡A¥Í²£¦¨¥»¨C§J¶È50¬ü¤¸ ------------------------------------------------------------------------------------------------- ·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/10 ¤U¤È 03:59:31²Ä 2220 ½g¦^À³ ¥t¥~SNP³£¤p¤À¤lÃĪ«¡A¦¨¥»À³¸Ó¨ã¦³¶W¯Å¤jªºÀu¶Õ¡C ---------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/5/7 ¤U¤È 05:44:04²Ä 1099 ½g¦^À³ Q2:ª¾¹DSNP-630«ÜÃø¦X¦¨¡A»s³y¦¨¥»¨s³º¦h°ª? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 08:56:07²Ä 2235 ½g¦^À³
|
¨S¦³¹ï·Ó²Õ¬Ý¤£¥X¼Æ¾Ú®t²§! 1.®Ú¾Ú²Îp¼Æ¾Ú¡A¥þ²y¦@¦³4.44»õNASH±wªÌ¡C VS. 2.¨Ì·Ó¥@¬É½Ã¥Í²Õ´¡]WHO¡^¦ôp¡A¥þ²y¨C¦~¬ù¦³300¦Ü400¸U¤H·P¬VC«¬¨xª¢¯f¬r¡A¬ù¦³1.3¦Ü1.7»õ¤H¤f±w¦³ºC©ÊC«¬¨xª¢¡C VS. 3.®Ú¾Ú¥@¬É½Ã¥Í²Õ´2019¦~ªº¦ôp¡A¥Ø«e·R´þ¯f±wªÌ³Ì¦hªº¦a°Ï¬O«D¬w¦a°Ï¡A¥þ²y¦³¶W¹L3,800¸U¤H·P¬V¤F·R´þ¯f¬r¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 08:47:50²Ä 2234 ½g¦^À³
|
¬ü°êNASH±wªÌ±q800¸U¤H§ó·s¬°1700 ¸U¤H 1.¦Ü¤Öªá8.7»õ¬ü¤¸ªºBI¡A¤j¼Æ¾Ú¦¬¶°: ®Ú¾Ú²Îp¼Æ¾Ú¡A¥þ²y¦@¦³4.44»õNASH±wªÌ¡A¥Ø«e©|¥¼¦³¥i¦æªºªvÀø¤è®×¡Cwww.boehringer- ingelheim.tw/nash 2.½÷·çºô¶:...¬ü°ê¬ù¦³ 1700 ¸UNASH±wªÌ ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/8/19 ¤W¤È 08:27:20²Ä 288 ½g¦^À³ 4.2019-07-03 Boehringer Ingelheim»PÁú°êYuhanñq8.7»õ¬ü¤¸¦X¦P---[Á{§É«e] ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/10 ¤U¤È 10:49:57²Ä 2221 ½g¦^À³ ...C¨x¦b¬ü°ê¬ù1%ªº¤H¿©±w(400¸U)¡A«D°sºë©Ê¯×ªÕ¨xª¢NASHªº¤ñ¨Ò°ª¹F2%+(¬ü°ê´N¦³600~800¸U¤H»ÝªvÀø)¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/7/12 ¤W¤È 07:54:11²Ä 2233 ½g¦^À³
|
Ó¤H¤]Æg¦P²{¦b¬OªÅÀY¥«³õ¡A«X¯Q¾Ôª§¦s¦b¥¨¤jªºÅܼơC ¿ú¬O¦Û¤vªº¡A¨º¸Ì¸Ó¶R¸Ó½æ¥»´N¸Ó¦Û§Úµû¶q¡C 170¤¸ªºªYÄ£¤W§ð¦³5¤d±i¦¨¥æ¶q¡A²{¤µ¥¼¥X²{¹L2¤d±i¡C ¥ú¦¨¥æ¶q´N©úÅ㤣¨¬¡A¦ó¨Óªºª£¡H°£«D¦n®ø®§¤w²{¡Aª½±µ¸õ¹L¡C ²{¤µ¡A®ÉªÅI´º¤S¤£¦P¤F¡A¦ó®É¤~¥X²{¡u¨}¾÷¡v¨S¤H»¡ªº·Ç¡C ÁÙ¬O¶Ì¶ÌªººCºCµ¥¡AÄ~Äò°µ¬ü¹Ú¡C |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2022/7/12 ¤W¤È 01:59:18²Ä 2232 ½g¦^À³
|
¦³¨Ç¤H¯u¬O¤õ®ð«Ü¤j ®ð¼P¼P ¤£ª¾¹D¦b®ð¤°»ò §Ú¥u¬O»¡ªÅÀY¥«³õºÉ¶q§C±µ ¤£°l°ª §Ú¨SÁ¿¡§§CÂI¡¨³o2¦r§a ¿ú¬O¡§·Q¡¨¥X¨Óªº¡H§Ú¥uª¾¹DªÑ»ù¬O¿ú°ï¥X¨Óªº ´I¶Q¡§ÀI¡¨¤¤¨D¡H§Ú¤ñ¸û³ßÅw´I¶Q䤨D §Ú¤£¬O¨S²¼ªº»Ä»Ä §Ú«ùªÑªYÄ£ ±q2x¨ì²{¦b ¤§«eª£¨ì§Ö180¤S«ç¼Ë Á{§É¨S¤jÅD¶i ¤j¼t¤]¤£Ã±¬ù ÁÙ¤£¬O±o¦^¨Ó §ÚÁÙ¯u´Á«Ý«Ü¦h´I¤H¥Î·Qªº §âªÑ»ùª£¨ì1000 §Ú³o½a¤H·|«Ü¼Ö·N½æµ¹´I¤H |
|
|
·|û¡G¤p«Óô10152857 µoªí®É¶¡:2022/7/11 ¤U¤È 11:57:04²Ä 2231 ½g¦^À³
|
®@Åý§A»~·|¤F,§Ú¤£¬O¦b¦^À³¦V¤j~ ¥u¬Oı±o¬Y¼Ó«Ü§®,¶R½æªÑ²¼ÁÙ»Ýn¤H´£¿ôÅý§Ú¤£¸T¯º¤F ¦³¨S¦³nª£.¦³¨S¦³ÃD§÷,©|»Ý®É¶¡ÃÒ©ú |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2022/7/11 ¤U¤È 10:44:03²Ä 2230 ½g¦^À³
|
¦V¤jµL»Ý¤¶·N¡A²ö¦W¨ä§®¼J¿Ø§¹§O¤H¦A¸É¤@¥y¦@«j¤§¶W¯ÅµL¨¥ªº¡K |
|
|
·|û¡G¤p«Óô10152857 µoªí®É¶¡:2022/7/11 ¤U¤È 10:31:13²Ä 2229 ½g¦^À³
|
«¢«¢«¢,§CÂI??10¤¸¶Ü?? ´²¤á¹w´Á¤ß²z´N¬OªÅÀY¥«³õ ¦bªÅÀY¥«³õ«o¯à¤@ª½©¹¤Wöt? §A«ç»ò·Q?? ¿ú¬O·Q¥X¨Óªº,´I¶QÀI¤¤¨D,¦³¿ú¤H©M½a¤HªºÆ[ÂI¥Ã»·¤£¦P ³o¤]´N¬O¬°¤°»ò½a¤H´N½a¤@½ú¤l,´I¤H¦b®À±Ñ«á©¹©¹ÁÙ¬O´I¥i¼Ä°ê ¦@«j¤§~ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/7/11 ¤U¤È 09:43:26²Ä 2228 ½g¦^À³
|
¶R¥Í§ÞªÑ¥»¨Ó´N¸Ó¦Û¦æ¿Å¶q·ÀI ÃĵØÃĦ³¥¦ªº½æÂI ªYÄ£¦³¦Û¤vªº½æÂI ·Qªø§ë¡B·mµu¡B§C±µ¡A¥ô§g¿ï¾Ü¡C ªYÄ£ªº810¡B610¦³¦Û¤vªº°ò¥»±¦b ¥«³õ¦Û·|¤ÏÀ³¸Ó¦³ªº»ùÈ |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2022/7/11 ¤U¤È 05:53:12²Ä 2227 ½g¦^À³
|
ªÅÀY®É´Áª£¥Í§Þ¶Ü ¨º±on¦³ÃD§÷ 6¨t¦CÁ{§É¶i«×ÁÙ¦b2b ¨ÖÁʥثe¨S¸ñ¶H 8¨t¦C¥Î¤w®³¨ìªºotcÃÄÃÒ§ð¬ü °£«D¤j¼tñ¬ùª½±µ®³¥¦ªºÃÄ¨Ó½æ ¤£µM§Ú¬Ý·¥«×Ãø ¤j¼t²{¦b¤]¨S«æ¢©Ê §O¬ÝÃĵإثe¥»¯q¤ñµL¤j ¥¦ªº¥¼¨Ó¥Ø«e¬O¬Ý±o²M·¡ªº ªYÄ£¥Ø«e«h¬OÂaÄg¬ü ¦b³oºØ±¡ªpµwª£ ¥i¯à¹ï¤w«ùªÑ¤j¤á¤]¤£¬O¦n¨Æ ³o¬O§ÚÓ¤H¤p´²¤á±qªÑ»ùÆ[ÂI¨Ó¬Ý¦Ó¤w |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/11 ¤U¤È 02:17:55²Ä 2226 ½g¦^À³
|
¥»¨Ó·Q¥Î®ã¤õ¥[½X¡A·Q»¡ªÅÀY¤]nª£ªÑªº¡A¥Í§Þ¦nµo´§ Å¥¯È¤jªº¡A§Ú85¥X¤@¨Ç¦n¤F¡A¤£µM¤S¬O¯È¤W´I¶Q ================================================== §ÚÓ¤H¬O»{¬°¦³¿³½ì§ë¸êªº¤H ÁÙ¬OºÉ¶q§C±µ¬°ì«h ²¦³º6¨t¦CÁ{§ÉÁÙ¦b2b °£«D¦³¤º½u ª¾¹D¥¦·|³Q¨ÖÁÊ ¦ý©Z¥Õ»¡¬Ý°_¨Ó¥Ø«e¨S³o²{¶H ¦Ó8¨t¦C°£«D2¤j¼t¤¤¨ä¤¤¤@¼t«Å§Gñ¬ù ¨Ã¥Î8¨t¦C¥þ±´À´«ÂÂÃÄ ¤£µM¾a8¨t¦CnÁÈ¿ú ¤]¬O»»»»µL´Á ¦b¥Ø«eªÅÀY¥«³õ ÁÙ¬O¯à§C±µ´N§C±µ |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2022/7/11 ¤U¤È 01:38:18²Ä 2225 ½g¦^À³
|
§ÚÓ¤H¬O»{¬°¦³¿³½ì§ë¸êªº¤H ÁÙ¬OºÉ¶q§C±µ¬°ì«h ²¦³º6¨t¦CÁ{§ÉÁÙ¦b2b °£«D¦³¤º½u ª¾¹D¥¦·|³Q¨ÖÁÊ ¦ý©Z¥Õ»¡¬Ý°_¨Ó¥Ø«e¨S³o²{¶H ¦Ó8¨t¦C°£«D2¤j¼t¤¤¨ä¤¤¤@¼t«Å§Gñ¬ù ¨Ã¥Î8¨t¦C¥þ±´À´«ÂÂÃÄ ¤£µM¾a8¨t¦CnÁÈ¿ú ¤]¬O»»»»µL´Á ¦b¥Ø«eªÅÀY¥«³õ ÁÙ¬O¯à§C±µ´N§C±µ |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/11 ¤W¤È 11:55:43²Ä 2224 ½g¦^À³
|
·sÃĤñ¥É®i®t??¾~¤ùÃþ¦¨Å}??¤Ó¤£È¤F!!!!!¥[ªo§r |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/11 ¤W¤È 11:10:00²Ä 2223 ½g¦^À³
|
µ²ªGÁÙ¬OBBQ¤F¡A¦³¥´¦^¦A±µ¡I³q¸ô¥ý¥X¤@¥b¤F!²KÂI®ã¤õ |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/11 ¤W¤È 09:44:05²Ä 2222 ½g¦^À³
|
¬Ý¨ÓÁÙ¬O¦P¾Ç¨º§Q®`¡A¤@©I¦Ê±i ³o¨½ÁÙ¬O¤Ó§N²M¡A¨S¥D¤O¬Ý |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/10 ¤U¤È 10:49:57²Ä 2221 ½g¦^À³
|
GLP1¦³¤@ݤGÅU¡AºN¸Ä¥Jݬ~¿ÇªºÀuÂI¡A¤£¤ÖNASH±wªÌ¤]¬O¿}§¿¯f±w¡A³o®ÉGLP1ÃÄ´N¬Oº¿ï¡C ³æ³æ±q±wªÌ¤H¼Æ»PªvÀø®É¶¡¬Ý¥«³õ¡ANASHºC©Ê¯f¤j©óC¨x(ªv¡)ÃĪ«¥«³õ! C¨x¦b¬ü°ê¬ù1%ªº¤H¿©±w(400¸U)¡A«D°sºë©Ê¯×ªÕ¨xª¢NASHªº¤ñ¨Ò°ª¹F2%+(¬ü°ê´N¦³600~800¸U¤H»ÝªvÀø)¡C ¬ü°êªº«D°sºë©Ê¯×ªÕ¨x¯fNAFLD(¥¼¨ÓªºNASH±wªÌ)¡A¿©±w²v§ó°ª¹F30%~40%¡C ---------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 01:35:37²Ä 2163 ½g¦^À³ ...¥¼¨ÓNASH»â°ì¯à¥´±o¦h¤õ¼ö? ¥i¥H°Ñ¦Ò´X½gC¨xÃĪ«ªº¬G¨Æ: |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/10 ¤U¤È 03:59:31²Ä 2220 ½g¦^À³
|
²{¦b³o»ù®æÀ³¸ÓSNP8¨t¦C´NȤF¡C SNP610ªºPH2b§@§¹¤j·§«á¦~¡Aè¦nNASH¤õÃz°_¨Ó¡A¥un°Æ§@¥Î¤p¤S¦³®Ä¡A¤£©È¨S¤Hn¡C ¥t¥~SNP³£¤p¤À¤lÃĪ«¡A¦¨¥»À³¸Ó¨ã¦³¶W¯Å¤jªºÀu¶Õ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/10 ¤U¤È 02:51:24²Ä 2219 ½g¦^À³
|
Intercept·Q¤jº¡³e¨úÃÒ¡A´N¬OnÁpÃĪvÀø! °ê¥~±À¦ôOcaliva¦bF2~F3®³ÃÒ¾÷²v60%(«¥¥[1¤À=¤C¤À¾a¥´«÷) F4ªºREVERSE study¦bQ3·|¥X¨Ó(¦]¨x¬r©Ê¡AF4®³ÃÒ¾÷²v§C=3¤À¤Ñª`©w=¤Hºâ¤£¦p¤Ñºâ) ----------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/7 ¤U¤È 12:23:54²Ä 1938 ½g¦^À³ ¦pªG§Ú¬OIntercept¤½¥qCEO¡A¦b®³¨ì²Ä1±iNASHÃÄÃÒ«á¸êª÷¤ô¦ìº¡·¸¡AnµÛ¤âOcalivaªº¤U¤@¥N·sÃÄ(§ó¨ã¦w¥þ©Ê»PÀø®Ä)¡A ¨º»òª½¨úSNP-630§@ÁpÃĶ}µo´N¬O³Ì¨Î³Ì§Ö³t¿ï¶µ¤§1 ! ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/7 ¤W¤È 10:02:17²Ä 1935 ½g¦^À³ FDA¹ïOcalivaªººÃ¼{¦b¦w¥þ©Ê(¨x¬r)! Ocaliva +SNP-630ÁpÃĦ³ÅãµÛªº¨ó¦P§@¥Î¡AOcaliva ¾¯¶q°§C¡AÀø®Ä»P¦w¥þ©Ê§ó°ª§ó¨Î! |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/7/10 ¤U¤È 02:00:52²Ä 2218 ½g¦^À³
|
GLP1©MFGF21 ¹vÂIªºÃÄ¡A¥Ø«e¦³¤j¤À¤l¤Î¤p¤À¤lÃÄ¡C¤j¤À¤l³q±`³£¬Oª`®g¾¯«¬¡A³oºØ¥ÎÃĤ覡¦b¤j¶q¥B»Ýªø´Á¨Ï¥ÎªººC©Ê¯f¨Ó»¡¡A¸û¤£°Q³ß¡A°£«DÃĮīD±`«D±`ÅãµÛ¥[¤W»¡ªø¶g´Á¡A»¤¦]¥i¯à·|¤j¤@ÂI¡C GLP1©MFGF21Y§ï¦¨¤p¤À¤l(¤fªA)¡A¥ÍÅé¥i§Q¥Î²v·|¤U°¡A©Ò¥H¦PÀø®Ä¤U¾¯¶qªÖ©wn¥[¤j¡A¦ý¦¹Á|°Æ§@¥Î·|§ó©úÅã¡A©Ò¥H SNP-6 ¨t¦CY°Æ§@¥Î»´·L«Ü¾A¦X»P GLP1©MFGF21 ¤p¤À¤lÃIJզX¥ÎÃÄ¡A¦p¦¹¥i´î¤Ö GLP1 ©M FGF21 ¤p¤À¤lªº¥Î¶q¡A¥H°§C°Æ§@¥Î¡A¦P®É¦h¹vÂIªvÀø¥[¼¤]¯à´£¤ÉÀø®Ä¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/10 ¤W¤È 09:27:33²Ä 2217 ½g¦^À³
|
KRAS¦´Á´ºªp¦p¦PNASH²{¤µªº«Í¾î¹M³¥¡AÅý§ë¸êªÌ»D¤§¦âÅܤ£´±§ë¸ê...µM«áFDA®Öã²Ä1¤äÃĪ«¥«ªp¦A¤«¼Q¡C «ø¥Ø¥H«Ýµ¥FDA®Öã²Ä1¤äNASHÃĪ«¡A¤ÞÃzNASH»â°ì!!! ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 01:35:37²Ä 2163 ½g¦^À³ ·í²Ä¤@ÓNASHÃĪ«¤W¥«¡ANASH»â°ì´N·|¯u¥¿ªº¤õÃz°_¨Ó¡C ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/1 ¤W¤È 11:22:42²Ä 1762 ½g¦^À³ ¥h¬Ý¬Ý¦b¥þ²yº´ÚKRAS¹v¦V药AMG-510(Sotorasib)¾_¾Ù¤W¥««á¡AKRASÅܦh¼öªù!(ÁÙ¦³¤@°ïÁ{§É«eªº¨S¯B¤WÂi±) 从¤£¥i¦¨药¨ì¬ã发¦¨ªG¡§¤«喷¡¨¡A细说KRAS www.drugtimes.cn/2021/10/29/congbukechengyaodaoyanfachengguojingpenxishuokras/ ---------------------------------------------------------------------------------------------- ¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1¶ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/1 ¤W¤È 11:01:40²Ä 1761 ½g¦^À³ DGAT1´¿¬O¥D¬y¹vÂI¡AKRAS¤§«e¤]¬O¸ó¤£¹L»Ùê¡A¤]³Q»{¬°¤£¯à¦¨ÃÄ¡C ²{¦b¤S¤@°ïÃĪ«¹v¦VKRASÅo! |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/10 ¤W¤È 05:11:03²Ä 2216 ½g¦^À³
|
Âà¶K¡A¸òroger¥Sªº¨£¸Ñ¤@P. ---------------------------------------- #·sÃĪѰò¥»±¤ÀªR-¥HªYÄ£SNP6¨t¦C·sÃĬ°¨Ò ¡¯¤@¼Ë¾ã¦¨¤@½g¤è«K¤j®a¾\Ū¦¬ÂáC ¡¯¥t¸É¤FJ¥®®E°|¤h¹Î¶¤µo©ú¨ú¥N¨x¬¡Åé¤Á¤ùÀË´ú¨xÅÖºû¤Æµ{«×ªº¥Íª«§Þ³N¤º®e¡C ¤@¡B°ò¥»ª¾ÃÑ (¤@)·sÃĪѸò¤@¯ë²£·~ªº¿ïªÑÅÞ¿è³Ì¤j¤£¦P¡A§Ú¦bÆä¥ÎªYÄ£¨Ó§@¨Ò¤l¡A±qÀY¨ì§À¥Ü½d¤@¤U«ç»ò¿ï¦³·dÀYªº·sÃĪÑÆ妳¤À¨É¤F¡A½Ð¥ý¬Ý¡A§Ú³oÃäºK¿ý¦p¤U¡G 1.¦¨¥\²v ³o¨Ç¥i¥H¥Î¾÷Âà§@¥Î¡BÁ{§É¸ÕÅçµ²ªG¡B°ê»Ú¤jÃļt±ÂÅv®ø®§¤Î¦³¿ú¤H§ë¸ê¤JªÑµ¥µ¥¡A¨Ó§PÂ_³o¤ä·sÃĬO§_¦³¸û¤jªº¦¨¥\²v¡A¨ä¤¤«e¤GÓ¬O·sÃIJ£·~¬O³ÌÁ¿¨sªº¬ì¾Ç¤Î¼Æ¾Ú¡A«á¨âÓ¬O»²§Uªº¡A¦]¬°°ê»Ú¤jÃļt¸ò¦³¿ú¤H¦³±Mªù¹Î¶¤¥ýµû¦ô¤F¡A¤ñ¤@¯ë¤H·V«¦h¤F¡C 2.¥«³õ»ùÈ ³oÓ¬O·sÃĪѸò¨ä¥L²£·~³Ì¤£¦Pªº¦a¤è¡A¦]¬°·sÃĪѥ»¨Ó´N¨SÁÙ¨S¦³À禬¡A§¹¥þ¤ñªº¬O·sÃĪº»ùÈ¡A¦Ó·sÃÄ»ùȬO¥Ñ·sÃĪº¬ãµo¶iµ{¤Î¥«³õ¦Ó©w¡C¦Ü©ó¥«³õ»ùÈ«ç»ò¦ô¡A¦³Ãöªº¦ôȤèªk¡Aº¡¤À¤j¤]¤À¨É¦bÆ亡¤À¤jªº¥Í§Þ·sÃĪѧë¸ê¿ïªÑÅÞ¿èÆå¡A¤]¥ý¥h¬Ý¡C (¤G)¹vÂI»P¾÷Âà ¦Ü©ó±yÃö·sÃĦ¨¥\²v¤Î¥«³õ»ùÈ´N¦b[¹vÂI(¹v¦V)]¡A¥²nn¹ï³oÓ¥ý¦³°ò¥»ª¾ÃÑ: 1.¤°»ò¬O¹vÂI¡H³oÓ¤j®a¥i¥H¥ý²ÂI²z¸Ñ¡A¤@¶µ¯f¡A³£¦³¥LªºP¯f¾÷Âà¯f²z¸ô³w¡A¦Ó·sÃĪº¹vÂI¡A´N¬On°w¹ï¬Y¶µ¯fªºP¯f¸ô³w¡A¥h§ä¬ÛÃö¹vÂI¡A³oÓ¹vÂI¥i¥H¤¤Â_P¯f¸ô³w¡A¥hªvÀø¬Y¶µ¯f¡C 2.¦P¤@ºØ¯f¡A¥i¥H¦³¤£¦P¹vÂIÃĪ«¥h¤¤Â_P¯f¸ô³w¡A©Ò¥H¦P¤@ºØ¯f¡A¥i¯à¤£¦P¹vÂIªº·sÃÄ¡A·N«ä¬O»¡¡A§A¤£¥un¬ã¨s§A§ë¸ê·sÃĤ½¥qªº·sÃĹvÂI¡AÁÙn¥h¬ã¨s¨ä¥L¤½¥q·sÃÄ°w¹ï¦P¤@¾AÀ³¯g¶}µoªº·sÃĪº¹vÂI¡C 3.¤£¦Pªº¹vÂI¡A¦³¤£¦P¾÷Âà§@¥Î¡A¤ñªº¬O¦w¥þ¸ò¦³®Ä©Ê¡A±`¨£²æ¹v¡]´N¬O³oÓÃĨS¦³¿ìªk°w¹ï¨º¹vÂIµo´§¥Î¡^©Î°Æ§@¥Î¡]³oÓÃĪº²æ¹v´Nºâ¤F¡AÁÙ§@¥Î¦b¨ä¥L¦a¤è¡A³y¦¨°Æ§@¥Î¡^¡C 4.¦³¨Ç¦³®Ä©Ê¤Î¦w¥þ©Ê¡An¬Ý¾AÀ³¯g¡A¦pªG¬On¤H©Rªº¯f¡A°Æ§@¥Î±j¤@¨Ç¡AFDA¥i¥H§Ô¨ü¡AÅý§A¤W¥«¡A¦ý¦pªG¬OºC©Ê¯f¡A°Æ§@¥Î¬OµLªk§Ô¨üªº¡C 5.¥t¥~¡A¤£¦P¹vÂIªº¤£¦P¾÷Âà¡A©Î³\¦³¥i¯à§@¬°ÁpÃĨϥΡA§Y¦P¤@¾AÀ³¯g¡A¥i¯àAÃĦ³®Ä©Ê°ª¡A¦ý¦³±j¯P°Æ§@¥Î¡A¦w¥þ©Ê¦³°ÝÃD¡F¦ý¢ÐÃĦ³®Ä©Ê¸û§C¡A¦ýµL°Æ§@¥Î¡A¦w¥þ©Ê¨S°ÝÃD¡C¨º³o®ÉÔ¡A¢ÐÃÄ´N¦³¾÷·|¡A§@¬°¢ÏÃĪº¨Ö¥ÎÃĨӪvÀø¦P¤@¾AÀ³¯g¡A¦]¬°BÃÄ¥i¥H°§C¢ÏÃĪº¾¯¶q¡A¦]¬°AÃÄ¥i¯ànªv¯fªº¬¡©Ê¦¨¤À¥Íª«§l¦¬²v¶W§C¡An¥Î¤j¾¯¶q¡A¦Ó¤j¾¯¶q¡A¤S·|³y¦¨±j¯P°Æ§@¥Î¡A©Ò¥H¢ÐÃÄ¥i¥H·f°tAÃĤ@°_¥Î¡A§ä¨ì¤@Ó¥i¥H±µ¨üªº¦³®Ä©Ê¤Î¦w¥þ©ÊªºÁpÃľ¯¶q¡C 6.¹vÂIªº¾÷Âà¡A´N¬O¦¨¥\²v¸ò¥«³õ»ùȪº©Ò¦b¡A¤]¬O°ê»Ú¦³Ãļtn¬ÝªºªF¦è¡C¹³¦X¤@¬°¤°»ò¦³¥Lªº°ò¥»»ùÈ¡A¦]¬°¥LªºÃĪº¹vÂI¡A³£¬O¤jÃĵ¥¯Åªº¡C ¤G¡B¤°»ò¬ONASH? (¤@)NASH¬O¤@ºØ¦]««×¯×ªÕ¨x¦Óµoª¢ªº¯f¡A¦]¬°Steatosis¯×ªÕ¹L«×°ï¿n¡A°l¦¨¨xµoª¢¡]inflammation¡^¡A¶i¦Ó³y¦¨¨x²ÓM·l¶Ë¡C (¤G)¨Å骺§K¬Ì¨t²Î§â³o¨Ç¦]¬°ª¢¯g¨ü¶Ëªº¨x²ÓM´«¦¨·sªº²ÓM¡A¥[³t¤F¨Åé§ó·s¨x²ÓMªº³t«×©M¦¸¼Æ¡C ¦pªG·sªº¨x²ÓM¨Ó¤£¤Î¸ÉÃa¦º¨x²ÓM¼Æ¶q¡A¨Åé´N·|¥ÎÅÖºû³J¥Õ¶ñ¥R¡A¤]´N¬OÅÖºû¤Æ¡C (¤T)ÅÖºû¤Æªº¨x²Õ´¥e¤F¨x²ÓM¦ì¸m¡A¨Ïªº¨x²ÓMÁ`ÅéÅܤ֤F¡AÁ`Åé¨xŦ¥NÁÂ¥\¯à¨ü·l¡C¥t¥~¼W¥[¤F¨x²ÓM§ó·s¦¸¼Æ¡A´N¨Ï±o¨x²ÓM¦b©T©w®É¶¡¤º°ò¦]¬ðÅܪº´X²v¼W¥[¡A¤]´N¬O¦³§ó°ªªº¨xÀù·ÀI¡C (¥|) NASH¶iµ{¶¥¬q¡A¥i¥H¤À¬° ¥¿±`¨x->¯×ªÕ¨x->ª¢¯gµLÅÖºû¤Æ¨x->¨xÅÖºû¤Æ¡A¨ÌÅÖºû¤Æµ{«×¤À¬°F1-F3¤T¯Å->¨xÅÖºû¤Æ¥[µw¤Æ¶i¤JF4¶¥¬q->¨xÀù¡C (¤)NASHÃĪ«¤T´Á¥DnÀø®Ä«ü¼Ð¤Î¸ÕÅç¥Ø¼Ð±Ú¸s (¬ü°êFDA¸ò¼Ú·ùEMA) 1. ¥DnÀø®Ä«ü¼Ð(end point) (1)¯×ªÕ©Ê¨xª¢®ø°h¡AÅÖºû¤ÆµL´c¤Æ(Resolution of steatohepatitis and no worsening of fibrosis.)¡C (2)ÅÖºû¤Æ±o¨ì§ïµ½¡A¯×ªÕ©Ê¨xª¢¨S¦³´c¤Æ(Improvement in fibrosis with no worsening of steatohepatitis) ¡C (3) ¤Wzªº¦@¦P¥Dn²×ÂI¦P®É¦³¡A©Î¨Ì¨ä§@¥Î¤è¦¡¡A¥i¥H¨Ï¥Î¨ä¤¤¤@Ó©Î¥t¤@Ó¡C 2. ¥Ø¼Ð±Ú¸s: ¬¡ÀË(§Y¶·¨xªº¬¡Åé¤Á¤ù)Ãҹꬰ¤¤«×/±ß´ÁÅÖºû¤Æ (F2/F3) NASH ±wªÌ(Patients with biopsy‐confirmed NASH with moderate/advanced fibrosis (F2/F3))¡C (¤»)NASH¬O¤@ºØºC©Ê¯f¡A¬ü°êFDA²M·¡ªí¥Ü¡A¤£¥i¯à±µ¨ü¦³ªø´Á°Æ§@¥Îªº·sÃÄ¡C (¤C)F4¶¥¬qªº¨xµw¤Æ¬°µLªk§ð§Jªº¸T°Ï¡A¨Ì¤Wz²{¦æNASHÃĪ«¥un¨D¯àªvÀøF2-F3ªºNASH´N¦n¡C¦ý¦pªG¥x±¤WªºNASH·sÃÄ¡A³sF4ªº¢ÜASH¨xµw¤Æ³£¦³ªvÀø®ÄªG¡A¥i¥H±±¨î©Î°fÂà¨xµw¤Æªº¶iµ{¡A¨º³o¤äÃÄ´NµL¼Ä¡Anµo¤j°]¤F¡C (¤K)F4¨xµw¤Æ¶¥¬q¡A¦³¤À¥NÀv©Ê¸ò¥¢¥NÀv©Ê¡A¥NÀv©Ê¨xµw¤Æªº¨xÁÙ¦³¤@ÂI§@¥Î¡AÁÙ¥i¥H¼µ¡A¦ý·|ºCºCÅÜ¥¢¥NÀv©Ê¡A¨ì¤F¥¢¥NÀv©Ê¨xµw¤Æ¡A¤j·§¨S¦h¤[´Nn¦A¨£¤F¡C ¤T¡B¹vÂI¤Î¾÷Âà (¤@)¤W½g¤S»¡¹L¡ANASHªºP¯f¾÷²z¸ô³wÃöÁä¦bÆä¨x¯×ªÕ°ï¿nÆåÆä¨xµoª¢Æå¤ÎÆä¨xÅÖºû¤ÆÆå¡A©Ò¥H¦³¥i¯à¤¤Â_NASHP¯f¹vÂI¥²¶·¬O§@¥Î¦bÆä¨x¯×ªÕ°ï¿nÆåÆä¨xµoª¢Æå¤ÎÆä¨xÅÖºû¤ÆÆå¤W±¡C (¤G)¨ä¤¤°¨x¯×ªÕ¬O³Ì²³æ¡A¦ý¬O¬O¶¡±µªº¡FªýÂ_¨xµoª¢ªº§ó¦n¡F¯àªýÂ_¨xÅÖºû¤Æ¡A¬ÆP¦b¥NÀv©Ê¨xµw¤Æ±¡§Î¯à°fÂàÅÖºû¤Æªº¡A§ó¬O¥þÅ|¥´¡C (¤T)²{¦b´N¥H¤W±¦U¶µ¤T¶µ¾÷Âà¡A¨Ó¤¶²Ð¥x±¤Wªº¦³·dÀYªº¥Nªí©Ê·sÃÄ¡]PH3§¹¦¨ªº¡B¶i¤JPH3§Y±N¶}¼úªº¡A¤Î¦bPH2b¶¥¬qªº¡^¡G 1. Áx»Ä¿E°Ê¾¯¡]¤½¥q:intercept¡^ ³oÓ¹vÂI´N§Q¥ÎÁx»Ä®ø¤Æ¯×ªÕªº¾÷Âà¡A©Ò¥H¥L¬O¤W±Á¿ªº°¯×ªÕªº¾÷ÂàÃþ«¬¡A¨Ã¤£¬O³Ì¦nªº¡C¥t¥~³oÓ¤w¸g¹L¤F¤T´Á¡A¦ý¬O¦b¥Ó½Ð¬üNDA®É¡A¦]¬°¥Íª«§l¦¬²v§Cªº¥i¼¦¡A¦Ó¥BÁÙ¦³¶W°ª¤ñ²vªº°Æ§@¥Î¡]æ±Äo¡B©Ô¨{¤l¤ÎLDL¤É°ªªº¤ß¦åºÞ·ÀI¡^¡A©Ò¥H³QCRL¥´ºj¤F¡C³oÓ·í®É³o®a¤½¥q¦]¬°¤T´Á¹L¥Ó½ÐNDA¥«È½Ä¨ì4000»õ¥x¹ô¡A¥i¨£NASHªº¥«³õ¦³¦h¤j¡C 2. Semaglutide¡A¹vÂIGLP1¡]¤½¥q: ¿Õ©M¿Õ¼w¡^ ³oÓ¬O¦ÑÃĤF¡A¿}§¿¯f©MªÎDªº¾AÀ³¯g³£§å¤F¡A³oÓ¥u¬O¿Õ©M¿Õ¼wªº¦ÑÃÄÂX¥R¾AÀ³¯g¡A²{¦b¦b¤T´Á§Y±N¶}¼ú¡AÀ³¸Ó¤T´Á·|¹F¼Ð¡C¬°¤°»ò©O¡A¦]¬°³oÓÃĤ]¬O°¯×¥ÎÃÄ¡A²z½×¤W¥un¦³°¯×®ÄªGªº¹vÂI¡A°ò¥»¤W³£¯à¦b¤@©wµ{«×§ïµ½NASH¯f¯g¡A¤£¹L³oÓ¾¯¶q¸ò°Æ§@¥Î¡A®£©È¦b¥Ó½ÐNDA®É¡A¤]·|¬OÓ°ÝÃD¡An¦b¬Ý¬Ý¡C 3. efruxifermin ¡A¹vÂIFGF21 (¤½¥q:Akero) ³oÓ¹vÂIFGF21¡A¤]¬O¦b½Õ±±¥NÁ¡A¤]¬O§@¥Î¦b¦å¿}¸ò¯×ªÕ¥Í¦¨ªº¡A©Ò¥H¥Lªº¾÷ÂàÁÙ¬O°¯×¡AÁÙ¬O¶¡±µªº¦³®Ä¡A³oÓ¤]¤T´Á¡A¤]§Ö¶}¼ú¡AÀ³¸Ó¤T´Á¤]·|¹F¼Ð¡A¤£¹L¤@¼Ë¦Ñ°ÝÃD¡A¾¯¶q¸ò°Æ§@¥Î¡A¤£ª¾¹D¡C 4. MGL-3196¡A¹vÂITHR-beta(¤½¥q:Madrigal) ³oÓ¬O§Q¥Î¥Òª¬¸¢¿E¯À¨üÅé£]¿E°Ê¾¯¡A¾÷Âà¬Ý°_¨Ó¤]¬O§í¨î¨xŦ¥Ìªo¤Tà¦X¦¨¡A¼W¥[¨xŦÁx©T¾J²M°£¡A´î¤Ö¯×½è¨I¿n¡A¦n¹³¤]¬O²Ä¤@¼hªº°¯×¡C³oÓ¤]¬O¤T´Á¡A§Y±N¶}¼ú¡A¤£¹L¤@¼Ë¾¯¶q¸ò°Æ§@¥Î°ÝÃD¡A³oÓ¦pªGª½±µ§@¥Î¨x¯×¡AÀ³¸Ó¾¯¶q¥i¥H¤Ö¤@ÂI¡A°Æ§@¥Î´N¥i¥H¤Ö¤@ÂI¡A³o¤äÃÄÀ³¸Ó¤ñ¸û¦³Àu¶Õ¡C 5. SNP610¡A¹vÂICYP2E1 + DGAT1 (¤½¥q:ªYÄ£) (1)²Ä¤@ÂI¹vÂICYP2E1¡G¦n¹³¬O°§C¨xŦ¤¤cytochrome P4502E1 (CYP2E1) ³J¥Õ½èªí²{¶q¡A¶i¦Ó´î½w¨xŦµoª¢ªº±¡§Î¡A©Ò¥H³o¬Oª½±µ¶i¨ì²Ä¤G¼hªº§Ü¨xµoª¢¡A¤½¥q¬O©xºô¬O³o¼Ë»¡ÆäSNP-6¨t¦C¥iª½±µ§í¨î¨xŦCYP2E1¬ÛÃö»Ã¯À¡B°§CCYP2E1¬ÛÃö°ò¦]ªºmRNA©M³J¥Õªí²{¶q¡A¨Ï±o·|¶Ë®`¨x²ÓM¡B»¤µoµoª¢¤ÏÀ³ªº¬¡©Ê®ñ¤Æª«½è(Reactive oxygen species, ROS)¤£¦A²£¥Í©Î°§C¡A¶i¦ÓªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢Æå¡C¤ñ«e±¨º¨Ç²Ä¤@¼h°¯×ªº¡A¨Óªºª½±µ¦³®Ä¡C (2)²Ä¤GÓ¹vÂIDGAT1¡G³oÓ¬O¤G酰¥Ìªo酰°òÂಾ酶¡A¬O¤TñQ¥Ìªo¦X¦¨³Ì«á¤@¨Bªº¶Ê¤Æ酶¡A¸ò¯×ªÕ¥NÁ¦³Ãö¡A§@¥ÎÀ³¸Ó¦b°¯×¡C¤£¹L³oÓ¹vÂI¦n¹³·|¦³¸¨«Ëªº°Æ§@¥Î¡A¤£¾å±oªYÄ£«ç»ò§â³oӰƧ@¥Î³B²z±¼¡A¤£¹L¬Ý¤½¥q³£¨S»¡¤G´Á¸ÕÅ禳°Æ§@¥Îªº¡A³oÓ¥i¯àn½T»{¡A¦pªG¨S°Æ§@¥Î¤]¬Onµo¤F¡C (3)³oÓªYÄ£ªºSNP6¨t¦C¡A¬Ý¹vÂI¾÷Âà¡A¬O¯à¦³Æä°¯×ÆåÆä§Üµoª¢Æå§@¥Î¡A¦ý¯«©_ªº¬OªYÄ£©xºô©~µM»¡:[ [SNP-610´Á¤¤¤ÀªR¦³¨xŦÅÖºû±½´y»öFibroscan data¡A°ò¦Ȱª(F4)ªº²Õ¡AªvÀø«e«á¦³ÅãµÛ®t²§¡C]©~µM³s²Ä¤T¼h[§Ü¨xÅÖºû¤Æ]¤]¦³§@¥Î¡A³oÓ´N°f¤Ñ¤F¡AnÁȤjµo¤F¡C (4)§Ñ¤F´£¡AJ¥®®E°|¤h¹Î¶¤¡A¦n¹³¦³¶}µo¥X¤@ºØ¤£¥Î¬¡Åé¨x¤Á¤ù´N¯à´ú¨xªºÅÖºû¤Æµ{«×ªº¥Í¤Æ§Þ¼Ð§Þ³N¡A³o¥NªíªYÄ£¹ï©ó¯f¤H¨xªºÅÖºû¤Æ±¡§Î¡A¤£¥Îµ¥¨ì¤T´Á§@§¹¨ú¯f¤H¨x¬¡Åé¤Á¤ù¡A´N¯à¥ýª¾¹D¨xÅÖºû¤Æ±¡§Î¡A«¢«¢«¢¡A¤j¤j¥[¤À¡C ¥|¡B¿ïªÑ ³oÓn¿ï·sÃĦ¨¥\²v°ªªº¡A·ÀI§Cªº ¡A¶·n¤j¶q°ò¥»±¬ã¨s¡A¥]¬A¡G (¤@)¾÷Âà§@¥Î 1.¥HªYÄ£¬°¨Ò¡A¥Lªº¾AÀ³¯g¬Oªv«D°sºë©Ê¯×ªÕ¨x(NASH)¡A²{¦b¤@¤G¤T´Á¦@¦³126ÓÁ{§É¸ÕÅç¡C 2.²Îªº¨Ó»¡¡A³o¨Ç126ÓÄvª§ÃĪ«ªº¾÷Âà¥iÂkÃþ¬°5¤jÃþ¡A¨ä¤¤¤T¤jÃþ³£¦³¦b¤@¡B¤G¡B¤T´Á¸ÕÅ祢±Ñªº¬ö¿ý¡A¦ÓªYÄ£ªºSNP6¨t¦C¤£¦b¨ä¤¤¡C 3.¦Ó¥BªYÄ£SNP6¨t¦Cªº¾÷Â঳¢±Ó¡A¤ñ¨ä¥LÄvª§ÃÄ¢±ª«¦h¤@Ó¡C (¤G)2´Á¸ÕÅçµ²ªG SNP6¨t¦C¤w¸g¤G´Á¡A¢ÞȪì¨BÅã¥Ü¨ã¦³·¥¬°ÅãµÛªº²Îp®t²§¡A¤w¸gªì¨BÃÒ©ú¦³®Ä©Ê¡C (¤T)°ê»Ú¤jÃļt±ÂÅv®ø®§ ³oÓ¦b¬YÓJ¥®®E°|¤h¼v¤ù¤¤¡AµL·N³zÅS¤F¥L̨ì°ê»Ú«e½B¤jÃļt½ÍSNP6¨t¦C±ÂÅvªº¨Æ¡Aªí¥Ü³o¤äÃĪº¾÷Âà§@¥Î¬OO¢Ùªº¡C (¥|)¦³¿ú¤H§ë¸ê¤JªÑ: ªYÄ£³Ìªñ¤@¦¸¼W¸ê¨p¹õ¡A¥Ñ´I¨¹½²©ú©¾ªº¤G®a§ë¸ê¤½¥q¡]¤Î¥L¦Û¤v)¤ÎÄ_¨Î¤ÖªFªL®a§»ªº§ë¸ê¤½¥q¡]¤Î¥L¦Û¤v¡^¦U¤JªÑ¤Fªñ10%¡AÁ`¦@ªñ20%ªºªÑ¥÷¡A¥L̨âÓ¬O¦³±Mªù§ë¸ê¹Î¶¤¦bµû¦ô§ë¿úªº¡A¥L̪º¤JªÑ»ù®æ¬O81¤¸¡A¨S¦³¤@©wµû¦ô¡A¤£¥i¯à¦¸¥á¨º»ò¦h¿úªº¡C (¤)ºî¤W¡AªYÄ£³o¤ä¦b·sÃÄ¥¢±Ñªº·ÀI¡A¤ñ¸û§C¤@ÂI¡C ¤¡B¦ôÈ (¤@)NASH¸¹ºÙ¬O³Ì«á¤@Ó¤j³W¼ÒºC©Ê¯f¥«³õ¡A«Ü¦h¥«³õµû¦ô¾÷ºc¡Aµû¦ô¤@¦~¦Ü¤Ö¦³350»õ¬üª÷¡A¦Ó¥B·|¦A¼W¥[¡C¬ü°êFDA´N¦b»¡¦]¬°NASH¬ü°ê¤@¦~ªá¶O200»õ¬üª÷¡C (¤G)¬Q¤Ñº¡¤À¤j¦³¤À¨É¹L¡A¤@¤äÃĪº¥«³õ»ùÈ¡A¦pªG¦³¥i¹ï¼Ðªº¤½¥q¨Ó¦ô¡A³Ì·Ç¡C¦³ÃöNASH¡A¨ä¤¤´¿¸g¦³¤@®a¤½¥qintercept ¥¦·í®É¤T´Á¸ÕÅç¹F¼Ð¡AªÑ»ù¼Q¨ì460¬üª÷¡AÁ`¥«È¨Ó¨ì4000»õ¥x¹ô¡C (¤T)¥H¤WÅã¥Ü¡AªYÄ£ªºSNP6¨t¦Cªº·sÃÄ»ùÈ·¥¬°Åå¤H¡A¥HªYÄ£²{¥«È56»õ¥x¹ô¡A³oÓ4000»õ¸ò56»õªº®t¶Z·¥¤j¡A¨ã¦³10¿¼É§Q¬ü¾Ç°ò¦]¡A»ù®tªÅ¶¡¶W¤j¡C (¥|)·íµM¡A¥«³õ¤j¡AÄvª§ÃĪ«´N¦h¡A¦ý¦bJ¥®¨j°|¤hªº¼v¤ù¤¤¡A¦³´£¨ìSNP6¨t¦C¦³¨ä¿W¯S¤G¶µ¾÷Âà¡A¸ò¨ä¥LÄvª§ÃĪ«¤£½Ä¬ð¡A¬O¥i¥H§@¬°ÁpÃĨϥΪº¡A§Y´Nºâ¦³¨ä¥LNASHÃĪ«¦¨¥\¡AªYÄ£ªºSNP6¨t¦CÃĪ«¡A¤´µM¥i¥H¨Ö¥Î¨ÓªvÀøNASH¡C³oªí¥ÜªYÄ£ªº¦w¥þ©ÊÀ³¸Ó«Ü°ª¡A¤~¯à¤£©È¦³°Æ§@¥Î¡C (¤)ªYÄ£ªºNASH·sÃÄ¥¿¦n³B¦b¥«³õ·¶³Åܦ⪺ÃöÁä®É´Á¡AÂi±¤W¨S¦³¦Û¤v¬ãµoNASH·sÃĪº°ê»Ú¤jÃļt¡Aµ´¹ï¤£¥i¯à©ñ±ó³o¶ô¤j»æªº¡A¤@©w·|§ä¦¨ªºNASH·sÃĤ½¥q½Í±ÂÅv©Î¨ÖÁʪº¡A¤£µM·|³Q»·»·¥Ï¶}¡C (¤»)³oÓNASH¥«³õ¤jªºÅå¤H¡A¥unÃĦ³®Ä¡A¦w¥þ©Êû{¡A®³ªº¨ìFDAÃÄÃÒ¡A´Nºâ¬O²Ä¢²Ó²Ä¢³Ó¶i¤J¥«³õ¡A¤´µM¬O¦Y¹¡¹¡¡A¤×¨äªYÄ£³oºØ¤~6»õ¸ê¥»ÃBªº¡C (¤C)ªYÄ£³o¤äªÑ¨ã¦³10¿¼É§Q¬ü¾Ç°ò¦]¡Aº¡¤À¤j¹ï©ó¤£¯à¦ôȪº·sÃĤ½¥q¡A³£¤£·|¶Rªº¡A¦]¬°¨S¦³¨¬û{ªº¼É§Q¡AµLªkcover·ÀI¡A©Ò¥H¿ï·sÃĪѺ«¦ôÈ¡A¨S¦³¿ìªk¦ôȩΦôȫܤpªº¡A´N¨S¤°»ò·dÀY¡Aº¡¤À¤j¨S¿³½ì¡C ¤»¡B¸êª÷¤À°t»P§ë¸ê«Øij (¤@)·sÃĪѥunÁÙ¨S®³¨ìÃÄÃÒ¥¿¦¡¤W¥«¡A³£¤£¯à¥þÀ£¡A¥u¯à¾a¸êª÷¤À°t¨Ó±±ºÞ·ÀI¡A¬Ý¤j®a¸êª÷³¡¤À¡A®³¶¢¿ú¨Ó§ë¡A§â³oµ§¿ú·íÁýª¯¡A¦³¿ú´NºCºC¶R¡C (¤G)«ù¦³´Á¶¡¡A¦³¥»¨Æ´N½Õ¸`¡A¨S¥»¨Æ¦³¿ú´N¶X§C»ù®ÉºCºC¶R¡A¤£n«æ¡A¦³·dÀYªº¼É§Q·sÃĪѡAȱoµ¥«Ý¡C (¤T)«O¯d¤@¨Ç¸êª÷¡Aµ¥½T»{«á«À£¡A¹³ÃĵءAÁÙ¦³¦X¤@ªºON101±ÂÅv¼t°Ó¬O¤£¬OSANOFI¡A¥un½T©w¬OÁɿյᨺ´N穏¤F¡C (¥|)¤£nÅ¥¥ô¦óªºÁÁ¨¥¡AÁÙ¦³¸£³UªÅªÅªºªÅx¡A¥un¶R¶i²z¥ÑÁÙ¦b¡AÁÙ¨S½T»{«e¡A¥Î¸êª÷¤À°t¨Ó±±ºÞ·ÀI´N¦n¡C |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/7/9 ¤W¤È 11:05:14²Ä 2215 ½g¦^À³
|
semaglutide ¦b¤G´ÁÁ{§É¡A¥u¦³¨xÅ֤ƥ¼´c¤Æ¦³¹F¼Ð¡A¨xÅ֤Ƨﵽ¨S¦³¹F¼Ð¡A¦Ó¥B³o¬O SC ¥ÎÃÄ¡A¨Ï¥Î¤W«Ü¤£¤è«K¡CÓ¤Hı±o¡A¤£¤Ó»ÝnÃöª` semaglutide ªº«áÄò¡C ÁöµM Ocaliva Á{§É¤T´Á¹F¼Ð¡A¦ý²Ó¬ÝÁ{§É¼Æ¾Ú OCA 25 mg n=308 22.4 % (At least one stage of fibrosis improvement with no worsening of NASH) ¡A 6.5% (with no worsening of liver fibrosis) ¡A¤G¶µ¥[Á`«á ¤j¬ù¬O 89¤H¹F¨ìÁ{§ÉÀø®Ä¡C´NºC©Ê¯f¨Ó¬Ý³o¼ËªºÀø®Ä¼Æ¾Ú¯uªº¤£¤ÓÀu¡A¦óªp¦b PBC ªvÀø¤WÁÙ¦³¥X²{¹LÄY«¨x·l¶Ë¾ÉP¦º¤`ªº¨Æ¥ó¡A§Ú·Q¡A³o¤]¬O¬°¤°»ò FDA ·|»¡¬Ý¤£¥X¯q³B( drug¡¦s benefit ¡§remains uncertain¡¨ and does not sufficiently outweigh its potential risks)ªº¥D¦]§a! NASH »Ýnªø´ÁªA¥Î¡A¦w¥þ©Êµ´¹ï¬O¸òÀø®Ä¦Pµ¥«n¡AOcaliva ³Ì«á·|¤£·|±o¨ì fda ªº«C·ý®³¨ìÃÄÃÒ¡A§ÚÓ¤Hı±o¬Oº¡´dÆ[ªº¡C ¸Ü»¡¦^¨Ó¡ANASH »Ýn¤@Ó FDA ÃÄÃÒ¡A¦p¦¹¤~¯à½T»{ FDA ªº¼Ð·Ç¬°¦ó¡A§_«h Ocaliva Á{§É¤T´Á¹F¼Ð¡A«oµLªk¨úªºÃÄÃÒ¡A³o·|Åý¥~¬ÉµL©Ò¾A±q¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/9 ¤W¤È 10:19:48²Ä 2214 ½g¦^À³
|
F4:¥NÀv©Ê¨xµw¤Æ»P¥¢¥NÀv©Ê¨xµw¤Æ(¤j·§¥u¦³´«¨x¤F) ªv¡C¨x¯«ÃĤ]Ãøªv¥¢¥NÀv©Ê¨xµw¤Æ¡C ----------------------------------------------------------------------------------- ¥þ¤fªAC¨x·sÃįǰ·«O(¥¢¥NÀv©Ê¨xµw¤Æ¡A¤£¯àªA¥Î¡^ www.liver.org.tw/journalView.php?cat=3&sid=32&page=2 ³o¨Ç¥þ¤fªAC¨x·sÃÄ [¬Û·í¦w¥þ]¡AÁקK²£¥Í¨x¬r©Ê(¥¢¥NÀv©Ê¨xµw¤Æ±wªÌ¤£¾A¥Î) ¡]1¡^½T©w¨xŦ´Ý¦s¥\¯à¬O¦bChild¤óA¯Å¡A¥ç§Y¬°¡u¥NÀv©Ê¡v¨xµw¤Æ¡]½Ð¨£ªí¤@¡Bªí¤G¡^¡A ¥B¹L¥h¤£´¿¦³B¯Å¤ÎC¯Å¤§¯f¥v¡]§YY¤w¦³¥¢¥NÀv©Ê¨xµw¤Æ¡A¤£¯àªA¥Î¡C¡^ ¡·¦p¦ópºâ¨xµw¤Æ¬OA¡BB¡BCþ¤@¯Å¡H ªí¤@¡BChild¤ó¨xŦ´Ý¦s¥\¯à¤ÀÃþªí |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 04:17:18²Ä 2213 ½g¦^À³
|
¤ð±e¹L¤À¾á¼~NASHÄvª§ªÌ¡A±z¦³°l®Ú¨s¬kªººë¯«¡A§âC¨xÃĪ«(ªv¡)¥«³õ¬Ý¤@¤U´N©ú¥Õ! ---------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 01:35:37²Ä 2163 ½g¦^À³ ·í²Ä¤@ÓNASHÃĪ«¤W¥«¡ANASH»â°ì´N·|¯u¥¿ªº¤õÃz°_¨Ó¡C°ê»Ú¤j¼t¨ì®É鹬°F¬Û争¡A¥Î¥L̪º¶¯«p°]¤O¦¬Áʤp¤½¥q(º®¯Î¤§§Q)¡C¥¼¨ÓNASH»â°ì¯à¥´±o¦h¤õ¼ö? ¥i¥H°Ñ¦Ò´X½gC¨xÃĪ«ªº¬G¨Æ: 1.www.gbimonthly.com/v11_2015/v11cover_2015_00.html 2.news.gbimonthly.com/tw/celebrity/show.php?num=18130 ²¦³ºNASH¬OÓ¥¨¤jªº¥¼¶}µoºC¯f¥«³õ!!! (JP:¦]¬°³oÓÃĪº¥«³õ¤Ó¤j¡A©Ò¥H§Ú¤£¥h·m²Ä1 ¤£·m²Ä2 ¤£·m²Ä3 §Ú·mÓ²Ä4³£¥i¥H«Ü¤j¤@¶ô.... )---³o¬q»¡ªkµ¥¦PC¨xÃĪ«¥«³õ²{ªp! www.facebook.com/watch?v=298211662214622 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 04:11:11²Ä 2212 ½g¦^À³
|
¥u¦³¼Æ¾ÚÁà¤~·|ÂÃþÓ±³þÓ©È别¤Hª¾¹D!!! ¼B¸³¦b¸Ñª¼°OªÌ·|»¡n¥Ó½ÐEUA¡A¦A±À°U¤£°e¥ó¡A§ë¸ê¤H¤@©w·|´£§i! ±µ¤U¨ÓFDA¦b21¤Ñ¤º·|µ¹¥X¦P·N©Î¤£¦P·N¶}pre-EUA meeting¡A³o³õEUA¾x¼@¤]´N¸¨¹õ¤F¡C ¤§«á¨p¶Ò¸U¤@¨S¦¨¡A³o®a¤½¥q¤j·§´N¥h¤F¤F! ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³ ¡§³Õ¾Ç¤§¡A¼f°Ý¤§¡A·V«ä¤§¡A©ú¿ë¤§¡A¿w¦æ¤§¡¨ ..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦bÓ¤H): www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/8 ¤U¤È 02:07:56²Ä 2211 ½g¦^À³
|
roger¥S¡C §Ú¦³¬d¤@¤UNIHªº¤å³¹¡A¨ºÓSemaglutideªº¹vÂIGLP1¡A¬Oªv¿}§¿¯fªº¡A¹vÂI¤£¦b¨x¤W±¡A¥u¬O¦]¬°³oӯתըx¥»¨Ó´N¬O¥NÁ¯e¯fªº¤@ºØ¡A¦³®Ä¤]¬O¶¡±µ¦³®Ä¡C ªYÄ£ªºSNPªº¾÷Âà¬Ý°_¨Ó¬Oª½±µ§@¥Î¦b¨x¤W±ªº¹vÂI¡AÀ³¸Ó§óª½±µ¡A¥u¤£¹LSemaglutideªº®ÄªG¬Û·í©úÅã¤S¬O¦ÑÃÄ¡A¬Ý°_¨ÓÄvª§¤£®z¡A¤£¾å±o¤T´Á¶i«×¦p¦ó? www.ncbi.nlm.nih.gov/pmc/articles/PMC8351017/ |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/8 ¤U¤È 01:46:57²Ä 2210 ½g¦^À³
|
OK¡Aroger¥S¡A§A¯uªº¬ã¨s«Ü²`¤J¡A³sÄvª§ÃĪ«³£¤@°_¬ã¨s¡C ±ßÂI¨Ó¬ÝFGF21¡A·P®¦¡C Akero efruxifermin(FGF21)¦b³o½g¦³«Ü¸ÔºÉ¤ÀªR: www.drugtimes.cn/2021/06/17/nashzhuanlanmantannashdafenziyaowu/ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 01:35:06²Ä 2209 ½g¦^À³
|
¿Õ©M¿Õ¼wsemaglutide¦bF2~F3: 59%±wªÌ½w¸Ñ ------------------------------------------------------------------------- ¦pªGªYÄ£¬OF4:¥¢¥NÀv©Ê¨xµw¤Æ¦³Àø®Ä¡A«¥®a·|½æ¥Ð½æ«Î¥þÀ£!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 01:28:48²Ä 2208 ½g¦^À³
|
F4:¥NÀv©Ê¨xµw¤Æ(³o¶ôÁÙ¦³±Ï->ªYÄ£»PAkero)»P¥¢¥NÀv©Ê¨xµw¤Æ(¥Ø«e¨S±Ï) F4ÃĪ«ªº¬ãµo¦³³æ¿Wªºguideline¡A©M³æ¿WF2-F3 NASH¤£¦P(©Ò¥HFDA®Ö㪺ÃÄÃÒ¾AÀ³¯g¤]·|¤À¦¨2°Ï¶ô) --------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 08:30:15²Ä 2172 ½g¦^À³ F4°ò¥»ºâ¬O¥Ø«eÃĪ«¬ãµoªº¸T°Ï¡A¯e¯f¶i®i¨ì¨xµw¤Æ¤§«á¦A°fÂà¬O«D±`§xÃøªº¡A¦pªG¯à°µ¥XÀø®Ä¡A¯uªº´N¤jº¡³e¤F¡C ©Ò¥HSNP-610´Á¤¤¤ÀªR:F4ªº²Õ¡AªvÀø«e«á¦³[ÅãµÛ®t²§]---¹Ú´K¥H¨D¦Ó¥B¬Ý¨ì$$$ª÷¥ú°{°{$$$ SNP-630ªºCOGS®£©È¤]«Ü°ª???(«ÜÃø¦X¦¨) Akero efruxifermin(FGF21)¦b³o½g¦³«Ü¸ÔºÉ¤ÀªR: www.drugtimes.cn/2021/06/17/nashzhuanlanmantannashdafenziyaowu/ |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/8 ¤U¤È 01:25:07²Ä 2207 ½g¦^À³
|
¨ºÓ«n¥P¤¦ÁÙ¦b·d? ³oÓ°ê³»¥D¤O¯uªº¬On¦Y·F©ÙÀR¡An·c°®´²¤á¨C¤@¤À¿ú¡C |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/8 ¤U¤È 01:15:03²Ä 2206 ½g¦^À³
|
roger¥S. ¨ìF4¾ãÓ¨x³£Ãa±¼¤F§a¡A¤£¬O¦bF2-F3¦³¿ìªk±±¨î¤£¦bÄ~Äò´c¤Æ´N¦n¤F¶Ü? Phase3 Trials to support a marketing application Primary Endpoint: Resolution of steatohepatitis and no worsening of fibrosis. Improvement in fibrosis with no worsening of steatohepatitis. A co‐primary endpoint of the above or depending on the mode of action, either one or the other can be used. Target Population Patients with biopsy‐confirmed NASH with moderate/advanced fibrosis (F2/F3). |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 12:27:15²Ä 2205 ½g¦^À³
|
NASH«Í¾î¹M³¥¡C ¦³¬ð¯}©ÊÀøªkªº¿Õ©M¿Õ¼wsemaglutide¦bF4¸T°Ï±¾¤F!!! 2022.7.1 www.healio.com/news/gastroenterology/20220630/ozempic-boosts-cardiometabolic-markers-falls-short-for-fibrosis-in-nashrelated-cirrhosis ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 08:30:15²Ä 2172 ½g¦^À³ F4°ò¥»ºâ¬O¥Ø«eÃĪ«¬ãµoªº¸T°Ï¡A¯e¯f¶i®i¨ì¨xµw¤Æ¤§«á¦A°fÂà¬O«D±`§xÃøªº¡A¦pªG¯à°µ¥XÀø®Ä¡A¯uªº´N¤jº¡³e¤F¡C ©Ò¥HSNP-610´Á¤¤¤ÀªR:F4ªº²Õ¡AªvÀø«e«á¦³[ÅãµÛ®t²§]---¹Ú´K¥H¨D¦Ó¥B¬Ý¨ì$$$ª÷¥ú°{°{$$$ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤W¤È 09:36:36²Ä 2204 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/11 ¤W¤È 06:25:36²Ä 1967 ½g¦^À³ ¥Ó½ÐFDA pre-EUA meeting¡AFDA¦P·N»P§_±oªá¦h¤[? ¥un6Ó¤u§@¤Ñ!!! Veru contacted on MAY 2 about FDA willing to meet on EUA and granted meeting MAY 10, TODAY, only 6 (SIX) BUSINESS DAYS AFTER! ------------------------------------------------------------------------------------------------- ¤£¤NÃø¼B¸³¡A¯à»PFDA¶}pre-EUA meeting¾÷²v¡A©ú¤é°_ºâ1¤Ñ´î1%¡Aº¡¦Ê¤é«h¾÷²v¬°0¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤W¤È 09:12:21²Ä 2203 ½g¦^À³
|
«ç»ò°h¨B¤F?¼Æ¾Ú©úÅ㤣¨Î¡A¬°¦óµwµÛÀY¥Ö¤]n¨«EUA¥Ó½Ð?(²ö«D©È¹¨¥³Q§i?) ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/16 ¤W¤È 07:42:26²Ä 2087 ½g¦^À³ Veru¥Ó½ÐEUA·Ó°_¤u3->4->5¡A°ê¹©¿W¨B¤Ñ¤U4->5¡C ------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/21 ¤W¤È 08:01:08²Ä 1807 ½g¦^À³ ... ³o¬OEUAªº¬yµ{7¨B¦±! ..Step 3: Pre-EUA Submission A pre-meeting will facilitate a rapid more complete EUA submission. Step 4: Submission of EUA This involves submitting an EUA request to be reviewed by the FDA. Step 5: Approve/Reject EUA After reviewing the EUA application, the FDA issues a formal approval or rejection. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤W¤È 09:01:59²Ä 2202 ½g¦^À³
|
2022.7.7°ê¹©:°ê¹©¥Í§Þ´£¥æªºPre-EUA Meeting Request Submission(ºò«æ¨Ï¥Î±ÂÅv«e·|ij½Ð¨D)Àò¬ü°êFDA¥¿¦¡¦^ÂЦ¬®×! ½¥Õ¸Ü:°ê¹©°e¥X¤å¥ó¦VFDA¥Ó½Ð¶}ÓPre-EUA·|ij¡AµM«áFDAµoӤ帹¡A¦^»¡¦³¦¬¨ì±zªº¥Ó½Ð¡A¶È¦¹¦Ó¤w¡C(Ãļt»P¤½®a¾÷Ãö¤å®Ñ ¨Ó©¹³W«h) «ÂI¦bFDA¬Ý§¹¸ê®Æ«á¦P·N©Î¤£¦P·N±ÆÓPre-EUA Meeting¤é´Á¡A¸ò±z¶}·|!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤U¤È 05:10:38²Ä 2201 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 11:26:27²Ä 2199 ½g¦^À³ MGL-3745¼g¿ù§ï¥¿¦¨MGL-3196(Resmetirom)¡C 2022.7.5 ¤û¬z¤j¾Ç¨x¯f¾Ç«È®y±Ð±Â´µ¸¦ªâ«¢¨½´ËÂå¾Ç³Õ¤h: Resmetirom¡§¦³¥i¯à¦¨¬°²Ä¤@Ó³Q§åã¥Î©ó NASH ±wªÌªºÃĪ«¡¨ www.healio.com/news/gastroenterology/20220705/resmetirom-has-potential-to-be-first-medication-approved-for-patients-with-nash ------------------------------------------------------------------------------------------------- µ²½×: ³Õ¤h¨S»¡ªº¨Æ¡AResmetirom¬O§_¯u¯à¦¨¬°²Ä¤@Ó³Q§åã¥Î©ó NASH ±wªÌªºÃĪ«¡AÃöÁä¦b¦~©³ªºÅ]¤ýÃö¥d¨x¬ïµ²ªG¦p¦ó?(¤T´Á±on¨x¬ïLiver Biopsy) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤U¤È 02:00:43²Ä 2200 ½g¦^À³
|
¤µ¦~ªº«½S¥æ©öÀq¨FªF±ý¦¬ÁÊADC?(¥Ø«e¦è¶®¹Ï°ò¦]¥«È325»õ¬ü¤¸) 1.2020¦~¦N§Q¼w¥H 210 »õ¬ü¤¸ªº°ª»ù¦¬ÁʤFADC¤½¥q Immunomedics¡A ³Ð¤U·í¦~³Ì°ª¥æ©ö¬ö¿ý¡C 2.2021¦~ºa©÷¥Íª«±ÂÅvADCÃĪ«µ¹¦è¶®¹Ï°ò¦]2»õ¬ü¤¸º¥I©M24»õ¬ü¤¸¨½µ{¸O³Ð¤U¤j³°26»õ¬ü¤¸±ÂÅv¬ö¿ý¡C 3.2022.6.21Àq¨FªF±ý¦¬ÁÊADC¡]§ÜÅé°¸ÁpÃĪ«¡^ª¾¦W¥ø·~Seagenªº®ø®§¶Ç¥X¡A¤]ÅýADCÃĪ«¦A¦¸¨ü¨ìÃöª`¡C www.163.com/dy/article/HACEH7BN0512D3VJ.html --------------------------------------------------------------------------------------------------- µ²½×: ¥iª`·N±i¤l¤å³Õ¤h¦¨¥ßªº§K¬Ì¥\§{(¸òÀH¤j¤û¨«¿ù¤£¤F) www.immunwork.com/edcontent_d.php?lang=tw&tb=1&id=14 ÃĪ«§ôªº¨Ò¤l (ADC¬O¥Ñ³æ§Ü¡B¬r¯À¡A³s±µ¤l¤T³¡¤Àºc¦¨ªº½ÆÂøµ²ºc) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 11:26:27²Ä 2199 ½g¦^À³
|
MGL-3745¼g¿ù§ï¥¿¦¨MGL-3196(Resmetirom)¡C 2022.7.5 ¤û¬z¤j¾Ç¨x¯f¾Ç«È®y±Ð±Â´µ¸¦ªâ«¢¨½´ËÂå¾Ç³Õ¤h: Resmetirom¡§¦³¥i¯à¦¨¬°²Ä¤@Ó³Q§åã¥Î©ó NASH ±wªÌªºÃĪ«¡¨ www.healio.com/news/gastroenterology/20220705/resmetirom-has-potential-to-be-first-medication-approved-for-patients-with-nash ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/5 ¤U¤È 05:47:26²Ä 2190 ½g¦^À³ ¦pªGInterceptªºOcaliva¨S¹LÃö¨úÃÒ¡A©ú¦~·¥¥i¯à¥ÑMadrigalªºMGL-3745¹Ü»í? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 10:21:25²Ä 2198 ½g¦^À³
|
NASHºC©Ê¯f±oªø´Á(©Î²×¥Í)ªvÀøªº«e´£¤U¡A³Ì¤jµ{«×¦a´î¤Ö°Æ§@¥Î«D±`«n!!!(±wªÌÄ@·N§Ô¨üªø´Á©Ô¨{¤läú¤ß?) ¹vFGF21ªº±`¨£°Æ§@¥Î¦P¬O[G¸z°Æ§@¥Î-¸¡Âmäú¤ß] 1.Akero FGF21(F4¸T°Ï¨´¤µ³Ì«½Sªº¼Æ¾Ú):±Nªñ50%ªº±wªÌ¦³¸¡Âm¡A1/3ªº¦³äú¤ß¡A1/3¦³µù®g¦ì¸m¤£¨}¤ÏÀ³¡C 2.BIO89-100 FGF21(°ª¥Ìªo¤Tà¦å¯g´§¥X¥þÂS¥´):¤j·§~30%ªº±wªÌ¦³¸¡Âm¡Aäú¤ß¡A1 3.SNP6¨t¦C¨S¸ê®Æ(ªÑªF·|¨S¤H°Ý)! --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/22 ¤U¤È 03:41:18²Ä 1053 ½g¦^À³ ³Ò¥hªÑªF·|ªÌ¸ß°Ý: SNP-610(CYP2E1 + DGAT1, ¥´2ÓÂI)NASHÁ{§É¤G´Á36¤H¦³¨S¦³G¸z°Æ§@¥Î??? ¦pªG¯à½T»{¸ó¹LG¸z°Æ§@¥ÎªùÂe»Ùê¡ASNP-610/ SNP-630¦¨¥\¾÷²v´N«Ü¤j¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 09:34:56²Ä 2197 ½g¦^À³
|
§Q¥ÎDGAT1[ÄY«ªºG¸z°Æ§@¥Î-¸¡Âm]--§ïªvÀø«K¯µ±wªÌ!!! 1. 2022.6.8 (DGAT1) Pradigastat ¦b¥\¯à©Ê«K¯µ±wªÌ¤¤ªº·§©ÀÅçÃÒ¬ã¨s clinicaltrials.gov/ct2/show/NCT04620161?term=NCT04620161&draw=2&rank=1 2. 2019.2.18 ¤¥´I¬ã发ºÞ线¡I¦w济药业获±o诺华pradigastat±Â权 www.163.com/dy/article/E94HUUBM0530JPJ4.html ªñ¤é¡A¦w济药业¥¿¦¡从诺华¡]Novartis¡^¤½¥q¡]NYSE: NVS¡^获±o¤Fpradigastatªº±Â权¡A进¤@¨B¤¥´I¤F¦w济ªº产«~ºÞ线¡C Pradigastat¬O¤G酰°ò¥Ìªo酰°ò转²¾酶¡]DGAT1¡^ªº¤p¤À¤l§í¨î剂¡A¦¹«e¤w¦b¥N谢¯e¯f¤W开®i¤F临§ÉIII´Á试验¡C¦w济计¦E 将pradigastat应¥Î¤_ªv疗¤@个·sÓì应¯g¡A§Y将¦b¤¤国ûD动针对该·sÓì应¯gªº临§ÉII´Á·§©À验证¬ã¨s... -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/2/7 ¤W¤È 10:00:40²Ä 751 ½g¦^À³ ´¿¬O¼öªùªºDGAT1¹vÂI¡A¦]¬°¤jÃļt»â¥ý¸s±µ³s±¾¦bÄY«ªºG¸z°Æ§@¥Î¡A¦]¦¹»{©w¦¨¤£¤FÃÄ¡A¯É¯É©ñ±óÂ੹¨ä¥L¹vÂI¡A¨S·Q¨ìÄ~SNP-810«á¡ASNP-610¦A¦¸¦¨¥\¸ó¶V¤@¹D¨ä¥L¤jÃļt¹L¤£¤Fªº[ÄY«ªºG¸z°Æ§@¥Î]»Ùê!!! ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 05:37:39²Ä 526 ½g¦^À³ SNP-610(CYP2E1 + DGAT1, ¥´2ÓÂI)¦b¤@´Á»P¤G´ÁÁ{§É¹êÅçÀ³¸Ó¬O¸ó¹LG¸z°Æ§@¥ÎªùÂe»Ùê¡A¦¨¥\¸ô¤W¦AÁÚªñ¤@¨B! (GSK / ¿ÕµØ/ªü´µ§Q±d/½÷·çªºDGAT1ÃĪ«¤À§O±¾¦bP1»PP2) |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/7 ¤W¤È 09:25:44²Ä 2196 ½g¦^À³
|
p¤j·PÁ±a¨Óº¡¤À¤j¸ê°T¡Aº¡¤À¤j¬O°]¸g¤H¤~¡F±zÅQ®ð§ë¸ê¥O¤H´º¥õ¡C±z©Ò¨¥ªÑ²¼ª±¨ì¥u³Ñ·sÃĪѡA³o´N¬O°l¨D¼É§Q¡A±M®a»¡ªº°ª³ø¹S¡A¥»Äær¤j¬O·sÃıM®aµ¹¯à¨£«×¡B¦ôÈ¡A«e±M¤j¶K¤å·sÃÄ°^Äm¤½¥qºâªk¡A§Æ±æ¦³§Ó¦@¦Pµo¤j°]¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 09:21:31²Ä 2195 ½g¦^À³
|
SNP-6¨t¦C¾AÀ³¯g°ª¥Ìªo¤Tà¦å¯g(HTG)? 1.SNP-6¨t¦C(DGAT1 + CYP2E1-->¿E¬¡FGF21)§¤¥ð®§°Ï(³æ¥´NASH) 2.VK1430 (DGAT1)´N¥´À»°ÏP1 (¥ª¥k¶}¤}NASH+HTG) www.vikingtherapeutics.com/pipeline/overview/ 3.BIO89-100(FGF21)´§¥X¥þÂS¥´(¥ª¥k¶}¤}NASH+HTG) -------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤U¤È 08:15:37²Ä 2187 ½g¦^À³ ÂùºÞ»ô¤UDGAT1(°§C¨xŦ¤T»Ä¥Ìªo¯×°ï¿n)+§í¨îCYP2E1¿E¬¡PPAR£\-FGF21¡A¯à»PBIO89-100(pegozafermin)¤@¸û°ª¤U? ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/2/27 ¤U¤È 03:53:49²Ä 1752 ½g¦^À³ NASHÁ{§ÉÃĪ«³Ì·s¸ê®Æ(SNP-630º²{) DGAT1 (1¤ä):VK1430(º²{) DGAT1+ CYP2E1: SNP-610»P SNP-630 |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/6 ¤U¤È 01:51:41²Ä 2194 ½g¦^À³
|
ROGER¥S °¤â©ö¥Í¤Ó¨è·N¤F¡AÁ¿ªºtoo much too over¡A¥u·|¤@ª½Á¿¥i¥H§@¬°ÁpÃĪ«¡A¥i¬O¥i¥HÁp¨ººØÀù¤]¤£ª¾¹D¡C ¥t¥~¡AÀù¯g¥ÎÃÄ«ÜÀt¤òªº¡A¤£¬Oµ¹§AÀH«Koff lable use¨Ö¥Îªº¡C ȳ£¦ô¤£¥X¨Ó¡A§ÚÓ¤H¬O¬Ý¬Ý´N¦n¡A°£«D¤Q¤j°ê»ÚÃļt½Í±ÂÅvªº®ø®§¥X¨Ó¡A»ùȦô¤£¥X¨Ó¡A§Ú¤£¸Iªº¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/6 ¤U¤È 12:16:16²Ä 2193 ½g¦^À³
|
¥_·¥¦³°¨û¸ò¦Ñ´ºïºï¦³¾l¡AADI-PEG20±ÂÅvª÷¥´¯}¥x·LÅé6.7»õ¬ü¤¸¬ö¿ý¦±ß¦Ó¤w¡AþÃä²D§Ö«¥þÃä«Ý¡C ¦Óº¡¤À¤jªº[ ¼É§Q¬ü¾Ç]®¼§l¤Þ¤Hªºµü->ªÑ¥»n¤p¥B¥«³õ¤j¤~¦³ÃöÁä°ò¦]¡C |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/6 ¤W¤È 10:43:36²Ä 2192 ½g¦^À³
|
ROGER¥S §Ú¤£¬OªL¥_¤j¡A¤£¹Lª±ªÑ²¼¨ì³Ì«á¡A¥u¹ï·sÃĪѦ³¿³½ì¡A®³Ó500¸U¥X¨Ó½ä¤@¤UªYÄ£¡A¿ï¹ï¤@¦¸P´I¡A°]´I¦Û¥Ñ¡A¤p¿ú¡C ¥_·¥¬P§Ú¤]¦³¦b¬Ý¡A¤£¹L¥L¨ºÓ¥«³õ¦ôÈ¡A©l²×µLªk¦ô¡A¤£¾å±oROGER¥S«ç»ò¬Ý¡H ·sÃĪѦôȳ̫n¡A´N¹³ªÑ¥«¦P¾Ç·|¨ºÓº¡¤À¤j¡A2¦~¦hªÑÄÖ¡A¸£³U¤£¿ù¡Aª¾¹D¦ôȪº«n©Ê¡C °ò¥»¤W¡A§Ú¹ï¦ô¤£¥XȪº·sÃĪѩΪ̥«³õ¤p¨S¤°»ò»ùȪº·sÃĪѡA§Ú¤£·|¶i¤@¨B¬ã¨sÃĪº¾÷Âà¸òÄvª§ÃĪ«¡C ³oÃä¤j®a¤ñ¸û±M·~¤@ÂI¡A½Íªº¤ñ¸û²`¤J¡AÁÙ¤£¿ù¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/6 ¤W¤È 10:33:59²Ä 2191 ½g¦^À³
|
¦bªÅÀY¥«³õ¡A³oºØ¤pªÑ¥»ªº¥Í§Þ(·sÄ£/³q¸ô=>¹ï¤ñ´I¨¹´Cª£¨ì2k)¬O¦n¾Þ§@ªº¡A§ë«H¤j¤á³£nÁÈ¿ú¡A¥uncopy°ê³»ªº¾Þ§@¡A¥»¯q¥»µ¹¨ì50¿©Î¥»¹Ú¤ñ(¦ôȹï¤ñ)³£¬Oª£§@ªºªÅ¶¡¡CÓ¤H²L¨£¡C§Æ±æ¤j®a¦b³oªÅÀY³£ÁÈ¿ú |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/5 ¤U¤È 05:47:26²Ä 2190 ½g¦^À³
|
¦ôȪkˬO»P«¥2¦~«e¤£¿Ñ¦Ó¦X¡C ¦pªGInterceptªºOcaliva¨S¹LÃö¨úÃÒ¡A©ú¦~·¥¥i¯à¥ÑMadrigalªºMGL-3745¹Ü»í? Peter Lin¥i¬OÃĵتOªºªL¥_¤j? ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/19 ¤U¤È 04:54:55²Ä 360 ½g¦^À³ ¤W¶g¤Madrigal¦¬½L¥«È15.8»õ¬ü¤¸ ¬Q¤ÑMadrigal¥«È18.9»õ¬ü¤¸(º¦20%) finance.yahoo.com/quote/mdgl/ Madrigal¤½¥q¥u¦³2¤äÃĪ«MGL-3196(P3¡ANASHÃĪ«) /MGL-3745(Á{§É«e¡ANASHÃĪ«)¡C ¥t¥~¡A§Þ³N¥¥x¤]¸òªYÄ£¦P¼Ë»EµJ¦b¨xŦ¯e¯f¤§ªvÀø! ¦ý¬O¥Ø«e¤G®a¤½¥q¥«È¤w®t¶Z¤Q¸U¤K¤d¨½! www.madrigalpharma.com/ourapproach/pipeline/ ........................................................................................ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/12 ¤U¤È 02:42:06²Ä 344 ½g¦^À³ SNP-6Àø®Ä¦w¥þ©ÊÀu©ó«eªuªºMadrigal MGL-3196?! ¦ý¬OªYÄ£¥«È«o¤£¤ÎMadrigalªº10%!!! ¶g¤ªYÄ£¥«È37.2»õ¥x¹ô(¬ù1.3»õ¬ü¤¸) ¶g¤Madrigal¦¬½L¥«È15.8»õ¬ü¤¸(°ªÂI¬O2018¦~ªº43»õ¬ü¤¸) Madrigal±q43×¥¿¨ì15.8¡A¦]¦¹n»¡°ê¥~°ª¦ôMadrigal¦æ¤£³q¡A¦]¬°°ê¥~¤ÀªR®v¤W½ÕMadrigalªºªÑ²¼¥Ø¼Ð»ù) Madrigal´N2¤äÃĪ«MGL-3196(P3) /MGL-3745(Á{§É«e)¡A¤G¤ä³£¬ONASHÃĪ«¡C(ªYÄ£5¤ä...) |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/5 ¤U¤È 05:16:19²Ä 2189 ½g¦^À³
|
ºK¦ÛªÑ¥«¦P¾Ç·|ªºº¡¤À¤j¡AÁÙ¬O¦³¤º¦æªº¦bª`·NªYÄ£¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¡¦³°ªºÝ¤À¤l¦b¥s¤F¡A¨º§Ú¤£©ñ¤½¶}ª©¡A¥uµ¹°lÂܪºªÑ¤Í°Ñ¦Ò¡C º¡¤À¤j¥ÎªYÄ£¨Ó§@¨Ò¤l¡A±qÀY¨ì§À¥Ü½d¤@¤U«ç»ò¿ï¦³·dÀYªº·sÃĪѡD ¤@¡B§P¶Õ (¤@)Á`¸g±:³oӽЬݺ¡¤À¤j¥t½g¤À¨Éªº[2022Á`¸gÁͶչw´ú]¡A¨Ìº¡¤À¤jªºÁ`¸g§P¶Õ¡Aº¡¤À¤j·¥«×¬ÝªÅªÑ¥«¡A³o®É¤£»´©ö¶i³õªº¡C (¤G)²£·~±: 1.¬Q¤Ñ§Ú¤À¨É¹L¡A¤j®anª¾¹D·sÃIJ£·~±q¬ãµo¨ìÁ{§É¤T´Á§¹¦¨®³ÃÄÃÒ¡A¨S¦³10¦~¥H¤W¬O¤£¥i¯àªº¡A¦ýè¦n²{¦b¥xÆW·sÃIJ£·~±q¤WÂd¥«¨ì²{¦b¡A®t¤£¦h³£§Ö10¦~¤F¡A³£¦³¤@¨Ç¶i«×¦¨ªG¡A¦p¾÷Âà§@¥Î¤w¸g³QÃÒ©ú¦³¥Î¤F¡B¤G´Á³£§@§¹¤F¡B¶}©l¦³±ÂÅv®ø®§¥X¨Ó¤F¡A³o¨Ç¸ê°T¨¬û{§@¬°µû¦ô§ë¸ê·sÃĤ½¥q·ÀIªº¨Ì¾Ú¤F¡A¦Ó¥B³o¨Ç¤½¥q°¨¤W´Nnªá¤F¡A§Y³oÓ·sÃIJ£·~n¶}©l¨«¦¨ªøÁͶաC 2.·sÃĪѤ£¸òÁ`¸gÀô¹Ò¦³¤Ó¤jÃö«Y¡A¦]¬°¥¦¥»¨Ó´N¨SÁÙ¨S¦³À禬¡A§¹¥þ¤ñªº¬O·sÃĪº»ùÈ¡A¦Ó·sÃĪº»ùȬO¥Ñ·sÃĪº¬ãµo¶iµ{¤Î¥«³õ¦Ó©w¡C 3.ºî¤W¡A¦bÆä§P¶ÕÆ嶥¬q¡A·sÃĪѤרä§Y±N¶}ªáªº·sÃĤ½¥q¡A¨¬¥H°fÁ`¸gªÅ¶Õ¦Ó¿W¦æ¡C ¤G¡B¿ïªÑ ³oÓn¿ï·sÃĦ¨¥\²v°ªªº¡A·ÀI§Cªº ¡A¶·n¤j¶q°ò¥»±¬ã¨s¡A¥]¬A¡G (¤@)¾÷Âà§@¥Î: 1.¥HªYÄ£¬°¨Ò¡A¥Lªº¾AÀ³¯g¬Oªv«D°sºë©Ê¯×ªÕ¨x(NASH)¡A²{¦b¤@¤G¤T´Á¦@¦³126ÓÁ{§É¸ÕÅç¡C 2.²Îªº¨Ó»¡¡A³o¨Ç126ÓÄvª§ÃĪ«ªº¾÷Âà¥iÂkÃþ¬°5¤jÃþ¡A¨ä¤¤¤T¤jÃþ³£¦³¦b¤@¡B¤G¡B¤T´Á¸ÕÅ祢±Ñªº¬ö¿ý¡A¦ÓªYÄ£ªºSNP6¨t¦C¤£¦b¨ä¤¤¡C 3.¦Ó¥BªYÄ£SNP6¨t¦Cªº¾÷Â঳¢±Ó¡A¤ñ¨ä¥LÄvª§ÃÄ¢±ª«¦h¤@Ó¡C (¤G)2´Á¸ÕÅçµ²ªG: SNP6¨t¦C¤w¸g¤G´Á¡A¢ÞȪì¨BÅã¥Ü¨ã¦³·¥¬°ÅãµÛªº²Îp®t²§¡A¤w¸gªì¨BÃÒ©ú¦³®Ä©Ê¡C (¤T)°ê»Ú¤jÃļt±ÂÅv®ø®§: ³oÓ¦b¬YÓJ¥®®E°|¤h¼v¤ù¤¤¡AµL·N³zÅS¤F¥L̨ì°ê»Ú«e½B¤jÃļt½ÍSNP6¨t¦C±ÂÅvªº¨Æ¡Aªí¥Ü³o¤äÃĪº¾÷Âà§@¥Î¬OO¢Ùªº¡C (¥|)¦³¿ú¤H§ë¸ê¤JªÑ: ªYÄ£³Ìªñ¤@¦¸¼W¸ê¨p¹õ¡A¥Ñ´I¨¹½²©ú©¾ªº¤G®a§ë¸ê¤½¥q¡]¤Î¥L¦Û¤v)¤ÎÄ_¨Î¤ÖªFªL®a§»ªº§ë¸ê¤½¥q¡]¤Î¥L¦Û¤v¡^¦U¤JªÑ¤Fªñ10%¡AÁ`¦@ªñ20%ªºªÑ¥÷¡A¥L̨âÓ¬O¦³±Mªù§ë¸ê¹Î¶¤¦bµû¦ô§ë¿úªº¡A¥L̪º¤JªÑ»ù®æ¬O81¤¸¡A¨S¦³¤@©wµû¦ô¡A¤£¥i¯à¦¸¥á¨º»ò¦h¿úªº¡C (¤)ºî¤W¡AªYÄ£³o¤ä¦b·sÃÄ¥¢±Ñªº·ÀI¡A¤ñ¸û§C¤@ÂI¡C ¤T¡B¦ôÈ»P¸êª÷¤À°t (¤@)¦ôÈ 1.¬Q¤Ñº¡¤À¤j¦³¤À¨É¹L¡A¤@¤äÃĪº¥«³õ»ùÈ¡A¦pªG¦³¥i¹ï¼Ðªº¤½¥q¨Ó¦ô¡A³Ì·Ç¡C¦³ÃöNASH¡A¨ä¤¤´¿¸g¦³¤@®a¤½¥qintercept ¥¦·í®É¤T´Á¸ÕÅç¹F¼Ð¡AªÑ»ù¼Q¨ì460¬üª÷¡AÁ`¥«È¨Ó¨ì4000»õ¥x¹ô¡C 2.³oÓÅã¥Ü¡AªYÄ£ªºSNP6¨t¦Cªº·sÃÄ»ùÈ·¥¬°Åå¤H¡A¥HªYÄ£²{¥«È56»õ¥x¹ô¡A³oÓ4000»õ¸ò56»õªº®t¶Z·¥¤j¡A¨ã¦³10¿¼É§Q¬ü¾Ç°ò¦]¡A»ù®tªÅ¶¡¶W¤j¡C 3.·íµM¡A¥«³õ¤j¡AÄvª§ÃĪ«´N¦h¡A¦ý¦bJ¥®¨j°|¤hªº¼v¤ù¤¤¡A¦³´£¨ìSNP6¨t¦C¦³¨ä¿W¯S¤G¶µ¾÷Âà¡A¸ò¨ä¥LÄvª§ÃĪ«¤£½Ä¬ð¡A¬O¥i¥H§@¬°ÁpÃĨϥΪº¡A§Y´Nºâ¦³¨ä¥LNASHÃĪ«¦¨¥\¡AªYÄ£ªºSNP6¨t¦CÃĪ«¡A¤´µM¥i¥H¨Ö¥Î¨ÓªvÀøNASH¡C ¡]¤T¡^¸êª÷¤À°t¡G ·sÃĪѥunÁÙ¨S®³¨ìÃÄÃÒ¥¿¦¡¤W¥«¡A³£¤£¯à·|¥þÀ£¡A¥u¯à¾a¸êª÷¤À°t¨Ó±±ºÞ·ÀI¡A¬Ý¤j®a¸êª÷³¡¤À¡A®³¶¢¿ú¨Ó§ë¡A§â³oµ§¿ú·íÁýª¯¡A¦³¿ú´NºCºC¶R¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/5 ¤U¤È 02:40:56²Ä 2188 ½g¦^À³
|
¦V¤j¤ÀªR«D±`²M·¡¡A¤À¼íª÷3¦Ê¤À¤ñ´N¬OªÑ¤ý¡I10¦Ê¤À¤ñ¤À¼íª÷¨Ã¤£¬O³Ì°ª¡A13¦Ê¤À¤ñ¤]¥i¯à¡F¨xÃij¡¤À¶W¹L¦Ê»õ¬ü¤¸§ó¬O¥i¯à¡IªÑ¤ý¹Ú¤j®aÁÙ¬O¥i¥HÄ~Äò°µ¡A¤Q¦~«áªÑ»ùY160¤¸¡A¤]¦³10¦Ê¤À§Q²v¡A¬O©w¦s§Q²v10¿¡FY3000¤¸¤j®a´N¼Ö¬n¤F¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤U¤È 08:15:37²Ä 2187 ½g¦^À³
|
ÂùºÞ»ô¤UDGAT1(°§C¨xŦ¤T»Ä¥Ìªo¯×°ï¿n)+§í¨îCYP2E1¿E¬¡PPAR£\-FGF21¡A¯à»PBIO89-100(pegozafermin)¤@¸û°ª¤U? ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 10:57:27²Ä 2158 ½g¦^À³ SNP-6¨t¦C¨ã¦³·¥¼eªº¦w¥þ¾¯¶q¡A¦w¥þµL¸·¡A¦P®É¦³§¹¾ãªº±M§Q«OÅ@¡A¨Ã¾Ö¦³·¥¨ã¥@¬ÉÄvª§©Ê¿W¯Sªº[¤T«§@¥Î]¾÷Âà¦p¤U : (1) ½Õ±±¨x¯×ªÕ¥NÁ (METABOLIC)¡A SNP-6¥i½Õ±±¤T»Ä¥Ìªoà¥NÁÂ/¦X¦¨¬ÛÃö»Ã¯À¦pDGAT1¡A°§C¨xŦ¤T»Ä¥Ìªo¯×°ï¿n¡A ªvÀø¤Î¹w¨¾¯×ªÕ¨x¡F (2) §Ü¯×ªÕ¨xª¢¡F SNP-6¥iª½±µ§í¨î¨xŦomega-oxidation¬ÛÃö»Ã¯ÀCYP2E1¡A¨Ï±o·|¶Ë®`¨x²ÓM¡B»¤µoµo ª¢¤ÏÀ³ªº ¬¡©Ê .... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤U¤È 08:03:35²Ä 2186 ½g¦^À³
|
²K¥[BIO89-100 FGF21Ãþ¦üª«ªvÀøÄY«ªº°ª¥Ìªo¤Tà¦å¯g´§¥X¥þÂS¥´: ----------------------------------------------------------------------------------------------- ±q 1.杨¨q伟团队½×¤å´£¥Xªº¾÷¨î:CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21¡C ¨ì 2.Efruxifermin(FGF21Ãþ¦üª«)¯à°÷¨ÏÅÖºû¤Æ°fÂ઺Á{§ÉÃÒ¾Ú¡AÁ{§É¼Æ¾Ú¬O¥Ø«e¤w¤½§GªºNASH³ÌÀuÀøªk¡C 3.BIO89-100 FGF21Ãþ¦üª«¦bªvÀøÄY«ªº°ª¥Ìªo¤Tà¦å¯g´§¥X¥þÂS¥´! (¤T»Ä¥Ìªoà¡ATriglycerides¡A²ºÙTG¬O¤HÅ餺ªº¤@ºØ¯×ªÕ) ¬Ý -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/6/2 ¤W¤È 10:49:19²Ä 1172 ½g¦^À³ ¼W¸ê»¡©ú®Ñ§â©³¤U³o¬q¥[²Ê¶Â¦r(109¦~³ø¨S¬Ý¨ì³o¬q±Ôz)! ...SNP-610(CYP2E1§í¨î)¸gÀø®ÄÃÒ¹ê(Proof of concept)¡A¨ä¤G´Á¸ÕÅçµ²ªGÀu©ó¤wµoªí¨Ã¶i¤J¤T´Á¤§¦U°ê NASH Ô¿ïÃĪ« |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤U¤È 07:58:17²Ä 2185 ½g¦^À³
|
FGF21Ãþ¦üª«¦bªvÀøÄY«ªº°ª¥Ìªo¤Tà¦å¯g´§¥X¥þÂS¥´! (¤T»Ä¥Ìªoà¡ATriglycerides¡A²ºÙTG¬O¤HÅ餺ªº¤@ºØ¯×ªÕ) 2022.6.29 BIO89-100 (FGF21Ãþ¦üª«)9 mg ¬° 57%¡A18 mg ¬° 56%¡A27 mg ¬° 63%¡C36 mg ²Õªºµ²ªG¤j¤£¬Û¦P¡G´î¤Ö¤F 36%(¥Ìªo¤Tà´î¤Ö40-50%©Î§ó¦h±N³Q»{¬°¬O ¥þÂS¥´ªº±¡ªp) PK Fibric acidsÃþªºÃĪ«°§C¬ù20~50% /StainsÃþªºÃĪ«¥i°§C¬ù7~30%¯× /Áx©T¾J§l¦¬§í¨î¾¯¬ù¥i°§C5~11% www.evaluate.com/vantage/articles/news/trial-results/89bios-home-run-fails-excite .. SVB ¦ôp¡A¦bÄY«°ª¥Ìªo¤Tà¦å¯g¤¤¡Apegozafermin ªº¾P°âÃB¥i¯à¹F¨ì 6.5 »õ¬ü¤¸¥ª¥kªº®pÈ -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:37:58²Ä 2161 ½g¦^À³ SNP6¨t¦CCYP2E1§í¨î-->>>FGF21(¤º·½©Ê¼W¥[)¡C±EÀu±E¦Hµ¥¸ÕÅç´¦¾å! Efruxifermin¬OFc-FGF21¿Ä¦X³J¥ÕÃþ¦üª«¡ABIO89-100»PPegbelfermin¬OPEG-FGF21Ãþ¦üª«¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤U¤È 04:36:29²Ä 2184 ½g¦^À³
|
Y¦³À£Intercept²×§½¤§¾Ô¡A¤p½ä´N¦n¡A¦w¥þºÃ¼{¯uªº¤j! --------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 06:38:08²Ä 2170 ½g¦^À³ Ocaliva ªvÀøPBCªº¾¯¶q¡]5mg¡A¨C¶g2¦¸¡^ VS. OcalivaªvÀøNASHªº¾¯¶q¨âºØ¾¯¶q¡]10mg©M25mg¡A¨C¤é¤@¦¸¡^ ¦w¥þ©Ê??? ----------------------------------------------------------------------------------------------- PharmaTimes ©ó 9 ¤ë 22 ¤é³ø¾É¡A¬ü°êºÊºÞ¾÷ºcµo¥¬¤F¤@¥÷¦w¥þĵ§i¡AºÙ Intercept »sÃĪº Ocaliva ¦bìµo©ÊÁx¥Ä©ÊÁxºÞª¢±wªÌ¤¤¨Ï¥Î®É¡A¤£¥¿½Tªº¾¯¶q¥i¾ÉPÄY«ªº¨x·l¶Ë©M¦º¤`·ÀI¡C¬ü°ê FDA ªí¥Ü¡A¦Û Ocaliva¡]¶ø¨©Áx»Ä¡^©ó 2016 ¦~ 5 ¤ëÀò§å¥Î©ó¨xŦ¯e¯f¥H¨Óªº 13 Ó¤ë¸Ì¡A¤w¸g½T»{¤F 19 ¨Ò¦º¤`¯f¨Ò¡A¨ä¤¤ 8 ¨Ò¦º¤`´£¨Ñ¤F¦º¦]«H®§¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/7/4 ¤U¤È 01:29:17²Ä 2183 ½g¦^À³
|
¥h¦~²{¼W75¤¸¡A¬¢¯S©w¤H¶WÃB»{ÁÊ5¤d¦h±i¡C ³o¨Ç¤j©@·|¨Ó»{ÁʬO¬Ý¥¼¨Ó¡A75¤¸¨S¶R¨ìªº¡A¤]¤£®t¥Ø«eªºªÑ»ù»ù®t¡C ¤]§Y¦³¥i¯à¦b¦¹°Ï¶¡¾_Àú¦¬Äw½X¡I ¦pªG¦³±ÂÅv¦X¬ù§@«p¬Þ¡A¥H¥«³õ¦Ê»õ¬ü¤¸¡]³B¤èñ¤Î«D³B¤è¡^ªº¤AñQÓi×ô¡A ¤À¼í1%´N¦³1»õ¬ü¤¸¡AEPS´N¶W¹L40¤¸¡A2%¦³80¤¸¡A3%120¤¸´N¯à·íªÑ¤ý¤F¡C ¦óªp¡AÁÙ¦³§ó¤j¥«³õªºàªÕ¨x¦b«á¡I µ¥«Ý¡A§@¹Ú¤¤¡I |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/4 ¤U¤È 12:19:54²Ä 2182 ½g¦^À³
|
§Ú¬Û«H«e±M¤j´£¥X°ê»Ú±ÂÅvª÷¼5¿¬O¤½¥q§Q±oºâªk¡A4¿¬O¤À¼íª÷³¡¤À¡FªÑ¤ý¬Oºâºâ¤~µo²{¥¼¨Ó¥i¯à¬O¡A®É¶¡n10¦~¡C¨C¤@®a¤½¥q³£¦³¾÷·|·íªÑ¤ý¡AªÑªF´Á«Ý¡B¹Ú·Q¤]¤£·|§ïÅܤ°»ò¡F³s¤j¥ß¥ú°ª¶¥¥DºÞ¦b»ù¦ì²Å¦X¦Û¤v´Á«Ý®É¤]½æ¤@¨ÇªÑ²¼¡A¥L¤]¤£ª¾¹D¦Û¤v¤½¥q·|ÁȨº»ò¦h¡CÁÂÁ§d¤jÂI¿ô¡I¥Ø«eÁÙ¦³«H¤ß¤¤¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/7/4 ¤W¤È 11:25:15²Ä 2181 ½g¦^À³
|
R¤j»¡ªº¹ï ¦³Á{§É¸ÕÅç¼Æ¾Ú°µ°ò¦¡A§@¹Ú¤]¸û½ñ¹ê¡I ¥Ø«e§Y¨Ï¦³±ÂÅv¤]·í¤£¤FªÑ¤ý ¤£¹L¦³±ÂÅv«á¡AªÑ»ù¤]·|¦³©Òªí²{¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤W¤È 10:43:03²Ä 2180 ½g¦^À³
|
¡½©P¬P¹£¡G°µ¤H¦pªG¨S¦³¹Ú·Q¡A¸òÄг½¦³¤°»ò¤À§O¡I ¤H¥Í¬O¹D¿ï¾ÜÃD¡An»ò¦w©ó²{ª¬¡A±Á{¥±e©Î¥¢±Ñ¡An»ò§ïÅܲ{ª¬¡A±Á{¥¢±Ñ©ÎªÌ¦¨¥\¡C ¦³Á{§É¬ã¨sÃÒ©ú¡A,°µ¹Ú¹ï¤HÅé¬O¦³¯q³Bªº¡C -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/5 ¤U¤È 05:04:51²Ä 1553 ½g¦^À³ ¾À¥ß¤d¥Q¡A µL±ý«hè¡C ®ü¯Ç¦Ê¤t¡A ¦³®e¤D¤j¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/4 ¤W¤È 09:44:14²Ä 2179 ½g¦^À³
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/6/23 ¤U¤È 05:02:32²Ä 2139 ½g¦^À³ §Ú¦]¥þ©ãªYÄ£... ---------------------------------------------------------------------------------------------- ·QcopyÃĵØ/°ê³»ªº¸ô§a ¥ý¤W¬Ý300/400¤ñ¸û²{¹êÂI ²{¦bn¦º¤£¬¡ªº ¤£nÅý§Ú¥¢±æ§r |
|
|
·|û¡G§d°ê¥°10151930 µoªí®É¶¡:2022/7/4 ¤W¤È 09:20:46²Ä 2178 ½g¦^À³
|
¦ÂIºÎ¹Ú¸Ì¤°»ò³£¦³ ¤]±ÂÅvª÷¦Ó¤w ·Q·íªÑ¤ýÁÙ¦¤F |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/4 ¤W¤È 08:03:18²Ä 2177 ½g¦^À³
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/6/23 ¤U¤È 05:02:32²Ä 2139 ½g¦^À³ §Ú¦]¥þ©ãªYÄ£... ---------------------------------------------------------------------------------------------- ·ÀI¹L¤j¡Cµ¥6©Î8¨t¦C»P¤jÃļtñ±ÂÅv¬ù¡A¹j¤é¦A°l»ù¥þ©ã¥d§´·í! |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/3 ¤U¤È 01:59:34²Ä 2176 ½g¦^À³
|
ÁÂÁ¡CªYÄ£¨«®Ú¥»¸Ñ¨M¯×ªÕ¡B¨xª¢¡BÅÖºû¯¾¡m·¥ÅãµÛÀø®Ä¡n¡BÅÖºû¤Æ¡mÅãµÛÀø®Ä¡n¡A²Å¦XªvÀøÃIJz¡C°ê»Ú¤jÃļtY¯à¨ú±o±ÂÅv2Áû¤@¨Ö¡A¨xÃĤѤU®³¤U¤j¥b¡I·íªÑªFªº½v½m¦n¤âÁu¡m¼Æ¿ú¤~¤£·|»Ä¡n¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤U¤È 01:34:16²Ä 2175 ½g¦^À³
|
Akero: 1. F1-F3: 48% 2. F2/F3: 68% had at least a 1-stage improvement in fibrosis, 50% had a 2-stage fibrosis improvement 3.F4:33% (F4¸T°Ï¨´¤µ³Ì«½Sªº¼Æ¾Ú) ---------------------------------------------------------------------------------- SNP-610¦bF4¸T°Ï®³´X%¡A¤½¥qÅS¥Xªº¸ê®Æ¤Ó¤Ö¡A¬G¤£ª¾! |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/3 ¤U¤È 12:46:40²Ä 2174 ½g¦^À³
|
akero 33¦Ê¤À¤ñÅãµÛÀø®Ä¡A¬O¥Nªí¬ù3¤À¤§¤@¦³ÅãµÛÀø®Ä¡A¥t3¤À¤§2¨S¦³¶Ü¡H¦pªG¬O³o¼Ë¡A¨º6¨t»ùÈ°ª¤F¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 08:53:38²Ä 2173 ½g¦^À³
|
«¥¬°¤°»ò»EµJ¦bSNP-610ªºF4Àø®Ä?Á٧ήe¹Ú´K¥H¨D¦Ó¥B¬Ý¨ì$$$ª÷¥ú°{°{$$$ ¦]¬°Gilead±q¤@¶}©l´N·Q©w¦ìF4³oÓ¸sÅé¡AµL©`across the board³£§ß¤£¤WÀð. ----------------------------------------------------------------------------------------------- °Ñ¾\³o½g´N©úÁA:NASH专栏¡UNASH update (3¤ë22¤é): FGF21这¬On¤@统¦¿´ò¤F¡H Î`习FDAªº谆谆±Ð诲±Ð诲¡AF4¥N偿¨xµw¤Æ¬O¥¨¤jªº¥¼满¨¬临§É»Ý¨D,±wªÌ¸sÊ^¤£¤p F4药ª«ªº¬ã发¦³单独ªºguideline¡A©M单独F2-F3 NASH¤£¦P ... ... F4ªº临§É预¦Z¬O«Ü®tªº (从Gilead¥¢败ªºSTELLAR studiesªº数Õu¤ÀªR¡A¥i¥H¬Ý¥X¦pªG纤维¤Æ¦³°f转¡A总Ê^预¦Z会¦n«D±`¦h) ©MF2 F3¤ñ¡A¤£¬O线©Ê¤W¤É¡A¦Ó¬O¦¨¿¼W长 Kaplan-Meier curve«Ü©ú显¬Ý¨ì¡A¤¦~¬O个§¢¤I 现¦bªº¥i¨Ñ²¾´Óªº¨x脏¾¹©x·½¡A远¤£¯à满¨¬»Ý¨D 12个¬¡检数Õu¨½±¦³4个¦³纤维¤Æ§ïµ½(这¬O³Ì«½Sªº数Õu¡A¦]为纤维¤Æ§ïµ½¥i¥Hª½±µ¼v响预¦Z) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 08:30:15²Ä 2172 ½g¦^À³
|
F4°ò¥»ºâ¬O¥Ø«eÃĪ«¬ãµoªº¸T°Ï¡A¯e¯f¶i®i¨ì¨xµw¤Æ¤§«á¦A°fÂà¬O«D±`§xÃøªº¡A¦pªG¯à°µ¥XÀø®Ä¡A¯uªº´N¤jº¡³e¤F¡C ©Ò¥HSNP-610´Á¤¤¤ÀªR:F4ªº²Õ¡AªvÀø«e«á¦³[ÅãµÛ®t²§]---¹Ú´K¥H¨D¦Ó¥B¬Ý¨ì$$$ª÷¥ú°{°{$$$ SNP-630ªºCOGS®£©È¤]«Ü°ª???(«ÜÃø¦X¦¨) Akero efruxifermin(FGF21)¦b³o½g¦³«Ü¸ÔºÉ¤ÀªR: www.drugtimes.cn/2021/06/17/nashzhuanlanmantannashdafenziyaowu/ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 07:05:53²Ä 2171 ½g¦^À³
|
¹Ú´K¥H¨Dªºµª®×!(¤ñ¨Ò¤£ª¾) SNP-610´Á¤¤¤ÀªR¦³¨xŦÅÖºû±½´y»öFibroscan data¡A°ò¦Ȱª(F4)ªº²Õ¡AªvÀø«e«á¦³[ÅãµÛ®t²§]¡C ------------------------------------------------------------------------------------------------ ½Ð°ÝSNP-610Á{§É¤G´Á¸ÕÅç¹wp¦ó®É·|¦³µ²ªG? SNP-610¶}©ñ¦¡Á{§É¤G´Á¬ã¨s¤wÀò±oÅãµÛ¤HÅéÀø®ÄÃÒ¾Ú¡C¾Ú109¦~7¤ë´Á¤¤¤ÀªRµ²ªG¡A35¦ì NASH¯f¤H¡A¥]§t17¦ì°ª¾¯¶q²Õ©M18¦ì¤¤¾¯¶q²Õ¡A¸g12¶gªvÀø«á¡A¥DnÀø®Ä«ü¼Ð¨xŦ¾¢Ói»Ä¤þ଻ÄÂà®ò°ò»Ã¯À(ALT)¦b°ª¾¯¶q²ÕÅãµÛ°§C¹F -29.5¡Ó33.0 U/L, p=0.002¡A¤¤¾¯¶q²ÕÅãµÛ°§C¹F -18.9¡Ó27.3 U/L, p=0.009¡C¨ä¥LÀø®Ä«ü¼Ð¦p¾¢Ói»Äf¾L»ÄÂà®ò°ò»Ã¯À(AST)¡B¨Å»Ä²æ²B酶¡]LDH¡^¡BÁͤƦ]¤lCCL2/CCL5¡BCasepase-3¡BªÅ¸¡¦å¿}ȵ¥¡A¥ç¬ÒÅãµÛ°§C¡CSNP-610´Á¤¤¤ÀªR¦³¨xŦÅÖºû±½´y»öFibroscan data¡A°ò¦Ȱª(F4)ªº²Õ¡AªvÀø«e«á¦³ÅãµÛ®t²§¡C¯×ªÕ¨x¡A¦b§C¾¯¶q²ÕªvÀø«á¦³¶i¨B¡C¥Ø«e¤´¦b¶i¦æ¤¤¡A¹wp¨ì109¦~©³¡C ---------------------------------------------------------------------------------------------------- |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 06:38:08²Ä 2170 ½g¦^À³
|
Ocaliva ªvÀøPBCªº¾¯¶q¡]5mg¡A¨C¶g2¦¸¡^ VS. OcalivaªvÀøNASHªº¾¯¶q¨âºØ¾¯¶q¡]10mg©M25mg¡A¨C¤é¤@¦¸¡^ ¦w¥þ©Ê??? ----------------------------------------------------------------------------------------------- read01.com/M2e6RKO.html#.YsDHXXZBzcs PharmaTimes ©ó 9 ¤ë 22 ¤é³ø¾É¡A¬ü°êºÊºÞ¾÷ºcµo¥¬¤F¤@¥÷¦w¥þĵ§i¡AºÙ Intercept »sÃĪº Ocaliva ¦bìµo©ÊÁx¥Ä©ÊÁxºÞª¢±wªÌ¤¤¨Ï¥Î®É¡A¤£¥¿½Tªº¾¯¶q¥i¾ÉPÄY«ªº¨x·l¶Ë©M¦º¤`·ÀI¡C¬ü°ê FDA ªí¥Ü¡A¦Û Ocaliva¡]¶ø¨©Áx»Ä¡^©ó 2016 ¦~ 5 ¤ëÀò§å¥Î©ó¨xŦ¯e¯f¥H¨Óªº 13 Ó¤ë¸Ì¡A¤w¸g½T»{¤F 19 ¨Ò¦º¤`¯f¨Ò¡A¨ä¤¤ 8 ¨Ò¦º¤`´£¨Ñ¤F¦º¦]«H®§¡C ¾Ú³ø¾É¡A¦b 7 ¨Ò¦º¤`¤¤¡A¦º¤`ì¦]¬Oìµo©ÊÁx¥Ä©ÊÁxºÞª¢ªº´c¤Æ¡A¦Ó¥t¤@¨Ò¦º¤`ªº±¡ªp«h¬O¤ß¦åºÞ¯e¯f¡C¦ÜÃö«nªº¬O¡A¦b³o 8 ¨Ò¦º¤`¯f¨Ò¤¤¡A¦³ 7 ¨Ò¤¤««×¨x¥\¯à´î°h±wªÌ¨C¤Ñ±µ¨ü 5 mg ªº¶ø¨©Áx»Ä¡A¦Ó¤£¬OºÊºÞ¾÷ºc«Øijªº¨C©P¨â¦¸¡A¤£¶W¹L 10 mg ªº¾¯¶q¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 06:27:54²Ä 2169 ½g¦^À³
|
¬°¤°»ò¥s¹Ú´K¥H¨Dªºµª®×??? [ų¤_ÅÖºû¤Æ·¥°ªªº¦MÀI©Ê¡A¦pªG¤@ºØÔ¿ïÃÄþ©È¤£¯àÅãµÛ°§CNASH¯gª¬¡A¦ý¥un¯àû{°fÂàÅÖºû¤Æ¡A¬ü°ê¹«~ÃÄ«~ºÊºÞ§½¡]FDA¡^³£Ä@·N±µ¨ü³o¼Ëªº·sÃĥӽСC±q¦³®Ä©Êªº¨¤«×¨Ó¬Ý¡AOcaliva¦³²z¥ÑÀò±oFDAªº§åã¡C] [ų¤_ÅÖºû¤Æ·¥°ªªº¦MÀI©Ê¡A¦pªG¤@ºØÔ¿ïÃÄþ©È¤£¯àÅãµÛ°§CNASH¯gª¬¡A¦ý¥un¯àû{°fÂàÅÖºû¤Æ¡A¬ü°ê¹«~ÃÄ«~ºÊºÞ§½¡]FDA¡^³£Ä@·N±µ¨ü³o¼Ëªº·sÃĥӽСC±q¦³®Ä©Êªº¨¤«×¨Ó¬Ý¡AOcaliva¦³²z¥ÑÀò±oFDAªº§åã¡C] [ų¤_ÅÖºû¤Æ·¥°ªªº¦MÀI©Ê¡A¦pªG¤@ºØÔ¿ïÃÄþ©È¤£¯àÅãµÛ°§CNASH¯gª¬¡A¦ý¥un¯àû{°fÂàÅÖºû¤Æ¡A¬ü°ê¹«~ÃÄ«~ºÊºÞ§½¡]FDA¡^³£Ä@·N±µ¨ü³o¼Ëªº·sÃĥӽСC±q¦³®Ä©Êªº¨¤«×¨Ó¬Ý¡AOcaliva¦³²z¥ÑÀò±oFDAªº§åã¡C] ----------------------------------------------------------------------------------------------- ªvÀø¶g´Á»P¦³®Ä©Ê¤ñ¨Ò!!! 1. Ocaliva¸g¹L18Ӥ몺°ª¾¯¶qªvÀø«á¡A14.9%ªºNASH±wªÌ¡]¥]¬A¤@´Á¡B¤G´Á©M¤T´ÁÅÖºû¤Æ¡^¨S¦³¥X²{ª¢¯g¡A»·°ª¤_¦w¼¢¾¯ ¹ï·Ó²Õªº7.9%¡C¤@´Á¡B¤G´Á©M¤T´ÁÅÖºû¤Æ--->F1 F2 F3 2. Akeroªºefruxiferminªv疗16©P¦Z¡A50%°ò线时显¥ÜF2/F3´Á纤维¤Æªº±µ¨üefruxiferminªv疗ªº±wªÌ实现¤Ftwo-stage ªº纤维¤Æ®ø°h¡C F4¨xµw¤Æ(ÄY«ÅÖºû¤Æ)-->°fÂà!!! ¤½¥¬¤F¤@项针对30¨Ò±ß´Á(F4)¨xµw¤ÆNASH±wªÌªºIIa´ÁBALANCED¬ã¨sªº扩®i队¦C结ªG¡A¦bªv疗16©P¦Z¡A 33%¡]4/12¡^±wªÌ纤维¤Æ显µÛ§ïµ½¥BNASHÆÓ恶¤Æ¡A¦w¼¢剂组这¤@¤ñ¨Ò为0% 3.SNP-610´Á¤¤¤ÀªR 1.F4(ÄY«ÅÖºû¤Æ)ªvÀø«e«á [¦³ÅãµÛ]®t²§¡Cªì¨B¼Æ¾ÚÀu©ó:Ocaliva , MGL3196 (Resmetirom¡^, Selonsertib |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 06:15:10²Ä 2168 ½g¦^À³
|
[InterceptªºNASH·sÃĸÕÅç¨ú±o¦¨¥\¡A¦ýúÒ·tÂùp°Ï] ¦¨¥\°§CÅÖºû¤Æ¶iµ{ ¤µ¦~2¤ë¡AInterceptµo¥¬ªº¬ã¨s¼Æ¾ÚÅã¥Ü¡AOcaliva¦b±wªÌª¢¯g¨S¦³´c¤Æªº±¡úG¤UÅãµÛ°§C¤FÅÖºû¤Æµ{«×¡C¤£¹L¥i±¤ªº¬O¡A¤G´Á©Î¤T´ÁÅÖºû¤Æ±wªÌªºNASH¯gª¬幷¥¼¥X²{ÅãµÛ§ïµ½¡C¦¹¥~¡AOcaliva¹ï¤_¤@´Á¨xÅÖºû¤Æ±wªÌªºªvÀø®ÄªG§ó爲©úÅã¡C¸g¹L18Ӥ몺°ª¾¯¶qªvÀø«á¡A14.9%ªºNASH±wªÌ¡]¥]¬A¤@´Á¡B¤G´Á©M¤T´ÁÅÖºû¤Æ¡^¨S¦³¥X²{ª¢¯g¡A»·°ª¤_¦w¼¢¾¯¹ï·Ó²Õªº7.9%¡C [ų¤_ÅÖºû¤Æ·¥°ªªº¦MÀI©Ê¡A¦pªG¤@ºØÔ¿ïÃÄþ©È¤£¯àÅãµÛ°§CNASH¯gª¬¡A¦ý¥un¯àû{°fÂàÅÖºû¤Æ¡A¬ü°ê¹«~ÃÄ«~ºÊºÞ§½¡]FDA¡^³£Ä@·N±µ¨ü³o¼Ëªº·sÃĥӽСC±q¦³®Ä©Êªº¨¤«×¨Ó¬Ý¡AOcaliva¦³²z¥ÑÀò±oFDAªº§åã¡C] ¦¨¥\I«áªº·tÁG Regenerate¬ã¨sµû¦ô¤F¨âºØ¾¯¶q¡]10mg©M25mg¡A¨C¤é¤@¦¸¡^ªºOcaliva¬Û¸û¦w¼¢¾¯ªº¦w¥þ©Ê©M¦³®Ä©Ê¡A¨ä¤¤§C¾¯¶q²Õªºµ²ªG¤£û{²z·Q¡C2¤ë¸ÕÅçµ²ªGµo¥¬«á¡AInterceptªºªÑ»ùÀ³Án¤U®À¡Aì¦]¬O¥«³õ»{爲¦³®Ä¾¯¶q¥i¯à¹L°ª¡C ÁöµM°ª¾¯¶qOcalivaªº¦³®Ä©ÊÀò±o»{¥i¡A¦ýúÒ·tÂõۥ¨¤jªºÁô¼~¡G51%±µ¨ü¦³®Ä¾¯¶qªvÀøªº±wªÌ¥X²{ºC©Êæ±Äo¡A幷¥B¨ä¤¤ÁÙ¦³9%ªº±wªÌ¦]爲æ±Äo¯g¦Ó²×¤îªvÀø¡C[[æ±Äo¥i¯à¬O¥Ñ¨ü·l¨xŦº¯º|Áx¥Ä»Ä©Ò¤Þ°_¡A¦]¦¹È±oÄYµÂ¹ï«Ý¡C]]¦¹¥~¡A¬ã¨s¤¤¤£¨ì1%ªº±wªÌªº¨x酶¤ô¥¹L°ª¡CIntercept¦b2¤ë«ü¥X¡A©Ò¦³3Ó¤À²Õ§¡¥X²{ÄY«¤£¨}¨Æ¥ó¡A¨ä¤¤¦³®Ä¾¯¶qªvÀø²Õªº³o¤@¼Æȧ󰪡C ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:12:28²Ä 2159 ½g¦^À³ F4¨xµw¤Æ(ÄY«ÅÖºû¤Æ)-->°fÂà!!! Akero¤½¥¬¤F¤@项针对30¨Ò±ß´Á(F4)¨xµw¤ÆNASH±wªÌªºIIa´ÁBALANCED¬ã¨sªº扩®i队¦C结ªG¡A¦bªv疗16©P¦Z¡A33%¡]4/12¡^±wªÌ纤维¤Æ显µÛ§ïµ½¥BNASHÆÓ恶¤Æ¡A¦w¼¢剂组这¤@¤ñ¨Ò为0% -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/2/23 ¤W¤È 07:53:57²Ä 830 ½g¦^À³ ¤°»ò¥s¹Ú´K¥H¨Dªºµª®×??? ¦]¬°SNP-610´Á¤¤¤ÀªR 1.F4(ÄY«ÅÖºû¤Æ)ªvÀø«e«á [¦³ÅãµÛ]®t²§¡C 2.ªì¨B¼Æ¾ÚÀu©ó:Ocaliva , MGL3196¡]Resmetirom¡^, Selonsertib |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 10:29:31²Ä 2167 ½g¦^À³
|
¤£³æÀu©óOCALIVA! Àu©ó³o¨Ç:SNP-610(CYP2E1§í¨î)¸gÀø®ÄÃÒ¹ê(Proof of concept)¡A¨ä¤G´Á¸ÕÅçµ²ªGÀu©ó¤wµoªí¨Ã¶i¤J¤T´Á¤§¦U°ê NASH Ô¿ïÃĪ«. Ocalivaªº°Æ§@¥ÎÆZ¦h¥B·|¦º¤Hªº! ±ß¦w~ --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/7 ¤U¤È 12:23:54²Ä 1938 ½g¦^À³ ¦pªG§Ú¬OIntercept¤½¥qCEO¡A¦b®³¨ì²Ä1±iNASHÃÄÃÒ«á¸êª÷¤ô¦ìº¡·¸¡AnµÛ¤âOcalivaªº¤U¤@¥N·sÃÄ(§ó¨ã¦w¥þ©Ê»PÀø®Ä)¡A ¨º»òª½¨úSNP-630§@ÁpÃĶ}µo´N¬O³Ì¨Î³Ì§Ö³t¿ï¶µ¤§1 ! ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/7 ¤W¤È 10:02:17²Ä 1935 ½g¦^À³ FDA¹ïOcalivaªººÃ¼{¦b¦w¥þ©Ê(¨x¬r)! Ocaliva +SNP-630ÁpÃĦ³ÅãµÛªº¨ó¦P§@¥Î¡AOcaliva ¾¯¶q°§C¡AÀø®Ä»P¦w¥þ©Ê§ó°ª§ó¨Î! -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/11/20 ¤W¤È 11:34:58²Ä 1477 ½g¦^À³ ²×§½¤§¾Ô! 2021.8.2 Intercept ø»sOcalivaÀò±oNASH §å㪺·s³~®|:¥un«O«ù¦w¥þ©Ê |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2022/7/2 ¤U¤È 10:12:57²Ä 2166 ½g¦^À³
|
R¤j ½Ð±Ð±z¡A¬°¤°»ò¤£¬Ý¦nINTERCEPT¤§NASHÃÄOCALIVA? ¦pªG¦¹ÃĹF¼Ð¹LÃö¡A¦ÓNP610¼Æ¾Ú¤ñ¨äÁÙÀu¡A¨ºªYÄ£¤£´Nµo¤F¶Ü¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 10:09:38²Ä 2165 ½g¦^À³
|
·í³sFDA COVID-19ÃĪ««ü«n(superiority:¥ÎÃIJջP¹ï·Ó²ÕªºÀø®Ä«ü¼Ð¹F¨ì²Îp¾Ç¤WªºÅãµÛ·N¸q)³£¤£¬Û«H¡A¹ç¥i¬Û«H[°ê¹©¦¡]¸Ñª¼¡A¯«¥P¤]Ãø±Ï!!! VERU¥Î¤°»òÁ{§É¼Æ¾Ú¥Ó½ÐEUA? ¤£´N¬O¥ÎÃIJջP¹ï·Ó²ÕªºÀø®Ä«ü¼Ð¹F¨ì²Îp¾Ç¤WªºÅãµÛ·N¸q! ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/8 ¤U¤È 06:57:41²Ä 1875 ½g¦^À³ FDA [[[strongly]]] recommends that drugs to treat COVID-19 be evaluated in randomized, placebo-controlled, double-blind clinical trials using a [[[superiority design]]] -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/3/22 ¤W¤È 09:09:37²Ä 1809 ½g¦^À³ ...2020.5.11 FDA COVID-19ÃĪ««ü«n www.fda.gov/media/137926/download ...FDA ¡§±j¯P«Øij¨Ï¥ÎÀu®Ä©Ê³]pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡BÂùª¼Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 04:48:53²Ä 2164 ½g¦^À³
|
Ocaliva[²×§½¤§¾Ô]´N¦b7¤ë! ²Ä1¤äNASHÃĪ«? Intercept set to meet with FDA in July about NASH drug ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/18 ¤W¤È 07:49:34²Ä 1600 ½g¦^À³ ·Q[½ä]¤@©]P´I?³o®aIntercept pharmaceuticalsªº[²×§½¤§¾Ô]¦³¼Éº¦10~20¿ªº¹ê¤O»P¾÷·|?! ì¦]: 1.ªÑ»ù¾ú¥v°ª 2014.1.6 $497¡A¾ú¥v§C:2021.8.16 $11.6 2.¬Q¤é¦¬½Lº¦7.96% ¦¬$17.76----¬ü°ê§ë¸êªÌ¶}©l©ãª`Ocalivaªº[²×§½¤§¾Ô] 2022.1.7---2022 ¦~¤£¥i¿ù¹Lªº 3¶µ....¹ï©ó³o¨Ç»sÃÄ°Ó¨Ó»¡¡A³o¥i¯à¬O«D±`¿E°Ê¤H¤ßªº¤@¦~¡C 3.¤@¾Ô¨M¥Í¦º®É¶¡:2022¦~¤W¥b¦~ 2021.12.20 Intercept ¥i¯à·|¦b 2022 ¦~¤W¥b¦~»P FDA «·s´£¥æ·|ij¡C 4.Ó¤H¤£·|©ãª`³o³õ½ä§½¡A°lÂÜFDA§å㪺²Ä1¤äNASHÃĪ«¥Î¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 01:35:37²Ä 2163 ½g¦^À³
|
·í²Ä¤@ÓNASHÃĪ«¤W¥«¡ANASH»â°ì´N·|¯u¥¿ªº¤õÃz°_¨Ó¡C °ê»Ú¤j¼t¨ì®É鹬°F¬Û争¡A¥Î¥L̪º¶¯«p°]¤O¦¬Áʤp¤½¥q(º®¯Î¤§§Q)¡C ¥¼¨ÓNASH»â°ì¯à¥´±o¦h¤õ¼ö? ¥i¥H°Ñ¦Ò´X½gC¨xÃĪ«ªº¬G¨Æ: 1.www.gbimonthly.com/v11_2015/v11cover_2015_00.html 2.news.gbimonthly.com/tw/celebrity/show.php?num=18130 ²¦³ºNASH¬OÓ¥¨¤jªº¥¼¶}µoºC¯f¥«³õ!!! (JP:¦]¬°³oÓÃĪº¥«³õ¤Ó¤j¡A©Ò¥H§Ú¤£¥h·m²Ä1 ¤£·m²Ä2 ¤£·m²Ä3 §Ú·mÓ²Ä4³£¥i¥H«Ü¤j¤@¶ô.... )---³o¬q»¡ªkµ¥¦PC¨xÃĪ«¥«³õ²{ªp! www.facebook.com/watch?v=298211662214622 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 12:18:10²Ä 2162 ½g¦^À³
|
¥h¦~¼W¦¬«¯g±wªÌ¡A«¥¤w´£¥Xĵ¥Ü¬Ýªk¡C1¤ë5¤é¤U¤È 04:14:55¡A¦A½èºÃ¸Ñª¼¨S¦³¹ï·Ó²Õ¼Æ¾Ú!!! 1/21¶K¥X[ÃÒ¨é´Û¶B]«ß®v¨Æ°È©Ò¥Nªí§ë¸êªÌ«Å¥¬¹ï NRx ¶i¦æ½Õ¬d¡C ºG½ßªº§ë¸ê¤H¸Ó«ç»ò°µ? ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/21 ¤W¤È 07:50:58²Ä 1611 ½g¦^À³ ¸g¹L°ò¨È»P¯E¹©¨Æ¥ó«á¡A§ë¸ê¤H¹ï¥Í§ÞªÑ¯d¤U¤£¦nªº¦L¶H¡A¤£§Æ±æ¾ú¥v¨Æ¥ó«ºt! 1. FDA©Úµ´NRxÃļtZyesami¥Î©óªvÀø¦M«¯f±w¤§EUA 2. 2022.1.20ÃÒ¨é´Û¶B«ß®v¨Æ°È©Ò¥Nªí§ë¸êªÌ«Å¥¬¹ï NRx ¶i¦æ½Õ¬d2021 ¦~ 6 ¤ë¡ANRx «Å¥¬¦V¬ü°êFDA´£¥æ¥Ó½Ð¡An¨DÀò±oZYESAMIªººò«æ¨Ï¥Î±ÂÅvEUA¡A¥HªvÀø±w¦³©I§l°IºÜªº¦M« COVID-19 ±wªÌ. ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/5 ¤U¤È 04:14:55²Ä 1548 ½g¦^À³ °ê¹©«ç¤£´£¨Ñ¹ï·Ó²Õ¼Æ¾Ú? ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/12/29 ¤U¤È 01:47:04²Ä 1534 ½g¦^À³ ... 4.¶·×§ï¤Ï˦³¤F¤£½T©w? (»´¤¤¯g¦º¤£¤F¤H¡A©Ò¥H¤£¥i¯à³Q²×¤î) °ê¹©:DMC«Øij¼W¥[¦¬ªv»Ýn®ñ®ð¤ä«ù¤§«¯g¦í°|¯f±w¡C(«D«I¤J©Ê³q®ð¡B°ª¬y¶q®ñ®ð©Î¸§J½¤) ³o®É¦³2ºØ¥i¯à©Ê:¤@¬O¦³®Ä©Ò¥H¥[¤J«¯g±wªÌ¡A¤G¬O¥i¯à»´¤¤¯g¦³®Ä©Ê¤£©úÅã¡A©Ò¥H¥[¤J«¯g±wªÌÁ{§É¬Ý¬Ý¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:37:58²Ä 2161 ½g¦^À³
|
SNP6¨t¦CCYP2E1§í¨î-->>>FGF21(¤º·½©Ê¼W¥[)¡C±EÀu±E¦Hµ¥¸ÕÅç´¦¾å! Efruxifermin¬OFc-FGF21¿Ä¦X³J¥ÕÃþ¦üª«¡ABIO89-100»PPegbelfermin¬OPEG-FGF21Ãþ¦üª«¡C EfruxiferminÁ{§É¼Æ¾ÚÀu©óBIO89-100»PPegbelfermin(²×¤î¸ÕÅç) ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/20 ¤W¤È 09:51:19²Ä 2120 ½g¦^À³ SNP610/SNP630(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-->FGF21(¤º·½©Ê¼W¥[)¡C ±EÀu±E¦Hµ¥¸ÕÅç´¦¾å! ------------------------------------------------------------------------------------------ [©Ò¥H¥~·½©ÊFGF21¤£¤@©w§ïµ½¥N谢¯¿乱¡C] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:24:48²Ä 2160 ½g¦^À³
|
¬Ý¬Ý¯E¹©¡ASNP-630¦¨¥»¬OÁô¼~?! ----------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/5/7 ¤U¤È 05:44:04²Ä 1099 ½g¦^À³ Q2:ª¾¹DSNP-630«ÜÃø¦X¦¨¡A»s³y¦¨¥»¨s³º¦h°ª? ----------------------------------------------------------------------------------------------- 2022¦~7¤ë2¤é ¶g¤» ¤W¤È4:10 ¯E¹©¡]4174¡^1¤é¤½§i¡AºX¤U§ÜÅé·sÃÄOBI-888Áö¨ãÁ{§É¶}µo»ùÈ¡A¦ý¥Í²£¦¨¥»°¾°ª¡A¥«³õ®Ä¯q°¾§C¡A¨M©w´£¦©ó²Ä¤G©u«á²×¤î¦¬®×¡A¥H¸û¨ã¶}µo»ùȪºOBI-999¬°Àu¥ýµo®i¼Ðªº¡C ¯E¹©¸³¨Æªø±i©À·O«ü¥X¡AOBI-888¶i¦æ¤¤ªºÁ{§É¤G´Á±Ú¸sÂX¼W¶¥¬q¸ÕÅç¡AÁöÁÙ¥¼¬Ý¨ì²Å¦X¹w´Áµ²ªG¡A¦ý¤w¥R¤ÀÅã²{OBI-888ªvÀøÀù¯gªº¬¡©Ê¡F°Ñ»PªvÀøӮפ¤¡A¦³¥|¦W¯f¤H©µªø¦s¬¡´Á¹F¤»Ó¤ë¥H¤W¡A¨ä¤¤¨â¤H¬Æ¦Üªø¹F¤QÓ¤ë¡A¨ÃÆ[¹î¨ì®ø´î¸~½FÅé¿nӮסA»¡©úOBI-888¤wÅã¥ÜÁ{§É®ÄªG¡A¦ý°ò©óÃÄ«~¤Æ¾Ç»s³y¡]CMC¡^²£¥X²v§C¡A¼vÅT¦¨¥»¬Æ¹d¡A¬°ªø»·µo®ip¡A¨M©w´£«e²×¤î¦¬®×¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:12:28²Ä 2159 ½g¦^À³
|
F4¨xµw¤Æ(ÄY«ÅÖºû¤Æ)-->°fÂà!!! Akero¤½¥¬¤F¤@项针对30¨Ò±ß´Á(F4)¨xµw¤ÆNASH±wªÌªºIIa´ÁBALANCED¬ã¨sªº扩®i队¦C结ªG¡A¦bªv疗16©P¦Z¡A33%¡]4/12¡^±wªÌ纤维¤Æ显µÛ§ïµ½¥BNASHÆÓ恶¤Æ¡A¦w¼¢剂组这¤@¤ñ¨Ò为0% -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/2/23 ¤W¤È 07:53:57²Ä 830 ½g¦^À³ ¤°»ò¥s¹Ú´K¥H¨Dªºµª®×??? ¦]¬°SNP-610´Á¤¤¤ÀªR 1.F4(ÄY«ÅÖºû¤Æ)ªvÀø«e«á [¦³ÅãµÛ]®t²§¡C 2.ªì¨B¼Æ¾ÚÀu©ó:Ocaliva , MGL3196¡]Resmetirom¡^, Selonsertib |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 10:57:27²Ä 2158 ½g¦^À³
|
SNP-6¨t¦C¨ã¦³·¥¼eªº¦w¥þ¾¯¶q¡A¦w¥þµL¸·¡A¦P®É¦³§¹¾ãªº±M§Q«OÅ@¡A¨Ã¾Ö¦³·¥¨ã¥@¬ÉÄvª§©Ê¿W¯Sªº[¤T«§@¥Î]¾÷Âà¦p¤U : (1) ½Õ±±¨x¯×ªÕ¥NÁ (METABOLIC)¡A SNP-6¥i½Õ±±¤T»Ä¥Ìªoà¥NÁÂ/¦X¦¨¬ÛÃö»Ã¯À¦pDGAT1¡A°§C¨xŦ¤T»Ä¥Ìªo¯×°ï¿n¡A ªvÀø¤Î¹w¨¾¯×ªÕ¨x¡F (2) §Ü¯×ªÕ¨xª¢¡F SNP-6¥iª½±µ§í¨î¨xŦomega-oxidation¬ÛÃö»Ã¯ÀCYP2E1¡A¨Ï±o·|¶Ë®`¨x²ÓM¡B»¤µoµo ª¢¤ÏÀ³ªº ¬¡©Ê ®ñ¤Æ ª«½è (Reactive oxygen species, ROS)¤£¦A²£¥Í©Î°§C¡A¶i¦ÓªvÀø¤Î¹w¨¾¯×ªÕ ¨xª¢¡F (3) §Ü¨xÅÖºû¤Æ¡ASNP-6°£¤F¥i¸g¥Ñ§í¨î¨xŦ CYP2E1°§C ROS²£¥Í¡A¤]¥i¸g¥Ñ¦¹¾÷Âà¡A°§C·|»¤µo¨xÅÖºû¤Æ§K¬Ì¤ÏÀ³ªº²Ó M ¶Ë®`²£¥Í¡A¥i°§C·|«P¶i¨xÅÖºû¤Æ¤Î¨xµoª¢ªºÁͤƦ]¤lCCLs¡A¹w¨¾¤ÎªvÀø¨xÅÖºû¤Æ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 10:49:56²Ä 2157 ½g¦^À³
|
±q 1.杨¨q伟团队½×¤å´£¥Xªº¾÷¨î:CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21¡C ¨ì 2.Efruxifermin(FGF21Ãþ¦üª«)¯à°÷¨ÏÅÖºû¤Æ°fÂ઺Á{§ÉÃÒ¾Ú¡AÁ{§É¼Æ¾Ú¬O¥Ø«e¤w¤½§GªºNASH³ÌÀuÀøªk¡C ¬Ý -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/6/2 ¤W¤È 10:49:19²Ä 1172 ½g¦^À³ ¼W¸ê»¡©ú®Ñ§â©³¤U³o¬q¥[²Ê¶Â¦r(109¦~³ø¨S¬Ý¨ì³o¬q±Ôz)! ...SNP-610(CYP2E1§í¨î)¸gÀø®ÄÃÒ¹ê(Proof of concept)¡A¨ä¤G´Á¸ÕÅçµ²ªGÀu©ó¤wµoªí¨Ã¶i¤J¤T´Á¤§¦U°ê NASH Ô¿ïÃĪ« |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 10:32:20²Ä 2156 ½g¦^À³
|
Efruxifermin显µÛ°f转¨x纤维¤Æ获FDA§Ö³t³q¹D资®æ ttps://xueqiu.com/8965749698/200635172 Efruxifermin¬OFc-FGF21¿Ä¦X³J¥ÕÃþ¦üª«¡ABIO89-100»PPegbelfermin¬OPEG-FGF21Ãþ¦üª«¡C 1.Efruxifermin(FGF21)¬OºÓÃÒ¹êFGF21Ãþ¦üª«¯à°÷¨ÏÅÖºû¤Æ°fÂ઺Á{§ÉÃÒ¾Ú¡A[¨äÁ{§É¼Æ¾Ú¬O¥Ø«e¤w¤½§GªºNASH³ÌÀuÀø ªk¡A³æÃĪvÀø®³ÃÒ¾÷²v¬Û·í°ª! 2.SNP610/SNP630(CYP2E1§í¨î->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[->¿E¬¡ PPAR£\->FGF21(¤º·½©Ê¼W¥[)---¹Ú´K¥H¨Dªºµª®×¤]¬OFGF21 ¾÷¨î??? 3.2022.6.16 :½÷·ç¥H2500¸U¬ü¤¸¤JªÑAkero¤½¥q¡A¾Ö¦³ Akero ¬ù 6.7% ªº¤wµo¦æ´¶³qªÑ¡C ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/25 ¤U¤È 11:04:16²Ä 2018 ½g¦^À³ §ì´X¤äªvÀøNASHªºCYP2E1-PPAR£\-FGF21ÃĪ«§@¬ö¿ý 1.CYP2E1/DGAT1-SNP610/630 ªYÄ£ 2.FGF21 Stimulants: a. BIO89-100 - 89bio b. Efruxifermin (EFX) - Akero Therapeutics c. Pegbelfermin - Bristol Myers Squibb/Ambrx Inc ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/2/23 ¤W¤È 07:53:57²Ä 830 ½g¦^À³ ¤°»ò¥s¹Ú´K¥H¨Dªºµª®×??? ¦]¬°SNP-610´Á¤¤¤ÀªR 1.F4(ÄY«ÅÖºû¤Æ)ªvÀø«e«á [¦³ÅãµÛ]®t²§¡C 2.ªì¨B¼Æ¾ÚÀu©ó:Ocaliva , MGL3196¡]Resmetirom¡^, Selonsertib |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 09:06:31²Ä 2155 ½g¦^À³
|
ºµ°ÆÁ`¤S½æ¦ÑªÑ»{·sªÑ?(³o¶gªÑÅv¤À´²ªí·s¼W199±i) |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/1 ¤U¤È 11:38:22²Ä 2154 ½g¦^À³
|
±M®a±À¦ôÁ`À禬200»õ¬ü¤¸¨¤«×¬ÝªYÄ£¤À¼íª÷20»õ¬ü¤¸¡AÀò§Q800¤¸¡AªÑ»ù¹F20000¤¸¡F©ñ10¦~ªÑ»ù¤¶6000¤¸¢w20000¤¸¤§¶¡¡C¥H¤W¬O±q¤£¦P±¦VpºâªÑ»ù¥i¯à©Ê¡A¤j®a·í°Ñ¦Ò´N¦n¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/1 ¤U¤È 04:49:40²Ä 2153 ½g¦^À³
|
©êºpºâ¿ù¡A20»õ¬ü¤¸¦X²z»ù4¤d¤¸¡C¤£¹L¡A§Ú®Ú¾Ú¦U±M·~¤j¶K¤å¡Aµû¦ô8¨t2Áû15»õ¬ü¤¸¡F6¨t2Áû20»õ¬ü¤¸¡A¦Xp35»õ¬ü¤¸¡AªÑ»ù6¤d¤¸¦X²z¡C¥H¤W«D±M·~µû¦ô®¤¤£t³d¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/7/1 ¤U¤È 03:11:29²Ä 2152 ½g¦^À³
|
dk¤j¡A±zµ¹¥¦¾Ö¦³30±i¡A©ñ8¦~³£¤£½æ¡AY2000¤¸¡A´N¦³6¤d¸U¤¸¡m¥b»õ¡n¡F¤j´²¤á±M·~r¤j«e¶K¤å¡A¨CÁû¤j©ó5»õ«Ü²M·¡¤]ºâ«O¦u¦ô¡A20»õ¬ü¤¸¦X²z»ù¬O6¤d¤¸ªÑ»ù¡CªÑ¤ý§Î¦¨n10¦~®É¶¡¡AY¦X²z»ù30±i¡A¦³¤@»õ8¤d¸U¤¸¡A¤¬«j¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/7/1 ¤U¤È 02:31:06²Ä 2151 ½g¦^À³
|
¤p§Ì°ê¹©¼Q¥X¨S§â´¤¨ì¡A³o¦¸·sÃÄn¼µ¦í!!ÁöµM§Ö¼µ¤£¤U¥h¤F ¦³Ó¥b»õ´N¨¬°÷ ============================================================================= ªYÄ£¨ãªÑ¤ý¬Û¡A¬ù§ë¸ê8¦~¡AªÑ»ù2000¤¸¡A§Ú60±i¤@»õ¤pô¡I¸ê²£¤W»õ¤¸¦º¦ÓµL¾Ñ¡IY¦³¨º¤@¤Ñ¡Ar¤j¦Ü¤Ö5»õ¤¸¡A¤£nÃø¹L¹L¥h¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/1 ¤W¤È 09:20:24²Ä 2150 ½g¦^À³
|
³o»ò¦h¥©¦X? 2022¦~¬ü°êÀò±oºÊºÞ¬ì¾Ç¤H¤~ÄvÁɪºÀò¼úªÌ¥X®u FDA www.fda.gov/science-research/advancing-regulatory-science/2022-winners-americas-got-regulatory-science-talent-competition-present-fda FDA¸ê§U.... ²Ä¤@¦Wªº¹Î¶¤¡C AcetaSAFE «Øij¸Ñ¨M¤è®×ªºÂ²n´yz¡C¸Ó¹Î¶¤´£¥X¤F¥L̪º·Qªk¡A¬°«D³B¤èÃÄ¡]OTC¡^ªº¹ï¤A酰®ò°ò×ô©M³B¤èÃĶ}µo¤@ÓQR½X¡C¨ä¥Øªº¬O´£°ª±wªÌ¹ï¹ï¤A酰®ò°ò×ô¾¯¶qªº»{ÃÑ¡C¸Ó¤p²Õµo²{¡A±wªÌ©¹©¹¹ï¥LÌ°w¹ï¤£¦P°·±d»Ý¨Dªº¾A·íªº¹ï¤A酰®ò°ò×ô¾¯¶q¯Ê¥F²M·¡ªº¤F¸Ñ¡A³o¥i¯à¨Ï®ø¶OªÌ±Á{¹L¶qªº·ÀI... ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/18 ¤U¤È 08:39:14²Ä 2117 ½g¦^À³ ²Ä¤@ÓAPAP¬r©Ê§Ö³t¶EÂ_´ú¸ÕAcetaSTAT¡A¥i¥H¦b¤j¬ù 20 ¤ÀÄÁ¤ºÀË´ú¥X¹ï¤A酰®ò°ò×ô¹L¶q¤Þ°_ªº¨x·l¶Ëªº¦å²G¼Ð»xª«¡C ¤S¬O¥©¦X¦b2022.3.4 ¬ü°ê¬rª«¤¤¤ß³ø§iªº¨àµ£¦Û±þ¨Æ¥ó«á |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/1 ¤W¤È 08:57:02²Ä 2149 ½g¦^À³
|
¨C¤ä±ÂÅvª÷³£>5»õ¬ü¤¸!!! SNP-810¯à¸Ñ¨MAPAP§x´o60¦~ªº¨x¬r°ÝÃD¡A±ÂÅvª÷[¤ñ¤H¥d²Óº~]??? 1.2014¦~Ofirmev (14»õ¬ü¤¸)->(º¤ä°w¾¯APAP) 2.2014¦~CL-108(6.8»õ¬ü¤¸)->Acetaminophen//hydrocodone(²B¥ià¬)/promethazine ¥[¤Jpromethazine(´NÈ6.8»õ¬ü¤¸Orz.)±j½Õ¯à§ïµ½ªü¤ùÃþÃĪ«ªºäú¤ß¹Ã¦R 3.2019.05.29 §¨Ó¥Hªñ10»õ¬ü¤¸»PCentrexion¦X§@ 4.2022.6.13¥x·LÅé»PEndo ±ÂÅv6.7»õ¬ü¤¸ -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/2/13 ¤U¤È 09:11:28²Ä 783 ½g¦^À³ §Ú̪YÄ£SNP-810´N [¤ñ¤H¥d²Óº~]¡H ¥¥Ãl¬O¤îµhÃÄ(2¤ä´N¬OAPAPÃĪ«¡A1¤ä«Dªü¤ùÃĪ«(¤£§tªü¤ùªº¤îµhÃijq³qºÙ¬°«Dªü¤ùÃĪ«:APAP/ ªü´µ¤ÇÆF...) 2014¦~Ofirmev VS 2014¦~CL-108 VS 2019.05.29 §¨Ó¥Hªñ10»õ¬ü¤¸»PCentrexion¦X§@ ¨º¤@¤ä±ÂÅvª÷<5»õ¬ü¤¸??? -------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/2/9 ¤U¤È 11:33:43²Ä 770 ½g¦^À³ ¬Y¨Ç¬ã¨s¶°¤¤©ó [«·s§Q¥Î] NSAID¡A¨Ò¦p¹ï¤A酰®ò°ò×ô(APAP)- 2019.05.29 §¨Ó¥Hªñ10»õ¬ü¤¸»PCentrexion¦X§@©Ý®i [«D]¾~¤ùÃþ¤îµhÃĪ«¥«³õ news.gbimonthly.com/tw/article/show.php?num=28151&page=258&kind=22 ------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/9 ¤W¤È 11:34:51²Ä 474 ½g¦^À³ SNP-840¡GSNP-810(Acetaminophen+¯S©w¤½»{¦w¥þ¦¨¤À)+ hydrocodone (²B¥ià¬) CL-108: Acetaminophen + promethazine +hydrocodone (²B¥ià¬) 2014¦~CL-108±ÂÅvª÷ 6.8»õ¬ü¤¸ www.fiercebiotech.com/biotech/daiichi-axes-650m-pain-pact-7-months-after-fda-setback .................................................. ......................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/2 ¤W¤È 11:04:43²Ä 334 ½g¦^À³ 2014.02.11 Mallinckrodt13»õ¬ü¤¸¦¬ÁÊCadence¥HÀò±oÂíµhÃÄOfirmev(º¤ä¹ï¤A酰®ò°ò×ôÀR¯ßª`®g¾¯)(³Ì²×¦¬ÁÊ»ù¬O14»õ¬ü¤¸) |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/6/30 ¤U¤È 10:15:53²Ä 2148 ½g¦^À³
|
ªYÄ£¨ãªÑ¤ý¬Û¡A¬ù§ë¸ê8¦~¡AªÑ»ù2000¤¸¡A§Ú60±i¤@»õ¤pô¡I¸ê²£¤W»õ¤¸¦º¦ÓµL¾Ñ¡IY¦³¨º¤@¤Ñ¡Ar¤j¦Ü¤Ö5»õ¤¸¡A¤£nÃø¹L¹L¥h¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/6/30 ¤U¤È 08:05:53²Ä 2147 ½g¦^À³
|
ªGµM¤@¤é¦æ±¡==>©ú¤Ñ¦¬¤ë½u¬Ý·|¤£·|¨ÓÓº²Â_ ·|û¡Gdk10140377 µoªí®É¶¡:2022/6/29 ¤W¤È 11:31:50²Ä 2141 ½g¦^À³ ¦³¤Hµo²{¤F·sÄ£ªº¦n¤F¶Ü?©Î¬OÃÓªá¤@²{?Ä_¹s²y³£¼Q¨ì¤Ñ¤W¤F¡C§ë¸ê¤j¤á¾Ç¤U±i§¡¥t¡A©ÔÓ1000±i¡A¤£ª¾¨ì·|¼Q¨ì¨º¥h |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/30 ¤W¤È 08:59:07²Ä 2146 ½g¦^À³
|
2022.6.29 ¬ü°êCDC¡G奥±K§J¦¥BA.4/5传¼½¨³²r ¤w¦¨¬ü国¥Dn¬y¦æ¬r®è 数Õu显¥Ü¡A¦bºI¦Ü6¤ë25¤éªº¤@©P¡ABA.4©MBA.5亚变Ïú导P¤F¬ü国¤j约52%ªº·s¼W·P¬V¡C这¤@¤ñ¨Ò显µÛ°ª¤_«e¤@©Pªº37%¡A¦Ó¦b5¤ëªì¡ABA.4©MBA.5¥u¥e·s¼W·P¬V¯f¨Òªº1%¡C这¨Ç数Õu³zÅS¤FBA.4©MBA.5Ìå¨ä®£©Æªº传¬V¯à¤O¡C ------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/29 ¤U¤È 10:11:09²Ä 2143 ½g¦^À³ 1.³¯¿ü®Ú«ü¥X¡A®Ú¾Ú6¤ë10¤é¸ê®Æ®w¤ñ¹ïµ²ªG¡ASNS812¹ï¥]§tOmicron BA.2¡B[BA.4 ]¡B[BA.5]µ¥·sÅܺئb¤ºªº·s«aÅܺخè¡A ¨ä²[»\²vºû«ù99.8%¡F§@¥Î¦ì¸m¤´¥¼²£¥Í¥ô¦ó¬ðÅÜ¡C 2.2022.6.28 ¡u°ÊºA²M¹s¡vÁÙn·d¦h¤[¡H²ßªñ¥·R±Nµo¨¥À~Ãa¤¤°êºô¥Á¡I½²©_¡G¥¼¨Ó5¦~¥_¨Ê±N°í«ù¨¾¬Ì 3.2022.6.13 钟«n¤sÆΦ{实验«ÇÉO¤¤¤Ñ¤W®ü¡B丽¯]医药µ¥¤»®a药¥ø签¸p§Ü¬Ì·s药¦X§@协 ---------------------------------------------------------------------------------------------- ¥H¤W¥i±À½×:¤@¥¹SNS812¦bP2¸ÕÅç§e²{¥¿±µ²ªG¡A¤£±Æ°£¤j³°¥ýµoµ¹EUA¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/30 ¤W¤È 08:19:34²Ä 2145 ½g¦^À³
|
T¤jÂW«¥ªº2»õ¤§µh!? ¤£¬O¥¢·N»P¦^¾Ð¡A¬O¯u¨S¤F~2»õªº¯uª÷¥Õ»È! |
|
|
·|û¡GTony10137427 µoªí®É¶¡:2022/6/29 ¤U¤È 10:19:59²Ä 2144 ½g¦^À³
|
¥xÆW¤§¥ú ÃĵØÃÄ6446 ©ó2022¦~2¤ë15¤é¡A¤½¥¬¼w°ê³Ì²×µô©wµ²ªG¡A§xÂZ¤½¥q1¦~¦hªº48»õ¤¸½ßÀv¡A½T©wµL¶·¤ä¥I¡C ¥u¤£¹L¡A¶D³^µo®iªº¹Lµ{¡A¹ï¤½¥qµo®i³y¦¨¤£¤Ö¼vÅT¡A¹ï¤pªÑªFªºÅv¯q¤]±a¨Ó½ÄÀ»¡C ±q¥h¦~11¤ë¤¤¨ú±o¬ü°êÃÄÃÒ¡Aªñ´Á¤S¤ÏÂà¸ó°ê¶D³^µ²ªG¡A§K½ß48»õ¤¸½ßÀvª÷¡AÃĵØÂåÃÄ¡]²ºÙÃĵØÃÄ¡^¥i»¡¬O¶i¤J¦¨¥ß22¦~¥H¨Ó¡Aµo®i«e´º³Ì¼ÖÆ[ªº®É¨è¡CµM¦Ó¡A»P¼Ú¬w¦X§@¹Ù¦ñAOPªº¯Éª§¨Ã¥¼ÀH½ßÀvª÷²×§P§i²×¡A¦Ó¥B¦]µu´Á¤º¦h¦¸µo°Ê¨p¶Ò¤]¤Þ°_¤pªÑªFªº¤£½Ì¸Ñ¡AÃĵØÃĪº¤U¤@¨B¨Ì¸ÜÃD©Ê¤Q¨¬¡C 2¤ë15¤é¡AÃĵØÃĤ½¥¬¼w°ê¶Ç¨Óªº®ø®§¡A¼w°êÁp¨¹³Ì°ªªk°|¥H²×§½½T©wµô©w¡AÃĵØÃļڬw¦X§@¹Ù¦ñAOP¤½¥q©Òn¨Dªº½ßÀv»P§Q®§¡AµL¶·¤ä¥I¡C³oÓµ²ªG¡AÅýÃĵØÃÄ°õ¦æªøªL°êÄÁª½¨¥¡G¡u¥¿¸q°¸º¸¿ð¨ì¡A¦ý¤@©w·|¨ì¡C¡v¦¹¥~¡A¬°¤F¦P¨Bªï±µ¬ü°ê¥«³õªº¦¨ªø¡AªL°êÄÁ¤]µÛ¤â·Ç³Æ·s¤@½üªº¨p¶Ò¡FY¦¨¯u¡A³o±N¬OÃĵØÃÄ2019¦~©³¥H¨Óªº²Ä5¦¸¨p¶Ò¡C ¥u¤£¹L¡A¦h¦¸¹ê¬I¨p¶Òªº§@ªk¡A¤wÅý¥«³õ¼öij¡A¾á¼~·l¤Î¤pªÑªFÅv¯q¡C¤×¨ä¥h¦~11¤ë¤¤¡AÃĵØÃĨú±o¬ü°êÃÄÃÒ¡AÀH§Y¦b12¤ëµo°Ê¨â¦¸¨p¶Ò¡AÅý¬Ý¦n¤½¥q«e´ºªº¤pªÑªFµL½t°Ñ»P¡C¬Æ¦Ü¥h¦~12¤ë13¤é¡A¨p¶Ò»ù®æ177¤¸¡A·í®ÉªÑ»ù¬ù¦b390¤¸¡A¤¤¶¡»ù®t¤§¤j¡A§óÅý¤pªÑªF¤£½Ì¸Ñ¡C ¨üªÈ¯É©ì²Ö ¤´¦C¥þÃB¥æ³ÎªÑ ¦Û2019¦~¥H¨Ó¡AÃĵØÃÄ4¦¸¨p¶Ò¡AÁ`p¼W¥[3.56»õ¤¸ªºªÑ¥»¡A¬O2019¦~©³¸ê¥»ÃB21.94»õ¤¸ªº16.24¢H¡C±¹ïªÑªFªº¾á¼~¡AªL°êÄÁ©Z¨¥I«á¦³µÛ¤½¥q¸gÀ窺Ãø³B¡A¯S§O¬OÃø¥H¨Ï¥Î¤½¶}¶Ò¸êªº¤è¦¡Äw¸ê¡C ªL°êÄÁ¥H2019¦~¡B2020¦~¨â¦¸¨p¶Ò»¡©ú¡A¡u¨º®ÉÔ¡A¤j®a³£Ä±±o§ÚÌn˱¼¤F¡C¡v¥«³õ¬ÝÃaÃĵØÃĵo®iªºª^³ò¡AÅý¤½¥q·Q³z¹L¤½¶ÒÄw¸ê¤]¬O§xÃø««¡C¦Ü©ó¥h¦~12¤ëªº¨â¦¸¶Ò¸ê¡AªL°êÄÁ±j½Õ¡A¬O¬°¤Fºû«ù¨ì¤µ¦~¦~¤¤ªºÀç¹B©Ò»Ý¡A¡u¦]¬°¬ü°êÀ禬¡A¤j¬ù¦~¤¤´N·|¥X¨Ó¡C¡vµM¦Ó¡A¥h¦~³Q¥´¤J¥þÃB¥æ³ÎªÑ¡AÅýÃĵØÃÄ·Qn¨«¤½¶Ò¤è¦¡Äw¸ê¡A½w¤£ÀÙ«æ¡C ½¾\ªk±ø¡A®Ú¾Ú¡mµo¦æ¤H¶Ò¶°»Pµo¦æ¦³»ùÃÒ¨é³B²z·Ç«h¡n¡]²ºÙ¡m¶Òµo·Ç«h¡n¡^²Ä¤K±ø¡A¦]¡u¤º³¡±±¨î¨î«×¡v°õ¦æ¦³¡u«¤j¯Ê¥¢ªÌ¡v¡Aª÷ºÞ·|¹ï¤½¶Ò¥Ó½Ð¡u±o°h¦^¨ä®×¥ó¡v¡C¥h¦~³QÃÒ¨éÂdý^¶R½æ¤¤¤ß³B¤À¥´¬°¥þÃB¥æ³ÎªÑ«á¡AÃĵØÃÄ»{¬°¹ê°È¤WÃø¥H¨ú±o¥DºÞ¾÷Ãö³\¥i¡A¬°¤F§Ö³t¨ú±o¨¬°÷¸êª÷¡A¤~§ä¤Wì©lªÑªF«ùÄò§ë¸ê¡C ¬Fªv¤j¾Çªk«ß¨t±Ð±Â¤è¹ÅÅï«ü¥X¡A¹ï©ó¤pªÑªF¡A¨p¶Ò¼vÅT³Ì¤jªº¬O»ù®æ¡AÁÙ¦³¹ïªÑÅvªºµ}ÄÀª¬ªp¡A¡u²z½×¤W¡A¤j³¡¤À¨p¶Ò¬O¦³µ¦²¤¥Ø¼Ð¡C¡v ¹ï©óÃĵØÃÄ¥´ºâ¦A¶i¦æ¨p¶Ò¡A¤@¦ìÃÒ¨é´Á³f§½©xûªí¥Ü¡A¤½¶Ò¥Ó½Ð®×¨Ì·Ó¡m¶Òµo·Ç«h¡n²Ä¤K±ø¡A¤º³¡±±¨î¨î«×ªº³]p©Î°õ¦æ¦³«¤j¯Ê¥¢¡A±o°h¦^®×¥ó¡CÁöµM¥Ø«eÃĵØÃĬ°¥þÃB¥æ³ÎªÑ¡A¦ý¤½¥q¤w¦b¥h¦~10¤ë¦VÂd¶R¤¤¤ß´£¥X¤º±±¯Ê¥¢§ïµ½pµe¡A§Æ±æ«ì´_¥¿±`¥æ©ö¡C¡u¦pªG¤½¥qn¤½¶}¶Ò¶°¸êª÷¡A§ÚÌ·|µû¦ô¥¦ªº¹ê»Ú¤º±±ª¬ªp¡A³o¬O¦³°Q½×ªºªÅ¶¡¡C¡v ¡u§Ú̲{¦b¬O¥þÃB¥æ³Îª¬ºA¡An¥Ó½Ð¤½¶}¶Ò¸ê¡A¤]·|Åý¥DºÞ¾÷Ãö¬°Ãø¡C¡vªL°êÄÁªí¥Ü¡C¦Ü©ó¸Ñ°£¥þÃB¥æ³Îª¬ºAªº¥i¯à¡A¥L±µµÛ»¡©ú¡G¡u¤´¦b´M¨D»PÂd¶R¤¤¤ß·¾³q¡A«ì´_¤@¯ë¥æ©ö¤è¦¡¡C¡v ¹ï¦¹¡AªL°êÄÁ»¡©ú¥òµôµ²ªG¥X¨Ó«e¡A¹L¥h5Ó¦h¤ë¤w»PÂd¶R¤¤¤ß·|½Í3¦¸¡A§Æ±æª§¨ú«ì´_¥¿±`¥æ©ö¡C¦ý¥Ñ©ó¥òµôµ²ªG¥¼¥XÄl«e¡A©|Ãø§¹¦¨«DñÃÒ·|p®vªº²Ä¤T¤è¬d®Ö¡A¾ÉP«e´X¦¸¥Ó½Ð³£¥¼¦³¨ãÅ馨ªG¡C¦ýµô©wµ²ªG¥XÄl¡AÅýªL°êÄÁ«Ü¦³«H¤ß«ì´_¥¿±`¥æ©ö¡AÃöÁä¦b©ó¤£¦ý¨S¦³±M§Q³Q©ç½æªº±¡§Î¡A¦P®É¤]½T»{µL¶·½ßÀv48»õ¤¸ªº½ßÀvª÷¡A¡u§ÚÌ·|ºÉ§Ö·Ç³Æ¡A3¤ë·|¦A·í±·¾³q¡A§Æ±æ4¤ëªì¥i¥H¬Ò¤jÅw³ß¡C¡v AOPÄò¿³³^ ©õ¤é¹Ù¦ñ¤¬«r ¨ú±o¨¬°÷¸êª÷ºû«ùÀç¹B¡A¯S§O¬O¬ü°ê¥«³õªº¦æ¾P»P·~°È±À¼s¡A±N·|¬O½T¥ßÃĵØÃÄÅ@«°ªeªºÃöÁä¡C¦Ü©ó¼Ú¬w»P¤¤ªF¦a°Ïªº¾P°â¡A¥Ñ©ó±ÂÅvAOPªº¦X¬ù¤º®e¤´Äݦ³®Ä¡A®É¨ì2039¦~¡A¦]¦¹¡A¦p¦ó»P¾P°âÅv²[»\¹F60Ó°ê®aªºAOPºû«ù¦X§@Ãö«Y¡A¤]¦¨¬°ÃĵØÃĤ£¥i»´©¿ªº³¡¤À¡C ¦^ÅU·í®É»PAOPªº¦X§@¡AÂù¤è¦b2009¦~¥¿¦¡Ã±q¦X§@«´¬ù¡A¥ÑAOP¶i¦æP1101¡]°Ó«~¦WBesremi¡^·sÃĪºÁ{§É¸ÕÅç¡A¨Ãµ¹¤©¼Ú¬w»P¤¤ªF¦a°Ïªº¾P°â±ÂÅv¡C¬Ý¦ü¬ü¦nªº¦X§@¡A«o¦b¤@¶}©l´N¥X¤F°ÝÃD¡C쥻¹w´ÁÀ³¸Ó¦b2014¦~´N¥i¥H§¹¦¨ªº¤T´ÁÁ{§É¸ÕÅç¡A¶i«×¤£Â_©ì©µ¡Aª½¨ì2013¦~9¤ë¤~¶}©l¶i¤J¨ì¤T´Á¶¥¬q¡C ªL°êÄÁ±µµÛ´£¨ì¡A¬ü°êÃÄÃҥӽФ]¨ü¨ì©ì©µ¡Aì¦]¦b©óAOP¤@¶}©l¶È´£¨ÑÁ{§É¸ÕÅçÁ`µ²³ø§i¡A¦Ó«D§¹¾ãªºÁ{§É¼Æ¾Ú¡A¬Æ¦ÜÅý¬ü°ê¹Ãħ½¡]FDA¡^¤@«×©Úµ´ÃĵØÃĪº¥Ó½Ð¡CÂù¤èªº¥Ù¬Þ¤£Â_¼W¥[¡A2018¦~4¤ë¡AAOP¤Ï¥HÃĵØÃĬG·N©µ¿ð·sÃĬãµo¶i«×¡A¾ÉPAOP¹w´ÁÀò§Q¨ü·lªº²z¥Ñ¡A¦b¼w°ê´£°_¶D³^¡AnÅýÃĵØÃÄ¥I¥X¼vÅTÀ禬ªº½ßÀvª÷¡C 2020¦~10¤ë¡A¼w°ê³Ì°ªªk°|§P¤U¤FÅýÃĵØÃÄ·N¥~ªºµ²ªG¡A¤]´N¬O¥²¶·½ßÀvAOP48»õ¤¸¡Cª½¨ì¤µ¦~2¤ë¡A¼w°ê³Ì°ªªk°|§ï§PÃĵØÃĵL»Ýµ¹¥I½ßÀvª÷¡A²×©óÅý¤½¥q¹Î¶¤¦Y¤F¤@°O©w¤ß¤Y¡C ¤ÏÀ»¶D³^¾Ô¶}¥´ Àç¹B²KÅÜ¼Æ µM¦Ó¡A¨Æ±¡¦ü¥GÁÙ¨S§¹¡C®Ú¾Ú¡m¦Û¥Ñ®É³ø¡n³ø¾É¡AAOP©x¤èÁn©ú¡u±NÄ~ÄòBesremiªº¾P°â¡A¨Ãn¨D½ßÀv¬ÛÃö·l¥¢¡C¡vAOP·|¤£·|¥t¥ß·s®×¿³³^¡H¤´µM¥Rº¡¤£½T©wªº¦]¯À¡C ¬°¤F§áÂà¤@¸ô®Á¥´ªº±¡¶Õ¡AÃĵØÃĤ]±Nµo°Ê¤ÏÀ»¾Ô¨î¿Å¡CªL°êÄÁ´£¨ì¡A·|¥H¦¹¦¸ªºµô©wµ²ªG¡A¤]´N¬OÂù¤è¦X¬ùÃö«Y¤´¦bªº°ò¦¤W¡A¡u®Ú¾Ú¦X¬ù¥h±±§iAOP¡C¡v°w¹ïAOP©ì©µªºª¬ªp¡A¶i¤@¨Bn¨D½ßÀv¡C ¨ä¤¤¡A°w¹ïAOP¨S¦³°µ¨ì¥t¥~¤T¶µ¾AÀ³¯gªº¸q°È¡A¥H¤Î¾ÉP¬ü°êÃÄÃҥӽЩµ¿ðªº³¡¤À¡AÃĵØÃĤw¸g¦b2020¦~11¤ë©ó¼w°ê´£§i¡C¦¹¥~¡A°w¹ïAOP¥ý«e¥H¡uÃĵØÃıM§Q³Q¦©©ã¡v¡B¡u±M§Q³Q©ç½æ¡vµ¥¤£¹ê°T®§¹ï°ÓÅAªº¼vÅT¡A¥H¤Î¥ý«eAOP¤í´Ú¤£ÁÙªº³¡¤À¡A¥t¥~·Ç³Æªk«ß¦æ°Ê¦^À»¡C ¯S§O¬O¹ï¹L¥hAOP¥¼¤ä¥IÅv§Qª÷¤À¼í¡A¦ýÃĵØÃĤ´¨Ì·Ó¦X¬ù«ùÄò¨Ñ³fªºª¬ºA¡AÃĵØÃĦbµô©w³Ó¶D«á±N®i¶}°l°Q¡AÂǦ¹«O»ÙªÑªFÅv¯q¡C®Ú¾ÚÃĵØÃĪº¸ê®ÆÅã¥Ü¡A¦Ü¤µ¨Ñ³fµ¹AOPªºÃĪ«¤w¹O10¸U°w¡A¦ÓAOPªº¤í´Ú¤]¹F¨ì¼Æ¤d¸U¼Ú¤¸ªº³W¼Ò¡C¬°¤FÁקKAOP«ùÄò±Ä¦æ¤£¥æ¥I¤À¼íªºª¬ªp¡A¡u¥h¦~¦~©³¡A§ÚÌ´N»¡n¥Î²{ª÷¥æ©ö¡A¤£µM¤£¥X³f¡C¡vªL°êÄÁ»¡¹D¡C ¥Î1¦~¦hªº®É¶¡¤ÏÂà¶D³^µ²ªG¡A¦p¤µ¡AÃĵØÃÄ®³¦b¤â¤Wªº¬ü°êÃÄÃÒ¡A¥i±æ¨«±o§óáB§ó»·¡C¦ýÃĵØÃÄ¥¼¨Ó¦b¥ú©ú¤¤¤´¦³³±¼v¡A»PAOPªºÄñ°«¯Éª§¡B¨p¶Òªºª§Ä³¡A³£¬O¸gÀç¹Î¶¤»P¥DºÞ¾÷Ãö¥²¶·¼f·VÀ³¹ïªº½ÒÃD¡C ©_Âݽ½L¡A¤@¥u§P¨M§K½ß48»õ¡K¥[¤W¥h¦~©³Àò±o¬ü°êÃÄÃÒ¡A³oÀÉ¡u¥þÃB¥æ³ÎªÑ¤ý¡v«e´º¯uÁŵM¶}®Ô¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/29 ¤U¤È 10:11:09²Ä 2143 ½g¦^À³
|
1.³¯¿ü®Ú«ü¥X¡A®Ú¾Ú6¤ë10¤é¸ê®Æ®w¤ñ¹ïµ²ªG¡ASNS812¹ï¥]§tOmicron BA.2¡B[BA.4 ]¡B[BA.5]µ¥·sÅܺئb¤ºªº·s«aÅܺخè¡A ¨ä²[»\²vºû«ù99.8%¡F§@¥Î¦ì¸m¤´¥¼²£¥Í¥ô¦ó¬ðÅÜ¡C 2.2022.6.28 ¡u°ÊºA²M¹s¡vÁÙn·d¦h¤[¡H²ßªñ¥·R±Nµo¨¥À~Ãa¤¤°êºô¥Á¡I½²©_¡G¥¼¨Ó5¦~¥_¨Ê±N°í«ù¨¾¬Ì 3.2022.6.13 钟«n¤sÆΦ{实验«ÇÉO¤¤¤Ñ¤W®ü¡B丽¯]医药µ¥¤»®a药¥ø签¸p§Ü¬Ì·s药¦X§@协 ---------------------------------------------------------------------------------------------- ¥H¤W¥i±À½×:¤@¥¹SNS812¦bP2¸ÕÅç§e²{¥¿±µ²ªG¡A¤£±Æ°£¤j³°¥ýµoµ¹EUA¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/29 ¤U¤È 09:56:51²Ä 2142 ½g¦^À³
|
¥xÆW¥Ø«e³o¤ä¦³§¹³ÓÀq§J½÷·çÆQ³¥¸qªº¼ç¤O¡A«Ý¸ÕÅç´¦¾å! 2022.6.13 创·s开©ñ¡A¿Ä¦X¦@赢¡A钟«n¤sÆΦ{实验«ÇÉO¤¤¤Ñ¤W®ü¡B丽¯]医药µ¥¤»®a药¥ø签¸p§Ü¬Ì·s药¦X§@协议www.joincare.com/news/329.html 钟«n¤s°|¤h对¤_ÉO¤¤¤Ñ¥Íª«¡]¥x湾¤j学¡^¦X§@开发ªºSNS812¯S别°µ¤F«点¤¶绍.... 这¨Ç数Õu显¥Ü¡ASNS812¬Oݨã [ªv疗]ÉO [预¨¾] ®ÄªGªº药ª« ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/24 ¤U¤È 06:13:46²Ä 1920 ½g¦^À³ §ÚÀ£¦X¤@[»ó]Ãú¼Q¾¯ªº²z½×°ò¦ (Omicron¶Ý»ó©Ê·¥¤Ö«¯g¡A Delta¶ÝªÍ©Ê«¯g¦h) 2020.11.26 www.nature.com/articles/s41385-020-00359-2 -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/3 ¤W¤È 08:31:34²Ä 1853 ½g¦^À³ §ÚÀ£: 1.¥þ²yº¤ä[»óÃú¼Q¾¯] ¦X¤@SNS812¼s®Ä«¬§Ü·s«a¬y·P¤p®Ö»Ä·sÃÄ¡A¤wn¥Ó½ÐP1 2.¦A¯}¥xÆW·sÃıÂÅv¬ö¿ýªºON101 ----------------------------------------------------------------------------------------------- ·|û¡G¬d²z¤ý10150572 µoªí®É¶¡:2022/1/21 ¤W¤È 07:36:20²Ä 1610 ½g¦^À³ ½Ð°ÝR¤j¤]¶}©lª±·s«a¬ÛÃöÃþªÑ¤F¶Ü? ªYÄ£ªºªÑ»ùÅý¤HµL¨¥.. |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2022/6/29 ¤W¤È 11:31:50²Ä 2141 ½g¦^À³
|
¦³¤Hµo²{¤F·sÄ£ªº¦n¤F¶Ü?©Î¬OÃÓªá¤@²{?Ä_¹s²y³£¼Q¨ì¤Ñ¤W¤F¡C§ë¸ê¤j¤á¾Ç¤U±i§¡¥t¡A©ÔÓ1000±i¡A¤£ª¾¨ì·|¼Q¨ì¨º¥h |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/25 ¤W¤È 08:48:35²Ä 2140 ½g¦^À³
|
¿ï²¼¦Ü¤W!!! 2022.6.23 «ôµnªº¤ä«ù²v³sÄò²Ä¥|©P¤U°¡A³Ð¤U¾ú¥v·s§C ³o¬O¤@Óĵ§i«H¸¹¡Aªí©ú¥L©ÒÄݪº¥Á¥DÄÒ¥i¯à¦b 11 ¤ë 8 ¤éªº¤¤´Á¿ïÁ|¤¤¥¢¥h¹ï¬ü°ê°ê·|ªº±±¨î¡C 7/15 PHE¨ì´Á~100%¦A®i©µ¡A¿ïÁ|«á¤~µ²§ôPHE¡C ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/13 ¤W¤È 08:54:28²Ä 2065 ½g¦^À³ ¦]¬°11¤ë¬ü°ê¤¤´Á¿ïÁ|¡A¿ï²¼¦Ü¤W¡A©Ò¥HPHE 7/16¨ì´Á8¦¨·|¦A®i©µ! XX¥Ó½ÐEUAªº¬üÄRÁÀ¨¥¥i¥HÄ~ÄòÄF¡A¤p¤ß³Ì²×µ²§½¬Û·í±~ºG¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/6/23 ¤U¤È 05:02:32²Ä 2139 ½g¦^À³
|
·PÁÂr¤j²M·¡¸Ô¸Ñ¡AÁÂÁ¡C§Ú¦]¥þ©ãªYÄ£¡A¤@©wnª`·N¥ô¦ó®ø®§¡C¿ï¾Ü¥Í§ÞªÑ½äª`«Ü¤j¡A¤§«eì¨Ó¬On¥þ©ã¦w¦¨¡A¤w¦³±ÂÅv¤S«K©y14¶ô¦h¡F¤Uª`«e¬Ý¨ìªYÄ£¬O¤ºªAÃÄ¡Aı±o»ùÈ°ª¤~Âà¦V¡A¦w¦¨¤]³Q¨ÖÁʤF¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/23 ¤U¤È 03:12:13²Ä 2138 ½g¦^À³
|
«n¥P¤¦ÅS¤Fª°§À¤Ú¡A«¥®a¤~·|»¡¤Æ¨¦b¦¹°Á{¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/23 ¤U¤È 02:57:10²Ä 2137 ½g¦^À³
|
¥h¦P¾Ç·|°ê¹©ª©¬Ý¬Ý¶Â¯»ª°´N¯à©ú¥Õ¡C Antroquinonol¬O¤@ÃĪv¦Ê¯fªº¥P¤¦¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2022/6/23 ¤U¤È 02:20:37²Ä 2136 ½g¦^À³
|
ªñ¤T«h¶K¤å³£¬O°ê¦r¡A«ç»ò¬Ý¤£À´¡H«n¥P¤¦«ü°ê¹©¶Ü¡HÁÙ¬O«üªYÄ£¡H¦³¸ê°Tª½¥Õ»¡¡AÃúÃúªº¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/23 ¤W¤È 10:39:24²Ä 2135 ½g¦^À³
|
XX·|¶Â¯»ª°¤Æ¨¦b¦¹°Á{? ±`¦b¦¹ª©µo¨¥ªº¦P¾Ç!~½Ð°Ý§A³£³æÀ£[«n¥P¤¦]¶Ü?~Y¬O~¥i§_¨ì·sÃĦU¯Z¥h¬Ý¬Ý!~¹L¥hÂ÷¶}³oùتº½×¾Â¤jô... ------------------------------------------------------------------------------------ ±zªº¶K¹Ï¡A¦³¨Ç·|¨Ï¤H¥´§NŸ¡A±aµÛÃø¥H¨¥ªíªº²`»··N¹Ò¡C «¥®a¬O¤À¨¥F³N! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/23 ¤W¤È 09:06:56²Ä 2134 ½g¦^À³
|
«n¥P¤¦(Ãø¦¨¥P¤¦¤§·N?): ¥ÎÃIJÄ14¤Ñ±d´_²v¬°97.9%(§ï100%)¡A¥ÎÃIJզb²Ä28¤Ñ©Ò¦³¯f¤H³£¨S¦³¦º¤`¡A¤]¨S¦³©I§l°IºÜ¡A±d´_²v¬°100%¡C ¹ï·Ó²Õ²Ä14¤Ñ±d´_²v¬O96.0%¡A¤]¥i±À¦ô[¹ï·Ó²Õ¦b²Ä28¤Ñ©Ò¦³¯f¤H³£¨S¦³¦º¤`¡A¤]¨S¦³©I§l°IºÜ¡A±d´_²v¬°100%¡C] ¦b¿³Âd§b³o»ò¤[¡A¯S§O¬O³o2¦~¨Ó[¤£²»¼x¥ü]¦h¡A¦ÑÁó«HÅA±½¦a¡A¤½¥q©RÄa1ª«¡A©^ÄU»·Â÷¡A¦w¥þ²Ä¤@! |
|
|
·|û¡GPeter Lin10152815 µoªí®É¶¡:2022/6/21 ¤U¤È 04:40:13²Ä 2133 ½g¦^À³
|
«n¥P¤¦¡A¥u¯à¨þ¨þ¤F¡C ¨þ¨þ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/6/21 ¤W¤È 10:00:42²Ä 2132 ½g¦^À³
|
«¥À£[ÁÙ¨S¶}©l]¦¬®×¡A¦³½Ð¥h¹q¸ß°Ý¤§¤H¤½¥¬µª®×! |
|
|
|